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(1). In this study, we improved the hatchability (!90%) of egg embryos after 
vaccination with live attenuate influenza vaccines using modified H7 and H9 
hemagglutinin (HA) proteins with amino acid substitutions at the cleavage site for 
those found in the H6 HA subtype. A single dose in ovo vaccination of 19-day old 
eggs provided complete protection against homologous challenge with low 
pathogenic H7 and H9 virus in !70% of chickens at 2 or 6 weeks post-hatching. 
(2). The HA titer of a recombinant live-attenuated influenza vaccine (2 
mouse-adapted(ma) Ca/04 H1N1:6WF10att) against pandemic H1N1 was improved 
through egg adaptation.  By whole viral genome sequencing and with viral knetics 
study of reverse genetics viruses, I found an aminno acid substitution in PA 
polymerase subunit, at position 59, from glutamic acid to valine, which is responsible 
for the enhancement of HA and viral titer. This mutation did not impair the 
  
temperature sensitive phenotype of prototypic live attenuated backbone, WF10att. 
The PA E59V mutation moderately enhanced the HA and viral titer of wt WF10 and 
ty/04att backbones. However, it had no effect on two commercially licensed 
influenza vaccine internal backbones PR/8- or ca Ann Arbor/60. Interestingly, 
although the E59V had no significant effect on increasing HA/NP ratio of the wt 
WF10 or WF10att system; both backbones resulted in higher antigenic content on 
viral particles than PR/8- or ca Ann Arbor/60-based virus particles. 
(3). Our laboratory previously generated an adapted virus from wildtype duck 
H9N2, A/duck/Hong Kong/702/79 virus, through 23 serial passages in lung of quail 
(QA23). QA23 gained the new phenotype of replicating and transmitting efficiently 
in chickens and quail.  NS1 protein localization studies demonstrated that QA23 NS1 
was mainly distributed in the cytoplasm; while WT702 NS1 predominantly 
accumulated in the nucleus; and nuclear localization sequence 2 is important for the 
nuclear import of NS1. QA23 NS1 up-regulated the viral protein synthesis in DF1 
cells; did not affect the inhibition of IFN- "; and greatly reduced the apoptotic activity 
level during infection. However, there is no evidence showing that QA23 NS1 is 
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Chapter 1: Influenza A virus 
Introduction 
Influenza viruses are enveloped single-stranded negative-sense RNA viruses, 
belonging to the family Orthomyxoviridae. There are 6 genera in this family, including 
Influenza A, B, C, Isavirus, Thogotovirus and an unnamed, novel and uncharacterized 
genus [1]. Influenza A, B and C viruses are classified according to the differences in 
matrix protein (M1) and nucleoprotein (NP). Influenza A viruses can infect humans and a 
broad range of animal species, including birds, pigs, horses, dogs and sea mammals; 
whereas Influenza B viruses infect only humans [2], seals [3] and ferrets [4]; and 
Influenza C viruses infect only humans, dogs and pigs [5]. Amongst them, Influenza A is 
the major pathogen causing the seasonal flu and sporadic pandemics. Pandemic flu in the 
20th century (1918 H1N1 Spanish flu, 1957 H2N2 Asian flu and 1968 H3N2 Hong Kong 
flu) caused millions of deaths [6]. The 2009 swine-origin pandemic H1N1 (pH1N1) 
influenza virus (“swine flu”) rapidly spread around the world. By July 2010, this 
pandemic resulted in more than 18,000 deaths worldwide [7]. Currently, highly 
pathogenic avian influenza (HPAI) H5N1 virus (“bird flu”) is circulating in many 
counties, occasionally infecting humans with mortality as high as 60% [8].  
Influenza A virus contains a genome with 8 RNA segments, which encode at least 
12 identified proteins. RNA segments 1, 2 and 3 encode polymerase basic proteins PB2 
and PB1 and polymerase acid protein PA, respectively. Segments 4, 5, and 6 encode 
hemagglutinin (HA), nucleoprotein (NP), neuraminidase (NA), respectively.  Segment 7 




protein 1 (NS1) and the nuclear export protein (NEP; also known as NS2). In addition, 
PB1-F2 and N40 are translated from PB1 mRNA by leaky scanning [9,10], and PA-X is 
translated by ribosomal frameshifting of the PA gene [11]. PB1, PB2 and PA are subunits 
of RNA-dependent RNA polymerase (RdRP). NP packages the segmented viral RNA and 
binds to RdRP to form the ribonucleoprotein (RNP) in the viral particles (Table 1.1 and 
Figure 1.1).  
Influenza A virus possesses a lipid bilayer envelope derived from the host 
membrane. HA and NA are surface glycoproteins on the viral envelope, and both proteins 
recognize sialic acid (SA) [12,13]. Influenza A viruses can be classified into 17 HA 
subtypes (H1–H17) and 10 NA subtypes (N1–N10) based on the antigenic differences of 
the proteins [14,15]. The virus strains from all HA and NA subtypes except H17 and N10 
were isolated from birds, and the novel strain H17N10 has only been found in bats.  
The influenza A virus RdRP lacks of proofreading activity, which leads to the 
sequence variations in the different strains and within the same strain. The accumulation 
of the mutations on the proteins possessing the neutralizing antibody-binding sites may 
result in the generation of escape-mutants, a process called antigenic drift [16,17]. Two 
subtypes of the influenza A viruses are currently co-circulating in humans: pH1N1 and 
H3N2. The influenza vaccine against seasonal flu needs to be designed according to the 
antigenic drift of the current year and updated annually.  
The most deadly pandemic in last century occurred in 1918-1920 and was caused 
by the H1N1 influenza virus (“Spanish flu”) of unknown origin. The disease was first 
observed in January 1918 in the US, and then the outbreaks began in several places of the 




rapid spread of the virus to Europe and Africa, and later, to Asia and Oceania by June 
1918. The second wave of the infection occurred in August 1918 from Europe across the 
world with much higher virulence than the first wave [19]. It is estimated that half of the 
population of the world at that time was infected with the pandemic 1918 influenza virus, 
which caused at least 20 million deaths [18]. Unlike other influenza pandemics, with a 
mortality rate less than 0.1%, the 1918 pandemic had an unusually high mortality rate 
among infected humans at 2.5% [20]. 
The infection of one single cell with two or more different influenza virus strains 
simultaneously can lead to gene mixing, or reassortment. The reassortment of the viral 
genomes may result in the generation of new subtype, which causes the generation of 
new influenza virus strains associated with the occurrence of human pandemics. This 
process is called antigenic shift. Pandemic 1957 Asian H2N2, 1968 Hong Kong H3N2 
and 2009 swine-origin H1N1 influenza are all reassorted viruses [21,22].  
The pandemic H2N2 (“Asian flu”) was first discovered in Guizhou province of 
China in February 1957 [23]. It rapidly spread to Hong Kong, Singapore and Japan, and 
then to the Southern Hemisphere, Europe and North America by August 1957. It is 
calculated that one fourth of the world’s population was infected with the virus, and the 
total deaths included more than one million people [19].  The 1957 pandemic H2N2 
influenza is an avian/human reassortant virus carrying the surface glycoproteins H2 HA 
and N2 NA and PB1 originated from avian [21]. 
Another avian/human reassortant H3N2 virus caused the pandemic “Hong Kong” 
flu in 1968. The outbreak first appeared in Hong Kong in July 1968; and then spread to 




This reassortant virus was generated from the pandemic 1957 H2N2 virus by replacing 
the HA and PB1 segments from an avian-origin virus [21]. It is estimated that this H3N2 
pandemic virus killed approximately one million people worldwide [25]. 
A novel swine-origin H1N1 emerged from Mexico in March-April 2009, and 
caused the first influenza pandemic of the 21st century. By June 2009, more than 29,000 
cases were confirmed from 74 counties. Up until July 2010, confirmed cases of the 2009 
pandemic H1N1 were reported from 214 countries, causing more than 18,000 deaths 
worldwide [26]. This pandemic influenza formed by a swine triple-reassortant virus 
(originated from classical swine H1N1, North American avian and human H3N2 viruses) 
reassorted with a Eurasian avian-like swine virus. The HA, NP and NS segments are from 
the classical swine virus; the PB2 and PA segments are from the North American avian 
virus; and PB1 is from the human H3N2 virus. The NA and M segments originated from 
Eurasian avian-like swine H1N1 virus [27,28]. After 2010, this pandemic H1N1 has 
moved into the post-pandemic period, but continues to circulate as a seasonal flu by 
replacing the former H1N1 strain.  
Aquatic birds are believed to be the natural reservoir of influenza A viruses, and 
the HA subtypes H1-H16 and NA subtypes N1-N9 have been isolated from them. Some 
of the avian viruses have sporadically crossed the species barrier and caused severe 
diseases in land-based birds and mammals, including humans.  
In May 1997, the first HPAI H5N1 virus infecting humans was found in Hong 
Kong, leading to 6 deaths in 18 infected patients [29,30].  This H5N1 virus disappeared 
after the poultry depopulation in Hong Kong [31]. The precursor of the H5N1 influenza 




Guangdong Province of China in 1996 [31]. The internal gene segments of the virus 
originated from a quail H9N2 virus, and the NA segment was from a duck H6N1 virus 
[29]. In February 2003, two people from Hong Kong who had travelled to southern China 
were confirmed to be infected with HPAI H5N1 [32]. Since 2003, at least 633 human 
cases of H5N1 infection were reported from 15 counties, including Vietnam, Indonesia, 
Japan, China and Egypt, and 377 of them died [33]. Meanwhile, the HPAI H5N1 virus 
spread throughout the counties in East and Southeast Asia, the Middle East, Africa and 
Europe since 1997, and caused the outbreaks in poultry farms. It is estimated that more 
than 400 million of the domestic birds were killed by the virus or depopulated to prevent 
the spread of the virus [34].   
From the 1996 precursor strain, the HPAI H5N1 virus has evolved into at least 10 
clades based on the genetic and antigenic differences in the strains infecting wild birds 
and domestic poultry species. Amongst them, clade 0, 1, 2 and 7 have infected humans, 
and clade 2 can be further divided into 3 subclades. For example, the virus strain that 
caused severe poultry loss and human illness in Indonesia belongs to subclade 2.1 [8]. 
Fortunately, no sustained human-to-human transmission of HPAI H5N1 has been 
observed since 1997 [35]. The potential of HPAI H5N1 acquiring the capability to 
transmit between humans and resulting in a human pandemic either by antigenic drift or 
antigenic shift, has been a hot spot for research during recent years. Adaptation studies 
with whole or reassortment of HPAI H5N1 virus were independently carried out in a 
ferret model by two different research groups, and the results emphasized the potential of 
this virus to acquire transmissibility in mammals and cause pandemic. Five amino acid 




amino acid substitutions (N224K, Q226L, T318I and N158D (H3numbering) with 
reassortment, might be sufficient to confer a virus with H5 HA (from HPAI H5N1) 
aerosol transmission capability in ferrets [36,37]. Amongst them, N224K and Q226L are 
receptor-binding substitutions, N158D and T160A are HA glycosylation sequon 
substitutions, and T318I is located at the stalk region. 
In March 2013, a novel reassortant avian-origin influenza A (H7N9) virus was 
identified to infect humans in eastern China [38]. Up to July 4, 2013, a total of 133 
people were infected, including 43 cases ending in death [39]. The phylogenetic analysis 
revealed that the genome of the novel H7N9 resulted from reassortment: the H7 gene 
most likely originated from the HA of the H7N3 virus isolated from Zhejiang Province of 
China; the N9 gene may come from the NA of the H7N9 virus of wild birds or ducks 
from Korea; and all six internal genes most likely originated from the avian influenza 
virus H9N2 circulating in chickens [40,41]. The virus strains isolated from human cases 
displayed several molecular virulence makers and pathogenic determinants related to 
human adaptation [38,42,43,44]. Although a recent epidemiological investigation report 
showed that the novel H7N9 may be capable of limited human to human transmission 
[45], no evidence has shown that this novel H7N9 virus sustained the transmission 
between humans by respiratory droplets. 
Low pathogenic avian influenza (LPAI) H9N2 virus has adapted to land-based 
poultry since the middle of 1990s, and mainly infected chickens. From then on, this virus 
has overcome the barrier of the host range and caused infections in different hosts, such 
as quail, turkeys, pheasants, ostriches, mallards and pigs, in many countries across Asia, 




sporadically isolated from humans with mild symptoms [49]. Despite the efforts to 
control the disease, the virus continued to cause the economic loss and public health 
concern in some of those countries. 
Viral proteins 
HA 
The influenza HA protein is the most important protein in influenza viruses, as it 
is a critical determinant of host range and virulence [50,51], and the main antigenic 
determinant of the virus [52]. Based on the sequences and antigenic properties, 17 HA 
subtypes can be classified into two groups: group 1(H1, H2, H5, H6, H8, H9, H11, H12, 
H13, H16 and H17) and group 2 (H3, H4, H7, H10, H14 and H15) [53,54]. 
HA is a homotrimer of three identical subunits [17]. The two main functions of 
HA during viral entry are receptor binding and viral-host membrane fusion. The 
precursor HA0 must be post-translationally cleaved into HA1 and HA2 by host 
extracellular proteases, and thus, the potential of the membrane fusion function of HA2 is 
activated [55]. HA1 (328 amino acids) and HA2 (221 amino acids) are connected by a 
disulfide bond linker [56]. The extracellular trypsin-like proteases are responsible for the 
cleavage of the HAs in LPAI viruses and mammalian influenza viruses [57]. These 
proteases recognize the HA cleavage sites with a single arginine, such as Q/E-X-R in the 
amino acid sequence [58]. Whereas, the HA of HPAI viruses (H5 and H7 subtypes) 
contain the polybasic amino acid cleavage sites, such as R-X-R/K-R, can be recognized 
by the intracellular ubiquitous proteases, such as furin-like protease [22,57]. The spread 




extracellularly on the host intestinal and respiratory mucus surfaces where the trypsin-
like proteases are found. Whereas the HPAI viruses cause systemic and virulent 
infections, because their HAs are cleaved intracellularly by the furin-like proteases which 
are distributed in multiple organs of the host [22].  
The terminal sialic acids (SA) of the glycoproteins and glycolipids on the cell 
surface are the receptors of influenza A viruses [52]. The receptor-binding site (RBS) of 
HA1 is located on the global head region, including four conserved secondary structures: 
the 130-, 150- and 220-loops, and the 190-helix [17,59,60,61], which contain several 
residues highly conserved in most subtypes of influenza [17,62].  Ser-136 and Tyr-98 
form hydrogen bonds with the carboxylate and the 8-hydroxyl group of the sialic acid, 
respectively. His-183 and Glu-190 form a hydrogen bond with the 9-hydroxyl group, and 
Trp-153 contacts with the methyl group of sialic acid through van der Waals force. Leu-
194 and Tyr-195 are also important residues for receptor binding [62,63,64].  
Avian-like influenza viruses preferentially bind to !-2,3-linked sialic acid (!-2,3-
SA), which are distributed on the epithelial cells of the intestine of birds and lower 
respiratory tract (LRT) of humans [65]. Human-like viruses preferentially bind to !-2,6-
linked sialic acids (!-2,6-SA), which are distributed on the bronchial epithelial cells of 
the human upper respiratory tract (URT) [65,66]. Interestingly, swine viruses may bind to 
both !-2,3-SA and !-2,6-SA receptors [67,68,69]; however, the 2009 H1N1 swine-origin 
pandemic influenza virus is reported to bind to !-2,6-SA, as well as limited !-2,3-SA 
[70,71]. Six residues in HA RBS, Ala-138, Glu-190, Leu-194, Gly-225, Gln-226 and 
Gly-228, are important determinants for the host range. They are highly conserved among 




the binding affinity to !-2,6-SA when adapted to humans [72]. The newly identified 
influenza A virus H17N10 has only been found in bats. The crystal structure and glycan 
microarray studies of H17 HA revealed that although the H17 has a protein folding 
similar to other HA subtypes, it does not bind to either human !-2,6-SA or avian !-2,3-
SA receptors; and no H17 binding was detected either using a glycan microarray with 
more than 600 known glycans [73,74]. The analysis of the H17 putative RBS showed that 
some key residues, such as Trp-153, His-183, Leu-194 and Tyr-195 are conserved as the 
typical influenza A HA, but substitutions Y98F, T136D, and G228D and the truncated 
150-loop due to a 157 and 158 aa deletion may account for the failure of H17 binding to 
canonical human or avian receptors [73]. The results suggested that H17N10 may utilize 
different receptor-binding and cell-entry mechanisms from other subtypes of the 
influenza A virus. 
Asp-190 and Asp-225 in the HA of 1918 pandemic and 2009 pandemic H1N1 are 
critical for the !-2,6-SA affinity in humans [66,75]. The studies have shown that HPAIV 
H5N1 HA preferentially binds to terminal !-2,3-SA moieties, but the H5N1 mutants 
discovered in recent years contained the substitutions G143R and N186K, or Q226Land 
G228S, or T160A, or Q196R in HA, which changed the receptor-binding specificity of 
the virus from !-2,3-SA to !-2,6-SA [76]. The amino acid substitution Q226L on the HA 
RBS of avian H9N2 viruses has been showed to increase !-2,6-SA binding affinity and 
enhance virus replication in human respiratory epithelial cells and in ferrets [77,78]. 
Q226L has also been found in the HA of two strains (A/Anhui/1/2013/and 
A/Shanghai/2/2013) from the novel avian-origin H7N9 virus, which indicate that the 




[38,42]. However, one of the latest structural analysis and glycan studies has shown that 
the binding of H7N9 HA to human receptors was limited; and further introduction of a 
single substitution G228S in HA would greatly increase the receptor binding affinity of 
H7N9, and result in a better fitness of the virus in humans [79]. 
HA is the main antigenic determinant of the influenza A virus. The antibodies 
against HA can be classified into two groups: the first group recognizes and binds the 
epitopes on HA1, blocking the attachment of HA on the receptors; whereas the second 
group prevents membrane fusion by binding to the stalk region of HA [80,81]. The 
antigenic sites of the first group, termed Sa, Sb, Ca, and Cb, are located on the globular 
head of HA surrounding the RBS [17].  In contrast, the antigenic binding sites of stalk 
antibodies are generally distant from the RBS [80]. Influenza viruses overcome the host 
antibodies through antigenic drift and antigenic shift. 
NA 
The influenza NA protein, an exosialidase (EC 3.2.1.18), catalyzes the cleavage 
between the terminal sialic acid and the adjacent sugar of the viral receptor. This 
receptor-destroying activity facilitates the release of the progeny virions from the surface 
of the infected cells [82], and it can be directly inhibited by the NA antibodies [83]. NA 
also plays important role in the early stages of viral infection by the removal of the 
glycan structure of mucus and promoting the binding of HA to the receptors in the 
respiratory tract [84]. The functional balance between HA receptor-binding and the 
receptor-destroying activity of NA is important for the efficient replication of the 
influenza virus. For example, the 1957 pandemic H2N2 virus strain possessed an HA 




1957, N2 gradually adapted with the HA sialic acid binding affinity and evolved to 
cleave both !-2,3 and !-2,6-SA receptors [85]. By now, ten subtypes of NAs have been 
identified in influenza A viruses. Influenza A NA can be phylogenetically classified into 
2 groups: the N1, N4, N5 and N8 subtypes belong to group 1, and the second group is 
composed of the N2, N3, N6 N7 and N9 subtypes [86]. Recent studies have demonstrated 
that the crystal structure of newly identified N10 (from influenza A virus H17N10, 
discovered in little yellow-shouldered bats) is similar to that of the other NA subtypes, 
but N10 exhibits extremely low NA activity [87,88]. 
NA forms a tetramer on the surface of influenza virus, and is also a glycoprotein 
(with a 60 kDa molecular mass for the monomer, and 240 kDa for the tetramer) [82]. The 
3D structures of N1, N2, N4, N8 and N9 have been resolved, showing that the protein 
contains cytoplasmic, transmembrane, “head” and “stem” domains [89].  The catalytic 
site and metal-ion binding domain are located in the head of the NA [90], and the amino 
acid residues 74-390 (N2 numbering) are highly conserved in this region in all subtypes 
of NA. The residues Arg-118, Asp-151, Arg-152, Arg-224, Glu-276, Arg-292, Arg-371, 
and Tyr-406 are critical to the function of the active site; and the residues Glu-119, Arg-
156, Trp-178, Ser-179, Asp (or Asn in N7 and N9) -198, Ile-222, Glu-227, Glu-277, Asp-
293 and Glu-425 stabilize the structure of the domain [89].  
N-Acetylneuraminic acid (Neu5Ac) is the predominant sialic acid existing on the 
surface of mammalian cells, and the binding of Neu5Ac to the active site of NA triggers a 
conformational change. Neu5Ac interacts with the residues Arg-118, Arg- 292 and Arg- 
371 of NA, and subsequently drives the cleavage of the sialic acid [91]. The NA 




(Relenza®) (containing the Neu5Ac2en group) are both sialic acid-mimicking drugs, 
which block the sialidase activity of NA by binding to the active sites [92,93].  
In the recent years, H274Y in group 1 NAs and R292K in group 2 NAs have been 
identified as the oseltamivir-resistant mutations [94]. The NA R292K mutation has also 
been found in two patients with novel H7N9 in China who received corticosteroid 
treatments [95]. Both the H274Y and R292K mutations in NA reposition the side chain 
of Glu-276, which developed oseltamivir resistance by distinguishing the L-ethylpropoxy 
group from the glycerol part of the sialic acid. Therefore, the mutant NA with H274Y or 
R292K lost the function of binding to the L-ethylpropoxy group of oseltamivir, but still 
retained the interactions with the glycerol part of the sialic acid receptors [93]. 
Deletions on the NA stalk region occur in the interspecies transmission of 
influenza viruses from aquatic birds to gallinaceous poultry (chickens or turkeys) 
[96,97,98,99], and during the transmission of influenza viruses in poultry [100,101]. In 
2000, the HPAI H5N1 strain with a 20-amino acid deletion (49-68 aa) in the NA stalk has 
been first discovered from human isolates. From 2000 to 2007, the percentage of human 
H5N1 isolates possessing this deletion dramatically increased from 15.8% to 100%. The 
NA with different stalk deletions has been demonstrated to be associated with the high 
virulence of HPAI H5N1 in chickens and mice [99]. The interspecies transmission 
studies of H2N2 and H9N2 avian influenza viruses from wild aquatic birds to quail and 
chickens led to a 27- and 21- amino acid deletions in the NA stalk, respectively, and 
enhanced virus replication in chickens and mice [96,98]. A 5-amino acid deletion (69-73 
aa) has also been detected from the NA stalk region of the 2013 novel avian-origin H7N9 




virulence in humans [102]. The mechanism of the deletion in the NA stalk region is still 
unclear, but the deletion generally appears following the increased glycosylation sites in 
HA, which may result in the immune escape from the neutralizing antibody recognition 
[103,104]. 
M1 
M1, the most abundant protein in the virion, is under the lipid bilayer membrane, 
and binds to the viral RNPs. M1 plays important roles in the life cycle of influenza virus, 
including uncoating, viral mRNA transcription, vRNA export, assembly and budding. 
The interactions among M1, vRNP and NEP trigger the export of vRNPs from the 
nucleus and the budding of the progeny virions from the cell surface [105,106]. 
The crystal structural study revealed that M1 is composed of an N-terminal 
domain and a C-terminal domain, which are connected by a linker. Both domains have a 
!-helical structure, and the N-terminal domain contains two subdomains. A binding 
domain is located on residues 89–164, which are responsible for the NEP binding [107]. 
This domain also consists of a well-characterized basic amino acid-rich nuclear 
localization signal (NLS) (101-RKLKR-105), which is critical for the transport of M1 
into the nucleus [108,109]. The newly synthesized M1 protein is imported into the 
nucleus by importin-!1 via the NLS [110]. In the nucleus, M1 interacts with the histones 
and involves in the release of vRNPs from the nuclear matrix [111]. The binding of M1 
to vRNP subsequently inhibits the viral mRNA transcription. M1 also binds to NEP to 
form the NEP–M1–vRNP complex, which is exported from the nucleus by a nuclear 




rich NES was also identified in the M1, and Leu-66 and Val-68 are critical residues for 
the export of the M1 into the cytoplasm [113]. In the cytoplasm, the binding of M1 to 
vRNP prevents the reentry of vRNP into the nucleus [114]. 
Three consecutive arginine residues 76 to 78 (76-RRR-78) in the M1 gene are 
highly conserved among the influenza A viruses. This basic amino acid stretch affects the 
M1 transportation, virus assembly and budding, and plays a critical role in the viral 
replication [115].  
Phosphorylated tyrosine is important to the nuclear import of M1 by binding the 
protein to the nuclear import factor importin-!1. The amino acid residue Tyrosine 132 in 
the M1 of the influenza virus A/WSN/1933(H1N1) has been identified as a 
phosphorylation site which is crucial to the nuclear import of M1 and virus replication 
[110]. 
M2 
M2 monomer is a polypeptide with 97 amino acids. The homotetramer of the M2 
protein forms a proton ion channel, which is regulated by pH. The N-terminal 
transmembrane (TM) domain of M2 extends outside the viral membrane, and the C-
terminal connects the viral interior [116]. The highly conserved residue His-37 is a “pH 
sensor” of the channel to enhance the H+ flow at low pH; and Trp-41 forms a “gate” to 
block the ion channel at high pH [117,118]. During viral entry, M2 pumps protons from 
the endosome and reduces the pH of the viral interior, subsequently dissociating M1 




(TGN), M2 prevent HA from premature conformational rearrangement by connecting the 
TGN with the cytoplasm and equilibrating the pH [119]. 
The anti-influenza drugs amantadine and rimantadine bind to the channel pore of 
the M2 as targets, and block the ion channel, so that they stop the acidification of the 
viral interior [120,121,122,123]. The X-ray and NMR structural studies of the M2 TM 
domain revealed that amantadine has two different binding sites on M2: at pH 5.3, it 
binds to M2 near Ser-31 and directly stops the proton flow [124]; and at pH 7.5, it binds 
to the TM helix near Trp-41 and allosterically blocks proton conductance [119].  
However, the use of M2 inhibitor drugs amantadine and rimantadine has caused 
the occurrence of resistant mutation strains in nature under selection stress [125,126]. In 
recent years, a typically resistant mutation N31S has also been discovered in numerous of 
virus strains from the M2 of different subtypes, such as the seasonal H3N2, 2009 swine-
origin pandemic H1N1, HPAI H5N1 infecting humans as well as the novel avian-origin 
reassortant H7N9 viruses [22,44,127]. The structural study demonstrated that the 
substitution N31S does not change the ion channel pore structure, but greatly reduces the 
affinity of anti-influenza drug binding to the allosteric site [128]. Therefore, N31S does 
not impair the M2 function on protons pumping, but blocks the binding of the M2 
inhibitors to the ion channel.  
NP 
NP encapsidates the segmented RNA and binds to the RdRP to form 




body domain, and folds into a crescent-shape. The exterior surface of the head and body 
domain has a single strand RNA binding groove. The tail loop (residue 408-419) of the 
NP protein inserts into the loop-binding cavity of a neighboring NP monomer, and self-
associates into the oligomeric structure. The loop-binding cavity is considered to be a 
potential target for anti-influenza drugs [93,129]. A salt bridge between Arg-416 in the 
tail loop and Glu-339 in the neighboring NP monomer plays an important role in the NP-
NP interaction and viral replication [130].  
The nuclear localization sequence (NLS) on the NP mediates the import of the 
vRNP complex into the nucleus in the influenza life cycle. The NP monomer contains 
three NLS: NLS1 is located at residues 3-13 at the N-terminus, NLS2 is located at 
residues 90-121, and NLS3 is located at residues 198-216 [131,132,133].  
NP is a major component of the influenza vRNP, which is responsible for the 
transcription and replication of viral RNA. A recent report revealed that NP is not 
necessary for the initiation or termination of viral transcription and replication, but a 
cofactor of RdRP for elongation during the replication of the full-length viral genome. 
The recruitment of NP to newly produced vRNA is mediated unidirectionally through NP 
oligomerization, and this processing is independent of RNA binding [129]. 
RNA-dependent RNA polymerase 
The influenza virus RNA-depedent RNA polymerase (RdRP), a heterotrimer of 
three subunits (PB1, PB2 and PA), with a combined mass of around 250 kDa, is 
resposible for viral RNA transcription and replication. The PA subunit, a 80 kDa subunit,  




domain interacts with the PB1 subunit. The crystal structure of both the N-terminal 
endonuclease activity domain (PAN: residual 1-197 aa) and C-terminal PB1 binding 
domain (PAC residual 237-716 aa) have been solved [134,135,136,137]. Recent strucural 
studies of PA have indicated that the N-terminal 209 amino acids are resposible for an 
endonuclease activity of the virus polymerase [134]. Manganese (Mn) ions play 
important roles in stabilizing the active site [134].  The crystal structure study 
demonstrated PA is a type II restriction endonuclease [134]. The active sites of PA bind 
to two manganese ions, following two-metal-dependent endonulease pattern. Two active 
sites involved in Mn++ binding were identified: Glu-80 and Asp-108 are critical for Mn1 
binding and His 40, Asp 108 and Glu 109 important for Mn2 binding [134,136] (Figure 
1.2). 
The synthesis of viral mRNA utilizes the short capped primers derived from the 
host cells using a ‘cap-snatching’ mechanism: PB2 binds to the cap of the cellular pre-
mRNA, the endonuclease activity of PA cleaves onto the 10-13 nt downstream the cap 
and then PB1 takes the short capped mRNA as the primer to synthesize the viral mRNA. 
The “cap” prevents the viral mRNA from degradation by exonuclease and promotes the 
viral mRNA translation [134,138,139,140]. The negative-sense vRNA is the template for 
both mRNA and cRNA, but cRNA does not consist of 5’-cap or 3’- poly(A) tail. 
Meanwhile, unlike mRNA transcription,  the replications of cRNA and vRNA are primer-
independent [141].  
C-terminal PA binds to the N-termial PB1 (PB1N) in the RdRP complex. The 
structure of PAC-PB1N demonstrated that the PA residues 257-716 contain a motif to 




showed that the first 12 amino acids of the N-terminal PB1 form the interaction interface, 
and could be enough for PA binding [142]. 
Some important residues on the PA have been identified for their biological 
functions. The mutation T157E dramatically decreases the RNP replication activity [143]. 
Ser-186 of the N-terminal PA plays an important role in the polymerase activity of the 
2009 swine-origin pandemic H1N1. While residual G186 is more common for most of 
the influenza virus PAs, PAs possessing S186 is more fit for PB1 and PB2 in the 2009 
swine-origin pandemic H1N1 strain, resulting in a high RdRP activity [144]. The PA 
subunit is also involved in the regulation of the RdRP activity in some temperature 
sensitive strains, and residue 114 is critical for stability under the thermal stress [145]. 
PB1 is another subunit of RdRP, which is responsible for the polymerase 
activities of viral mRNA transcription and cRNA and vRNA replication. Four conserved 
motifs have been identified in PB1, which are responsible for the RNA-dependent RNA 
polymerase activity and RNA-dependent DNA polymerase activity: A (residues 298-
311), B (residues 399-412), C (residues 438-453) and D (residues 474-484) [146,147]. In 
addition, motifs pre-A and E are also responsible for the RNA-dependent RNA 
polymerase activity [148]. However, the structure of the catalytic sites have not yet been 
resolved yet, and detailed information about the motifs is unclear [56]. The C-terminal 
region (residues 678-757) of PB1 binds to the N-terminal region (residue 1-37) of PB2 
(Figure 1.2).  
A small helix containing the residues PTLLFLK of PB1 N interacts with a cleft 




complex between the domains of PB1 and PA. The amino acid residues on the PAC and 
PB1N interface are highly conserved among all subtypes of influenza A viruses [135,137]. 
PB2 has been featured in binding the “cap” of host pre-mature mRNA to its 
binding domain (residue 318-483), and facilitating the cleavage of the downstream 
mRNA by PA following the “cap-snatching” mechanism [134,138,139,140]. A RNA-
binding domain is located at residues 535-684. The PB2 contains at least one NLS at C-
terminus, which binds to the cargo adaptor importin-! and mediates the import of the 
vRNP into the nucleus [149]. The crystal structure of the PB2-human importin-!5 
complex displayed the presence of NSL: 736-KRKR (X)12K-752 [150,151]. Another 
putative binding domain of PB2 is located on residues 535-684, which is next to the 
NLS-containing domain, and has been identified as an RNA binding domain [152,153] 
(Figure 1.2).  
Position 627 in PB2 has been recognized as a key host range determinant: 
glutamic acid is generally found at residue 627 in the avian virus isolates, whereas almost 
all human isolates present a lysine at this position. The PB2 627K has been identified 
from most human H1N1 and H3N2 virus strains. HPAI H5N1 carrying 627K showed 
enhanced virulence in humans, and caused a systemic and lethal infection in mice 
[154,155].  The virus bearing the PB2 K627 residue can replicate efficiently in the URT 
of humans at 33°C. In contrast, the avian-like viruses containing E627 in the PB2 
preferentially replicate in the intestinal tract at the temperature of 41°C [155]. Therefore, 
position 627 in the PB2 is a temperature sensitive determinant for viral replication in 




Another important mutation D701N in the PB2, has been identified from HPAI 
H5N1 isolates from infected humans, and is believed to be associated with the enhanced 
virulence when the avian viruses adapted in mammal hosts [156]. D701N modulates the 
transmissibility of the influenza virus in mammal hosts for the lack of E627K. D701N 
may enhance the viral replication by facilitating the import of PB2 into the nucleus of 
human cells, but not avian cells [157]. Interestingly, both E627K and D701D mutations 
have been discovered from the PB2 protein of the novel avian-origin H7N9 isolates, 
which suggest that these two mutations are critical for the adaptation of the avian virus to 
replicate in human cells [38]. The 2009 pandemic H1N1 strain does not contain K627 or 
N701 in the PB2 gene, but is replicated and transmitted efficiently in humans. It has 
recently been reported that the residue R591 in the PB2 protein is responsible for the 
enhanced replication of pandemic 2009 H1N1 in mammals in the absence of K627 and 
N701 [158]. 
NS1 
The non-structural protein 1 (NS1) of the influenza A virus has been identified to 
be the protein with multiple accessory functions during viral infection, and virulence 
determinant. Phylogenetic analysis of the influenza A virus NS1 amino acid sequences 
showed that they can be divided into two groups: allele A and allele B [97,159]. The NS1 
in all human, swine, equine, and most of the avian influenza viruses are allele A, while 
the NS1 in other avian influenza virus belongs to allele B [159].  
NS1 protein contains 230-237 amino acids, depending on the strains, and has a 
molecular weight around 26 kDa. According to the biological function, NS1 can be 




(residues 84-207) effector domain (ED), which are connected by a linker. The structure 
of the 20 amino acids on the C-terminal domain may be naturally disordered [160]. The 
RBD domain is reported to be a homo-dimer made up of two monomers with three !-
helices [161]. Dimerization is critical for dsRNA binding, and several residuals 
contribute to this RNA-protein interaction [162], amongst them, two basic residues Arg-
38 and Lys-41 are critical to the RNA-binding activity [160]. Structural studies indicated 
that the ED domain may homodimerize independently, and that the monomer contains 
three !-helices and seven "-stands [163]. However, the latest NS1 protein x-ray 
structural study of HPAI H5N1 virus suggested that the NS1 formed multimers instead of 
separated homodimers, and that three NS1 chains can interact together to form a “tubular 
organization” [164]. It seems that this model may explain why NS1 can interact with 
dsRNA and imprtin-! by its RNA-binding domain, simultaneously [164]. 
There are generally two nuclear localization sequences (NLS1 and NLS2) and one 
nuclear export sequence (NES) on NS1: 35-41 are highly conserved amino acids for 
NLS1 (R38 and K41 are critical amino acids for importin-# binding and translocation), 
and NLS2 (with basic amino acids at position 219, 220, 224, 229, 231 and 232) is 
deficient in some of the strains [165]. A newly identified nucleolar localization signal 
(NoLS) overlaps with NLS2, and residue Lys-221 was identified as the critical residue 
for NoLS [166]. Newly synthesized NS1 is imported into the nucleus by binding to 
cellular importin-! [165], while it has been reported that NS1 also has a potential nuclear 
export signal (NES) responsible for the nucleo-cytoplasmic transportation. Leu-144 and 




 NS1 interacts with multiple host factors through its binding sites on the protein 
during viral infection [160] (Figure 1.3). One of the major functions of NS1 is to 
antagonize the innate immune response of the host during influenza infection, especially 
to limit the production of interferon beta (IFN-") induction by both pre-transcription and 
post-transcription. In the pre-transcription process, NS1 can inhibit the activation of 
transcription factors on the IFN-" signaling pathway, such as IRF-3, c-Jun/ATF-2 and 
NF-#B, by binding to dsRNA [168,169]. In the post-transcription process, NS1 can block 
cellular mRNA maturation by binding to the 30 KD cleavage and polyadenylation 
specific factor (CPSF30) and poly(A)-binding protein II (PABPII) [170,171].  
The study of the mechanism found that NS1 also directly binds to the cytosolic 
sensor RIG-I, forming a complex, and inhibiting its functions of inducing the expression 
of IFN-" [172,173,174]. The mechanism revealed that TRIM25 activates RIG-I by 
ubiquitinating RIG-I N-terminal CARD domain; while NS1 inhibits the ubiquitination of 
the CARD domain and blocks type I IFN production [175]. Residues 200 and 205 of the 
NS1 have been identified as being critical for the antagonistic activity of type I IFN in the 
ferret model [176]. 
A recent study has shown that avian H5N1 NS1 disrupts the IFN-" signaling by 
decreasing STAT1, STAT2 and STAT3 and limiting the phospho-STAT2 nuclear 
translocation [177]. Additionally, ISG15, a type I IFN induced, ubiquitin-like molecule, 
has been demonstrated to target influenza NS1 and protect the cells from viral infection; 
and the ISGylation of NS1 can prevent the nuclear import of the NS1 protein. Lys-41 has 




ISG15 [178]. Herc5, an ISG15 E3 ligase, could catalyze the conjugation of ISG15 onto 
the NS1 protein [179].     
NS1 can also regulate some other important host cell signaling pathways during 
influenza virus infection, such as the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, 
which plays the central role in a number of functions in the host cells, such as anti-
apoptosis, cell proliferation and cytokine production [180,181,182,183]. PI3K is a 
dimeric lipid kinase consisting of a regulatory subunit p85" and a catalytic subunit p110 
[184]. Akt, a serine/threonine protein kinase, is a downstream PIP3-binding effector of 
PI3K. In the early phase, the attachment of the virus to the cell surface transiently induces 
PI3K signaling [185]. In the later phase, PI3K is activated by NS1 and the influenza viral 
RNA through the stimulation of the cytosolic receptor, RIG-I, promoting the production 
of type I IFN [186,187]. NS1 activates PI3K signaling by directly binding to inter-HS2 
(iSH2) domain of the regulatory subunit p85 of PI3K, and prevents the premature 
apoptosis of the infected cells, facilitating the viral replication [188,189]. It has been 
reported that NS1 can preferentially interact with phosphorylated Akt in the nucleus, 
altercating Akt anti-apoptotic activity [190].  
 NS1 can also interact with a number of host proteins to overcome the innate 
protection of the host, and facilitates viral replication during infection. NS1 enhances the 
viral protein synthesis by binding the eukaryotic translation initiation factor eIF4GI to the 
viral mRNA 5’ untranslated region [191]; meanwhile, it limits the expression of the host 
antiviral gene [137]. It has been also reported that NS1 can suppress the host antiviral 
function by blocking 2’-5’-oligoadenylate synthetase (OAS) [192] and serine/ threonine 




Some species-specific and strain-specific studies were carried out to understand 
the different effects of NS1 on multiple viral and host functions. NS1 from the human 
influenza virus has the typical C-terminal RSKV motif, while the motif of avian influenza 
virus is ESEV at the C-terminus. This four-amino acid domain is a species-specific 
virulence domain [194]. The typical avian influenza NS1 ESEV is also a PDZ-binding 
motif (PBM), which has an anti-apoptosis function during viral infection through NS1-
PDZ interaction to inhibit the proapoptotic function of Scribble [195]. However, the NS1 
ESEV motif doesn’t have a significant effect on the virulence of the highly pathogenic 
avian influenza virus A/Vietnam/1203/04 (H5N1) in the host [196]. Glycine 184 in the 
NS1 of A/PR/8/34 is reported to dramatically affect the virulence through an unclear 
mechanism other than through IFN signaling [197]. Different HP H5 and H7 NS 
segments were placed into the background of HP H7N1 (A/FPV/Rostock/34) to generate 
reassortant influenza viruses, which showed that the host range, viral replication, host 
type I IFN response and apoptosis were affected by the origin of the NS segment [198]. 
Comparing NS1 of the highly pathogenic H7N1 (A/ostrich/Italy/984/00) to its low 
pathogenic precursor H7N1 (A/chicken/Italy/1082/99) showed that the difference is only 
two mutations in NES, and a 6-amino acid truncation at the C-terminus resulted from the 
third mutation by introducing a new stop codon. The cytoplasmic accumulation of NS1 is 
responsible for the enhanced pathogenicity of HP H7N1 [199]. The 2009 pandemic 
H1N1 NS1 encodes only 219 amino acids with 11 amino acids truncation at the C-
terminal domain, resulting in the loss of the NoLS and PABP II binding domain. The 
restoration of those 11-amino acid did not enhance the viral replication, but did increase 





NEP, a 121 amino acid polypeptide, is produced from a spliced form of segment 8 
mRNA [201]. NEP was considered to be non-structural protein, and named as NS2. 
However, NEP was later found to interact with the M1 protein and exists in the viral 
particles, and thus, NS2 was renamed nuclear export protein (NEP) [202,203]. NEP 
consists of an N-terminal domain (residues 1-53) that is sensitive to protease, and a C-
terminal domain (residues 54-121) that is resistant to protease [204]. The C-terminal 
domain contains two !-helices, C1 (residues 64-85) and C2 (residues 94-115) [205]. 
The functional study of NEP revealed that it is an adaptor protein, binding to both 
RNPs and the cellular protein Crm1, and mediates the nuclear export of newly produced 
RNP. NEP interacts with Crm1 via the nuclear export signal (NES), which is located at 
the N-terminal domain at residues 12-21 [204,205]. W78 was demonstrated to be critical 
for the binding of the M1 protein [206]. The recent studies demonstrated that NEP is 
important in modulating the accumulation of viral vRNA, cRNA and mRNA during 
infection. The function of NEP on the regulation of viral RNA transcription and 
replication plays an important role in the adaptation of the HPAI H5N1 influenza virus to 
mammals [207]. In addition, NEP contains the motifs for phosphorylation and 
SUMOylation, but the functional importance is still unclear [202,208,209]. 




Entry into the host cell and uncoating 
In the first stage of viral entry, influenza A virus surface glycoprotein HA 
recognizes and binds to the sialic acid (SA) receptors on the cell surface with its receptor-
binding sites (RBS). Another surface glycoprotein NA facilitates HA in accessing the 
receptors in the respiratory tract, by cleavage of the glycans of the mucus [84]. The HA-
receptor binding, in turn, initiates receptor-mediated endocytosis, and the virus enters the 
endosome of the host. Influenza viruses utilize clathrin-mediated endocytosis and other 
mechanisms, such as caveolae,  nonclatherin/noncaveolae pathway and 
macropinocytosis, in this step [210]. The low pH of the endosome triggers a 
conformational change in the HA, and the HA2 fusion peptide is exposed. This fusion 
peptide inserts itself into the endosomal membrane, bringing the viral lipid-bilayer 
membrane and endosomal membrane close to each other, and fusing the membranes 
[141]. However, the details about this membrane fusion process are unclear.  
In the endosome, the protons flow into the interior of the virions through the M2 
ion channel, creating a low pH environment, and dissociating the vRNPs from the M1 
protein [141]. This process is called uncoating [211]. In the cytoplasm, the vRNPs are 
imported into the nucleus through the host importins, which recognize and bind the NLS 
of the NP protein. A recent study revealed that the interactions between the 
unconventional NLS1 (residues 3-13) in the NP, and the cellular import cofactors 
importin-!1, !3 and !5, are critical to the nuclear localization of vRNP. NLS1 may 





mRNA transcription and genome RNA replication 
Host RNA polymerase II activity is important to viral mRNA synthesis. The 
cellular mRNAs acquire the 3’ end poly(A) tails by cleavage at the polyadenylation 
signal (AAUAAA). However, influenza viral genomic RNA does not have this sequence, 
but viral mRNA generates a poly(A) tail following a “stuttering” mechanism: RdRP 
polyadenylates the viral mRNAs by moving back and forth at a stretch of five to seven 
uridine residues on the 5' ends of the viral RNA templates [213]. The viral mRNAs are 
exported into the cytoplasm and translated into viral proteins by ribosomes.  
The polymerase activity of PB1 is responsible for both transcription and 
replication. vRNA replicates with steps of (-)vRNA!(+)cRNA!(-)vRNA in a primer-
independent manner [141]. However, the mechanism of vRNA replication is still unclear. 
A internal initiation model has been proposed for vRNA repliaction recently [214]. In the 
(-)vRNA!(+)cRNA step, the host RNA-specific rinonucleotidyltransferases add one 
nucleotide to the 3’-end of cRNA and initates the full-length copy of (-)vRNA. In the 
(+)cRNA!(-)vRNA step, the nucleotides AG were synthsized using the nucleotides UC 
on the 3’-end of cRNA by RdRP, and AG is taken as the primer for the full-length copy 
of (+)cRNA. The RdRP cannot form the stable intiation complex until it reads through 
the UUU of cRNA and UUUU of vRNA at their 3’-ends [214]. 
In the vRNP complex, NP directly binds to the PB1 and PB2 subunits; NP also 
binds to the RNA in a sequence-independent manner; and NP is essential for the full-
length genome replication of the influenza A virus. However, the role of NP in 
transcription and replication has long remained unclear. One latest study has revealed that 




genome, but has no effect on the initiation or termination of transcription and replication. 
The recruitment of NP to newly produced vRNA is mediated through NP oligomerization 
in a “tail loop first” direction in an RNA binding independent manner [129]. 
The recent study demonstrated that the differences in the importin-! isoform 
specificity affect the efficiency of viral RNA transcription and replication in different 
hosts: PB2 and NP of the human-like viruses prefer importin-!7, whereas PB2 and NP of 
the avian-like viruses perfer importin-!3. Interstingly, the 2009 pandmic H1N1 showed 
both importin-!7 and importin-!3 specificities [215]. Another study showed that the 
substitutions D701N in PB2 and N319K in NP increased the binding affinity of these two 
proteins to importin-!1 in the mammalian cells, but had no effect in avian cells [157]. 
The negative-sense small viral RNAs (svRNAs) have been identified as an 
important regulatory enhancer of viral polymerase activity. svRNAs are produced from 
the viral positive-sense genomic RNA, and bind to the PA subunit. In the nucleus, 
svRNAs promote the viral genome replication and maintain the RNA segment balance 
[216]. 
The M2 and NEP proteins are produced from the spliced forms of segment 7 and 
8 mRNA, respectively; and utilize the host splicing machinery in the nucleus. NS1 is 
translated and transported into the nucleus, and facilitates the splicing of viral mRNA by 
binding to and re-localizing the splicing components [217]. NS1 also blocks the export of 
cellular mRNAs by binding to CPSF 30 and PABPII, and preventing the maturation of 
cellular mRNAs [170]. 
Recent studies have shown that NEP plays a critical role in regulating the 




Furthermore, M16I and other mutations in the NEP of human H5N1 isolates can enhance 
the polymerase activity of the avian H5N1 virus carrying 627E in PB2. The result suggest 
that adaptive mutations on NEP can compensate for the lack of 627K in PB2, and 
increase the viral replication of avian viruses in human cells [219]. 
The export of vRNP 
Newly produced vRNP, M1 and NEP proteins are transported to the nucleus. The 
C-terminus of M1 binds to the vRNP through NP, and the N-terminus of M1 binds to the 
C-terminus of NEP with its NLS. The N-terminus of NEP binds to Crm1 through its 
NES, along with GTP-bound Ran (RanGTP), a cofactor of Crm1 [220]. (Crm1–
RanGTP)–NEP–M1–vRNP (also been called the “daisy-chain” complex) mediates the 
export of vRNP to the cytoplasm [204]. However, a study has shown that without M1 and 
NEP, NP can directly interact with Crm1 and mediate the export vRNP from the nucleus 
[221].  
The M1 protein plays important roles in the export of vRNP, in addition to 
forming the complex with vRNP and NEP. In the nucleus, the binding of M1 to the 
histones may be associated with releasing vRNP from the nuclear matrix [111]. After 
transportion into the cytoplasm, the binding of M1 to vRNP prevents the reentry of vRNP 
into the nucleus [114].   
Recent studies identified several other host factors that aid or inhibit the export of 
the vRNP complex from the nucleus. Serum- and glucocorticoid-regulated kinase 1 
(SGK1) has been identified as a host factor playing an important role on the nuclear 




elucidated [222].The SUMOylation of M1 at K242 by the SUMO-conjugating enzyme 
Ubc9 is critical to the interaction between M1 and vRNP to form the M1-vRNA complex. 
Without SUMOylated M1, vRNP export is inhibited, and the viral protein and vRNP are 
accumulated in the cells [223]. The heat shock protein 70 (HSP70) has been identified as 
a host factor inhibiting the nuclear export of vRNP at both 37°C and 41°C. HSP70 
interacts with the vRNP complex, and disassociates M1, but not NEP from vRNP, so that 
it blocks the export of vRNP [224].  
Multiple approaches have been used to search for the host factors associated with 
influenza A virus life cycles. Several novel host factors that may be involved in the 
transport of vRNP from the nucleus to the cytoplasm, such as AKT1, mouse double 
minute 2 homolog (MDM2) and I-kappa- B kinase epsilon (IKBKE), have been 
identified by an RNAi-based genome-wide screen. However, the functions of those 
factors in the influenza life cycle need to be further elucidated [225].   
Assembly and budding 
The surface proteins HA, NA and M2 are translated by ribosomes associated with 
the rough endoplasmic reticulum (ER), and processed by post-translational modifications, 
such as glycosylation at the Golgi apparatus, and then transported to the plasma 
membrane via the cellular secretory pathway [141]. The study of mutated and truncated 
M2 suggests that the location of M2 in this process is crucial to the formation of viral 
particles in that M2 may control the budding process [226]. The NEP–M1–vRNP 
complex exports into the cytoplasm, mediated by host Crm1 [160]. The M1 protein alone 




the HA and NA concentrate on the plasma membrane with higher cholesterol 
components, and form a lipid raft microdomain, or bud [226]. A bud neck emerges at the 
boundary of the lipid raft and the plasma membrane by a line tension. M1 recruits small 
quantities of the proton ion channel M2 molecule for “membrane scission”, where 
transmembrane M2 molecules accumulate at the bud neck, and cleave the viral particles 
from the cell membrane [226]. Therefore, unlike some other enveloped viruses, the 
influenza A virus evolved the strategy to utilize its own molecule M2 ion channel for 
budding, instead of the classic endosomal sorting complex required for the transport 
(ESCRT) pathway [226].  
Packing all 8 genomic segments with each into the virions is important for 
producing an infectious particle [226]. However, the packaging mechanism is still in 
being debate, though there are two main models: the incorporation of a full genomic 
complement; and a model which the segments are randomly selected but packaged in 
sufficient numbers to ensure the newly produced virions are properly formed [227]. In a 
recent study, the copy number of each RNA segment within a single virus particle was 
counted using the method based on multicolor single-molecule fluorescent in situ 
hybridization (FISH) [228]. The result demonstrated that, for the majority of these 
detected wild type viruses, one virus particle only possessed one copy of each RNA 
segment, which supports the first RNA packaging model [228]. The packaging signals of 
the influenza virus located in the coding and non-coding regions have been well mapped 
[229,230,231]. The sorting of the influenza virus RNA segment occurs, more likely, after 




After the NEP–M1–vRNP complex associates with the plasma membrane, the 
membrane fuse and release the progeny virions [227]. However, the mechanism of this 
step is not fully understood. In the budding process, the cleavage of the sialic acid and the 
adjacent sugar by NA is critical, as HA and NA are both glycoproteins binding to the 
sialic acid of the host surface membrane. The lipid bilayer envelope of the influenza virus 
is derived from the host plasma membrane in the budding process [141]. A recent study 
showed, after the vRNP export, that the binding of NEP to the cellular ATPase F1Fo 
localizes in the cytoplasm, and is crucial to the efficient budding of the influenza virus 



















Table 1.1. Influenza A virus genome segments and genes. 
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Table 1.2. The strain-specific functions of NS1. 
Host factors  
The motif  or 
critical residues 
on NS1 





PDZ domain-NS1 interaction is associated with the virulence. 
Human-like viruses generally carry a “RSKV/KSEV” motif, 
whereas avian-like viruses carry a “ESEV” motif, the 2009 
pandemic H1N1 virus has a truncation of the motif on NS1 
[22,195,233]. 
CPSF30 
Residues 103, 106, 
and 144-188 
NS1 blocks CPSF30-mediated cellular pre-mRNA processing. 
However, the 2009 pandemic H1N1 NS1 cannot bind to CPSF30 
[160,234]. An HPAI H5N1 and a LPAI H5N2 NS1 have different 
effect on pre-mRNA processing and mRNA translation [235].  
PABP II Residues 223-230 
NS1 blocks PABPII-mediated cellular pre-mRNA processing. 
The 2009 pandemic H1N1 NS1 is lack of this function as it has an 
11-amino acid truncation at the C-terminus [160,236].  
Host factors 
involved in IFN- 
! induction 
RNA-binding domain 
and other residues 
NS1 from different H1N1 and H3N2 strains inhibit IFN response 
with different efficiencies and mechanisms [237].  
PI3K (p85!) 
Residues 89,164 and 
167 
The NS1 of a mouse-adapted rPR8 strain stimulated the activation 





Residue 92 has been identified as a virulence marker in HPAI 
H5N1. The presence of glutamic acid at this position is associated 





Figure 1.1. The structure of the influenza A virus. The influenza A virus is an enveloped 
single-stranded negative-sense RNA virus, belonging to the family Orthomyxoviridae. The 
influenza A virus contains a genome with 8 RNA segments, which encode at least 12 identified 
proteins. RNA segment 1, 2 and 3 encode three RNA-dependent RNA polymerase (RdRP) 
subunits: polymerase basic proteins PB2 and PB1 and polymerase acid protein PA, respectively. 
Segment 4, 5, and 6 encode hemagglutinin (HA), nucleoprotein (NP) and neuraminidase (NA), 
respectively.  Segment 7 encodes matrix protein 1 (M1) and M2 protein. Segment 8 encodes the 
non-structural protein 1 (NS1) and nuclear export protein (NEP; also known as NS2). In addition, 
PB1-F2 and N40 are translated from PB1 mRNA by leaky scanning, and PA-X is translated by 
the ribosomal frameshift of the PA gene. PB1, PB2 and PA are subunits of RdRP. NP packages 
the segmented viral RNA and binds to RdRP to form the ribonucleoprotein (RNP) in the viral 
particles. 






Figure 1.2. The structure of the domains of influenza A virus polymerase complex. The 
heterotimeric polymerase composes of PA, PB1 and PB2 subunits. The PA subunit contains an 
endonuclease activity domain (residues 1-197) at the N-terminus, which is responsible for the 
cleavage of the “cap” from the cellular pre-mRNA and a PB1 binding domain (residues 257-716). 
PA binds to two manganese ions to its active sites, following two-metal-dependent endonulease 
pattern. Two active sites involved in Mn++ binding were identified: Glu-80 and Asp-108 are 
critical for Mn1 binding, and His 40, Asp 108 and Glu 109 are important for Mn2 binding. The 
PB1 subunit binds with PA subunit via first 15 N-terminal amino acids, and interacts the PB1 N-
terminal binding domain (residues 1-35) through its PB2 binding domain (residues 685-757). 
Four conserved motifs have been identified in PB1, which are responsible for the RNA-dependent 
RNA polymerase activity and the RNA-dependent DNA polymerase activity: A (residues 298-
311), B (residues 399-412), C (residues 438-453) and D (residues 474-484). In addition, motifs 
pre-A and E are also responsible for the RNA-dependent RNA polymerase activity. The PB2 
subunit contains a cap-binding domain (residues 318-483) and a RNA-binding domain (residues 
535-684). Two nuclear localization sequences (NLS) are located on the nuclear import domain at 
the C-terminus of the PB2. 






Figure 1.3. The interactions of NS1 with host factors. NS1 (blue) is a nonstructural protein 
possessing 230-237 amino acids depending upon the strain. NS1 can be divided into an N-
terminal RNA-binding domain (RBD), effector domain and C-terminal disordered “tail”. NS1 
consists of two nuclear localization sequences (NLS1 and NLS2) which are located at RBD and 
C-terminus, and a nuclear export sequence (NES). A nucleolar localization sequence (NoLS), 
which is overlaps with NLS2 at the C-terminus, has been found in some strains. Arg-38 and Lys-
41 are important residues for RNA-binding, as well as inhibiting the RIG-I-mediated induction of 
IFN- ß by directly binding to it. NS1 is a multifunctional protein which contains several motifs to 
interact with host factors, including the poly(A)-binding protein I (PABPI), p85!, CPSF30, 
eIF4GI, hStaufen, PKR, poly(A)-binding protein II (PABPII), p15, Crk/CrkL and PDZ domain-
containing proteins. 






Figure 1.4. The life cycle of the influenza A virus. The surface glycoprotein HA binds to the sialic acid 
receptors on the cell surface, which initiates the receptor-mediated endocytosis, and then the virus enters 
the endosome. The low pH of the endosome triggers a conformational change in HA2, and exposes the 
fusion peptide, which triggers the viral envelope and endosomal membrane fusion. The proton flows into 
the virus through the M2 ion channel, resulting in the dissociation of vRNP from M1. In the nucleus, the 
synthesized viral mRNA utilizes the short capped primers derived from the host cells following a ‘cap-
snatching’ mechanism, and the vRNA replicates with steps (-) vRNA!(+) cRNA!(-) vRNA. Newly 
syntheszed viral proteins needed for replication and transcription are imported into the nucleus. The vRNPs 
are exported to the cytoplasm for packaging by binding with M1 and NEP. HA, NA and M2 are post-
translationally modified and transported to the plasma membrane by the trans-Golgi secretory pathway. 
Budding occurs by the cleavage of the M2 on the lipid raft neck, and then the receptor-destorying activity 
of the NA releases the new virions from the host cells.  




Chapter 2: Influenza Vaccines 
Introduction 
Vaccination is the main strategy for prevention and control of influenza in 
humans. The human influenza virus was first isolated in 1933, which led to the 
characterization of the virus and development of vaccines against influenza [240]. In 
1945, the first whole-inactivated influenza virus vaccine was licensed in the US [241]. 
The amino acid mutations occur at relatively high frequencies in influenza viruses 
due to the error-prone property of the viral RdRP. The accumulation of small changes in 
the HA and NA antigenic sites, known as antigenic drift, may result in a new strain that 
circumvents the pre-existing immunity in humans, and causes seasonal influenza 
epidemics [16,17,242]. Current trivalent influenza vaccines consist of influenza A 
(pH1N1), influenza A (H3N2), and influenza B viruses. The World Health Organization 
(WHO) and the US Public Health Service (PHS) are responsible for the reference strains 
recommendations. The reference strains for vaccines are determined according to the 
surveillance data from epidemics around the world, and those with the highest likelihood 
of circulating in the coming winter season [243].  
The egg-based inactivated trivalent vaccines against seasonal flu have long been 
used for seasonal flu from 1945 in the US. The egg-based live-attenuated trivalent 
vaccines were licensed in 2003 in the US, although the development started in the 1960s 
[243]. In November 2012, the first cell-culture based vaccine against seasonal flu was 
licensed by the US Food and Drug Administration (FDA) [244]. The latest vaccine, 
FluBlok, is a trivalent recombinant vaccine produced from insect cells using the 




effectiveness of the vaccines depends on the age and immune competence of the person 
being vaccinated, and the antigenic relatedness of the vaccine strains to the circulating 
ones. The effectiveness may reach 70-90%, if the relatedness is high. However, the 
vaccine is generally poorly effective among aged and immunocompromised persons 
[243].  
For the seasonal epidemics, a predicted vaccine strain may occasionally not match 
with the circulating strain, leading to suboptimal protection [246]. However, seasonal 
vaccines cannot induce protection against a pandemic influenza outbreak. Therefore, 
developing a strategy for the quick generation and distribution of pandemic vaccines is a 
huge challenge for pandemic outbreaks [246,247]. Compared with antigenic drift, 
antigenic shift may cause the dramatic changes in HA, and generate the new influenza 
virus strains.  If the new strain infects humans with completely new antigens, and no one 
has the pre-existing immunity against it, the strain may cause a new human pandemic 
[248].  
The outbreaks of HPAI and LPAI have resulted in the depopulation of flocks and 
major economic losses in the poultry industry worldwide. The increasing number of 
reports on the direct transmission of the avian influenza viruses (such as H5N1 [249,250] 
and H7N9 [251,252]) to human highlights the threat of HPAI and LPAI to public health. 
In recent years, vaccination has become a key strategy to provide protection to high-risk 
birds and reduce the possibility of transmission among birds and/or to mammals 
[253,254]. Currently, there are three types of avian influenza vaccines (AIVs) licensed 
worldwide: inactivated whole AIV vaccine, recombinant fowlpox virus-vectored vaccine 




an H5 HA gene insert [255].  
However, the limitations of the currently licensed vaccines call for the more 
effective and efficient vaccines. Several novel vaccines, or called “next generation 
vaccines”, have been developed on the basis of new technology, and some of them are 
being tested in clinical trials [256].    
Inactivated vaccines 
The licensed inactivated trivalent influenza vaccines have been applied in the US 
since 1945 [243]. These vaccines are amplified in eggs and purified, and then chemically 
inactivated with formalin. Generally, detergent, such as Triton X-100 is further added to 
make the viral surface antigens soluble. Furthermore, the detergent mediated disruption 
(‘splitting’) of influenza viruses reduces the reactogenicity, while retaining the 
immunogenicity of the viral proteins. Since the 1970s, the detergent has been applied to 
‘split’ the vaccines in most of the manufacturing, although the whole-virus vaccines are 
highly effective [257,258]. 
In adults, a single dose of 15 µg of HA of the egg-based inactivated trivalent 
vaccines is sufficient to elicit an acceptable level of antibodies. Whereas children 
generally need two doses of the inactivated vaccine to produce a protective level of 
antibody as they are naïve to the viral antigen [257]. In April 2007, the first vaccine 
against the H5N1 avian influenza in humans was licensed in the US by FDA [259]. Two 
doses of 90 µg of HA of this vaccine with intramuscular injections provided the patients 
enough protection against H5N1 in the clinical trial [260].  However, it is difficult to 




A/Puerto Rico/8/34 (PR8) (H1N1) virus is the “master” donor of inactivated 
influenza vaccines. The vaccine generated is typically a “6+2” reasortant virus, in which 
6 internal genes (PB1, PB2, PA, NP, M and NS) are from PR8, and two glycoprotein 
genes are from the circulating strains. Co-infecting the eggs with the wild type strain and 
the high yielding virus strain PR8 is a classical approach to generating the reassortant 
virus. The viruses are collected and propagated in eggs with the addition of anti-PR8 
antiserum that can eliminate the virus with PR8 HA or NA [262].  
The reverse genetics technology is well developed to realize the fast generation of 
the recombinant virus without co-infection and screening. Transfection of the cells with 
plasmids containing RNA polymerase I/II transcription cassettes and influenza genome 
cDNA fragments, leads to the viral RNA synthesis by cellular RNA polymerase I, and 
viral mRNA synthesis by cellular RNA polymerase II. In this way, the reassortant 
influenza virus can be generated completely from cloned cDNA [263]. 
The trivalent inactivated influenza vaccine (TIV) is administered intramuscularly 
or intradermally by injection. It is approved for use among persons 6 months and older. 
The administration of TIV, although inducing serum antibodies IgG, does not elicit the 
nasal mucosal neutralizing antibody IgA, which is critical to the protecting of the upper 
respiratory tract in humans [264,265]. 
Flucelvax® is the first cell-culture based influenza vaccine licensed in the US. 
Flucelvax® is produced from the MDCK cell-culture, and then purified, chemically 
inactivated and disrupted by detergent. The trivalent vaccine contains three influenza 
strains for seasonal flu as an egg based TIV, and is administered intramuscularly or 




mammalian cell lines for large-scale vaccine production, and may greatly decrease the 
requirement for the embryonated eggs in TIV manufacturing [267]. The human influenza 
virus strains generally produce mutations when adapting in eggs, which may affect the 
antigenicity of the egg based vaccine; whereas Flucelvax® remains the amino acids 
unchanged in the cell culture. Furthermore, Flucelvax® is egg-free, and can be safely used 
by the people allergic to egg proteins [259,266].  
Inactivated whole-virus vaccines are also made up the majority of currently 
licensed influenza vaccines in poultry farms. The seed strains for inactivated vaccines are 
generally LPAI isolates from outbreaks in poultry, or from the surveillance of wild birds 
[268,269]. Similar to human vaccines, the wild-type donor avian vaccine is used to co-
infect the egg embryos with an egg-adapted stain, and serially propagated in eggs to 
generate a reassorted seed strain with the appropriate antigens and high virus yield 
[268,269].  
In the US, inactivated vaccines were mainly applied to protect turkey breeders 
against different subtypes of the swine influenza viruses. For example, approximately 2.6 
million doses of inactivated vaccine were used to immunize turkeys against swine H1 
influenza during 2006 in the US [270]. 
Although inactivated vaccines (“killed virus”) are safe to the host, and stimulate 
immune responses in different species of poultry, the usage of inactivated vaccines in 
poultry still has several limitations. Differentiating infected from vaccinated animals 
(DIVA) is difficult with inactivated whole-virus vaccines, as the strategy requires a 




Furthermore, the vaccination of poultry is heavily time-consuming, requiring each bird to 
be vaccinated individually with a high labor cost for parenteral inoculation [271,272].  
Live attenuated vaccines 
Currently, FluMist® is the only licensed LAIV in humans in the US. Different 
from TIV, FluMist® is administered by using a nasal spray. LAIV stimulates the 
production of both mucosal IgA and serum IgG antibodies [273], therefore it could 
protect both the upper and lower respiratory tracts from invasion by the influenza virus. 
Meanwhile, LAIV may elicit cell-mediated immunity with limited replication in the 
upper respiratory tract [274].  
The LAIV strain is featured with cold-adapted (ca), temperature-sensitive (ts) and 
attenuated (att) characteristics. These characteristics lead the LAIV to replicate 
efficiently at low temperatures, restrict at 37°C and 39°C, and cause no disease 
(attenuated).  The master donor virus of LAIV, A/Ann Arbor/6/60 (H2N2) and B/Ann 
Arbor/1/66 were developed by Maassab and his collaborators following the strategy of 
serially propagating the virus in primary chicken kidney cells at low temperature (25°C) 
[275]. 
The sequence analysis demonstrated that the multiple mutations on the internal 
genes are responsible for the ca, ts and att phenotypes of the cold-adapted virus. Eleven 
amino acid mutations were found in the attenuated AA/60 (A/A/60 att) strain, and the 
study demonstrated that introducing five ts loci, including K391E, E581G, and A661T on 
the PB1gene, N265S on PB2 gene, and D34G on the NP gene, is necessary to confer the 




LAIV generates “6+2” reassortant vaccines against the circulating influenza with 
6 internal genes (PB1, PB2, PA, NP, M and NS) from a “master donor” A/A/60 att, and 
two glycoprotein genes from the circulating strain [275]. FluMist® is approved for use in 
the population in ages from 2 to 49, except in the pregnant women. LAIV achieved a 
higher protection efficiency than TIV in children, but is less effective in adults 
[277,278,279].  
To generate attenuate influenza against avian viruses in poultry, several different 
strategies have been developed [280,281,282,283,284]. An avian influenza 
(A/FPV/Rostock/34 (H7N1)) was genetically attenuated by replacing the M2 cleavage 
site with that of the NP’s. Vaccination with a single dose of this attenuated virus was 
sufficient to completely protect the chickens from lethal FPV infections [281]. A live-
attenuated recombinant H5N1 influenza virus was generated by removing the polybasic 
cleavage site from the HA, substituting residue 627 from lysine to glutamic acid in the 
PB2, and generating a C-terminal truncation of the NS1. This live-attenuated vaccine 
provided chickens with full protection against the homologous virus and a high level of 
protection against the heterologous HPAI H5N1 challenge [284].  
In our previous reports we demonstrated the potential of a genetically modified 
LAIV with the internal gene backbone of A/guinea fowl/Hong Kong/WF10/99 (H9N2) 
(WF10att) as a vaccine backbone for H5N1 influenza viruses [254]. The WF10att 
backbone carries mutations in the PB1 (K391E, E581G and A661T) and PB2 (N265S) 
genes. In addition an HA tag was cloned in the frame at the C-terminus of PB1, and 
enhanced the att phenotype. We also showed that an H5N1 virus carrying the backbone 




against H5 HPAI virus in chickens [254,285]. 
However, field application of these vaccines is difficult due to the inherent 
segmented nature of the influenza genome and the fear that LAIVs could expand the 
plethora of influenza viruses through reassortment. Despite recent reports of the potential 
genomic manipulation of influenza to prevent undesired reassortments, it is unclear how 
these viruses will behave under more natural conditions; either by providing adequate 
protection or reverting to wild type-like viruses. 
Vaccines expressed by viral vectors 
The genetically modified viruses causing no disease have been used as the viral 
vectors for foreign antigen delivery. Multiple viral vectors, such as Newcastle disease 
virus, adenoviruses, and vesicular stomatitis virus were used to carry the influenza HA 
gene from seasonal or H5N1 viruses, or both, and expressed the antigen in animals. The 
results showed the viral vector-based vaccine elicited protective humoral and CTL 
responses [286,287,288]. In the early phase of the clinical trial, adenovirus-based HA 
vaccines yielded encouraging results [289]. 
For poultry, several viral vectors, such as fowl poxvirus [290], Newcastle disease 
virus (NDV) [280,291], vaccinia virus[292], and adenoviruses [293] have been used for 
vaccine development against avian influenza. Currently, the recombinant fowl poxvirus-
AI-H5 (rFP-AIV-H5, or Trovac AI-H5) and recombinant NDV-AI expressing H5 HA 
gene are licensed against avian influenza virus infection. Both of the vaccines are safe, 
and elicit host humoral and cellular immune responses. DIVA strategies are easy to 




However, pre-existing maternal and neutralizing antibodies against fowl poxvirus or 
NDV may limit the replication of the vaccine, and reduce the host immune responses 
[271,294].  
Virus-like particle vaccines 
In the assembly step of influenza virus life cycle, the structural proteins HA, NA, 
and M1 are transported into the plasma membrane and embed onto it, and bud out of the 
host cells after the vRNP complex interacts with the M1 protein. The baculovirus 
expression vector (BEVS)/insect cell (IC) system mimics this self-assembly process and 
produces non-infectious virus-like particles (VLP) via the recombinant baculovirus 
vector containing the HA, NA and M1 proteins. VLP influenza vaccines are in highly 
safe, as the particles do not contain the genome of the virus [295]. Other influenza or 
non-influenza proteins can be introduced into the VLP to enhance the immune responses 
to vaccines [256]. A VLP containing the HA and M1 proteins from the canine influenza 
virus H3N2 subtype provided the dogs protection against the wild type virus challenge 
[296]. Interestingly, the triple-subtype VLPs co-expressing influenza HAs were derived 
from H5N1, H7N2 and H9N2, respectively, and the NA and M1 genes were from PR8 
that were produced in the insect cells. The intranasal vaccination with the triple-subtype 
VLPs induced efficient protection against wild-type H5N1, H7N2 and H9N2 infections in 
ferrets by neutralizing antibody responses [297]. 
FluBlok® is the first LVP vaccine licensed in the US that is produced from insect 
cells using the baculovirus expression system [245]. FluBlok® contains recombinant 
trivalent HA derived from the same seasonal influenza strains as TIV, but its HA content 




injection, and it is approved to use in persons 18 through 49 years of age. In the clinical 
development, vaccination with FluBlok® resulted in a long-term immune response and a 
cross-protection against viral mutants [298,299]. 
Universal vaccines 
Recombinant M2 vaccine 
M2 is a membrane protein with proton channel activity [119]. During infection, 
M2 triggers the uncoating of vRNP by introducing H+ from the low pH endosome. The 
extracellular domain of M2 (M2e) is highly conserved in the different subtypes of 
influenza virus, which renders M2e a good candidate for universal vaccine development. 
Recombinant vaccines based on the full length or M2e with different carrier, such as VLP 
and GST, have been evaluated in animal models. It was reported that the M2 vaccine 
induced cross-protection [300]; however, the protection efficiency of M2 universal 
vaccines is lower than that of inactivated vaccines. This may be because the M2 antibody 
is involved in the opsonophagocytosis of macrophages, and cannot neutralize the virus. A 
clinical trial is needed to further evaluate whether M2 universal vaccine candidates can 
elicit efficient protection in humans [257]. 
HA stalk vaccine 
The fusion peptide region of the HA2 is highly conserved among all HA proteins 
[301], and is responsible for the viral and host endosome membrane fusion of influenza 
virus in the uncoating process. The HA2 subunit is also relatively conserved with a 
higher than 85% sequence homology in different subtypes. Universal vaccines based on 




neutralizing antibody was produced in the HA2 stalk study in mice [302,303]. The 
antibodies are likely to block the virus-cell membrane fusion in the endosome [81,304], 
and inhibit virus uncoating. 
DNA-based vaccines 
DNA-based influenza vaccines have been studied for more than 2 decades. The 
plasmids containing the HA or NA genes were intramuscularly injected into different 
animals, inducing protective responses [305,306]. However, recent clinical trials did not 
show promising results in humans [307,308].  Thus, the potential of DNA-based vaccines 
becoming commercial products is uncertain. 
DNA vaccines against avian influenza virus have been reported in recent years. 
An influenza gene (generally HA) is cloned and inserted into to the eukaryotic expression 
vectors, and delivered to the host by intramuscular or intradermal injection. 
Subsequently, the viral proteins are synthesized via the host transcription or translation 
mechanism, then taken and processed by antigen-presenting cells (APCs) or myocytes. 
The viral antigens are presented on the MHC class I and II molecules, eliciting both 
humoral and cell-mediate immune responses [309]. However, more efforts are needed to 
improve these promoters for poultry [310]. The prohibitive costs of the vaccine 
preparation may limit the commercialization of DNA vaccines in poultry [309,311]. 
 
 




Chapter 3: Host immune responses and evasion 
strategies of influenza A virus  
 
Innate immune response 
The innate immune response is the first line of defense against the attack of 
influenza virus. The innate immune system recognizes pathogen-associated molecular 
patterns (PAMPs) by endogenous pattern recognition receptors (PRRs), and broadly 
establishes an antiviral state to the infected tissues. The following responses include the 
induction of type I and type III interferons (IFNs), recruitment of antigen-presenting cells 
(APCs), and programmed cell death of the infected cells [312]. 
The TLR pathway 
Toll-like receptors (TLRs) are one of the main families of PRRs. They play a 
critical role in the innate immune system. Amongst them, TLR3 recognizes double-
stranded RNA (dsRNA) and TLR7/8 recognizes single stranded RNA (ssRNA), and both 
of them may be involved in the immune responses to influenza virus [313]. The binding 
of dsRNA with TLR3 triggers the activation of transcription factors, such as IFN 
regulatory factor (IRF) 3, p50/p65 (NF"B) and activator protein 1 (AP1) [314]. IRF3, 
NF%B and AP1 are all the components of IFN-ß enhanceosome (a protein complex which 
binds to the “enhancer” region of a gene [315]), which may relocate into the nucleus and 




The plasmacytoid dendritic cells (pDC), which mainly circulate in the blood, are 
the major source of type I IFN production during the influenza infection. pDCs recognize 
influenza virus through TLR7 [317]. The mechanism of influenza virus antagonizing 
TLR signaling during infection remains unknown [312].  
RIG-I 
Retinoic acid-inducible gene I (RIG-I) is a well-featured member of this PRR 
family, along with the melanoma differentiation-associated protein (MDA) 5. RIG-I, a 
cytosolic sensor, contains a repressor domain (RD) and two caspase-recruitment domains 
(CARD). The binding of RD to 5&-triphosphate dsRNA of influenza virus can cause 
conformational changes of RD, and activate RIG-I [318]. Activated RIG-I interacts with 
mitochondrial antiviral-signaling protein (MAVS), which is located on the mitochondria, 
through its CARD, and MAVS, in turn, activates the components of IFN-" 
enhanceosome including IRF3, IRF7 and NF%B, relocating them into the nucleus to 
activate the transcription of IFN- " and inflammatory cytokines [312]. 
Type I IFN signaling 
The cytoplasmic sensors, such as TLR-3 and RIG-I, recognize influenza virus by 
binding to the dsRNA or 5&-triphosphate dsRNA, and triggering the cascade of the 
signaling pathway. The re-location of the enhanceosome into the nucleus subsequently 
activates the transcription of type I IFN (IFN-# and "). INF-# and " express and bind to 
the type I IFN receptor IFN-#/"R on the same infected cell (autocrine signaling) or the 
neighboring cells (paracrine signaling) [318] . The IFN-#/"R is a heterodimer containing 




tails of the receptors trigger the signaling cascade and activate the nuclear IFN-stimulated 
gene factor-3 (ISGF3), which subsequently stimulates the transcription of IFN-sensitive 
regulatory element (ISRE) [318]. By now, more than 300 interferon-stimulated genes 
(ISGs) have been identified, including dsRNA-activated protein kinase R (PKR; 
translational repression) [319]; 2&-5& oligoadenylate synthetase (OAS; activator of 
RNaseL for mRNA decay) [320]; and INF-stimulated gene (ISG)15 (a modifier to 
regulate a number of IFN-stimulated genes) [321]. The main functions of the ISGs 
include recognizing of the PAMP molecules, regulating the transcription and translation 
of the host cell, and initiating programmed cell death.  
The interaction of innate and adaptive immune responses  
The communication between innate and adaptive immune systems is important 
for the successful defense against the invasion of the influenza virus.  During infection, 
the innate immune components initiate the response against the influenza virus, and then 
stimulate the adaptive immune system to participate in the battle. Antigen presenting 
cells (APCs), especially dendritic cells (DCs) are pivotal to the communication between 
innate and adaptive responses [312]. 
The macrophages and dendritic cells in the upper respiratory system are generally 
infected and activated at first by the influenza virus. The activated macrophages secrete 
many inflammatory cytokines, such as IL-6 and TNF-#, to stimulate the synthesis of 




DCs undergo maturation with the up-regulated expression of receptors CD80 and 
CD86, and present the specific peptides derived from the influenza virus to the TCR of 
the naïve T cells via the MHC class II molecule in the draining lymph nodes of the lung; 
and in turn activate T cells into effector cells. However, the presentation of viral antigens 
may be affected by the virus and cause the down-regulation of the MHC class II and co-
stimulatory receptors on the DCs [323]. NS1, the antagonist of type I IFN, may inhibit 
and postpone the innate immune response by different mechanisms of blocking the 
cascade of type I IFN signaling.  
Adaptive immune response 
The major function of the humoral, or neutralization antibody response against the 
influenza virus, is blocking the entry to the host cells. Whereas the cellular response is 
important for clearing the infected cells [312]. 
Humoral response 
Neutralizing antibodies inhibit the viral infection via two different mechanisms: 
binding the epitopes on the globular head of the HA1, and blocking the attachment of the 
HA on the receptors; or preventing the viral envelope and cell membrane fusion by 
binding to the stalk region of the HA [80,81]. 
Humoral immunity may last from several months to a lifetime [324]. The surface 
proteins of influenza HA, NA and M2 are targets for the neutralizing antibodies. 
However, HA is the most important, as the binding of the neutralizing antibodies may 




specific and M2-specific antibodies may contribute to the elimination of the virus 
infected cell by antibody-dependent cell-mediated cytotoxicity (ADCC) [326,327]. 
IgM is the first antibody isotype produced after the primary infection of influenza. 
It can mediate the neutralization of the virus and activate the complements. IgG 
antibodies are produced by plasma B cells, and provide the host with long-term 
protection [322]. More importantly, mucosal secretory IgA antibodies may protect airway 
epithelial cells from infection by inhibiting membrane fusion, or preventing the 
attachment of the influenza viruses [328]. 
Cell-mediated immune response  
The APC cells activate naïve CD4+ T cells by presenting the influenza virus-
derived peptide on MHC II molecules together with the second signal [322]. The 
activated CD4+ T cells differentiate into T helper (Th1) or Th2 cells. Th2 cells secrete IL-
4, IL-5 and IL-13, and activate the humoral response against the influenza virus. Th1 
cells produce IL-2 and IFN- #, and promote the cytotoxic (CD8+) T lymphocyte (CTL) 
response [322].  
Naïve CD8+ T cells are activated by APC cells via recognition of the viral 
peptides on the TCR-class I MHC molecules in the presence of the second signal, and 
then differentiated into CTLs. The infected host cells present the processed peptides 
derived from the influenza virus with class I MHC molecules. The activated CTLs 
recognize the “foreign” peptides on the class I MHCs and clear the infected cells by 
programmed cell death [312,322].  Interestingly, human influenza virus-specific CTLs 




and PB2, which result in CTLs creating the cross-protection among different subtypes of 
influenza A viruses [322]. 
Evasion of innate immune response by influenza virus 
Influenza virus has evolved multiple strategies to inhibit the innate immune 
response. Several viral genes, including NS1, PB1-F2, RdRP and NP are involved in 
antagonizing antiviral activity for successful evasion [322].  
In particular, NS1 is a potent antagonist of type I IFN, and has evolved various 
mechanisms to block the host innate immune response during infection. First, NS1 can 
inhibit the activation of transcription factors on the IFN-" signaling pathway, such as 
IRF-3, c-Jun/ATF-2 and NF-#B, by directly binding dsRNA to its RNA binding domain 
(RBD), and preventing the recognition by TLR-3 [168,169]. Second, the intracellular 
sensor RIG-I binds to the viral genome 5’-triplephosphate dsRNA, and initiates type I 
IFN production by interacting with mitochondrial antiviral signaling protein MAVS. NS1 
inhibits the activation of RIG-I by directly binding to the RIG-I and forming the NS1-
RIG I complex [172,173,174]. TRIM25 activates RIG-I by ubiquitinating the RIG-I N-
terminal CARD domain. NS1 inhibits the ubiquitination of the CARD domain and blocks 
RIG-I signaling [175]. Third, in the nucleus, NS1 can block the processing and nuclear 
export of all cellular mRNAs by binding to CPSF30 and PABPII [170,171].  
Additionally, NS1 can interfere with the function of multiple ISGs. NS1 
competitively binds dsRNA with its RBD, and inhibits the activation of two antiviral 
proteins PKR [329] and OAS [192] in the cytoplasm. ISG15, an IFN-#/"–induced, 
ubiquitin-like protein, inhibits the nuclear import of the influenza NS1 protein by the 




interaction. Interestingly, NS1 binds to Herc5, the major E3 ligase for ISG15 conjugation, 
and limits the function of ISG15 [178].  
NS1 was reported to play both pro- and anti-apoptotic functions during influenza 
infection in different studies [330,331,332], and NS1 was demonstrated to play important 
roles in regulating the phosphatidylinositol 3-kinase (PI3K)/Akt pathway 
[180,181,182,183]. PI3K is a dimeric lipid kinase consisting of a regulatory subunit p85" 
and a catalytic subunit p110 [184]. Akt, a serine/threonine protein kinase, is a 
downstream PIP3-binding effector of PI3K. In the early phase, the attachment of the virus 
to the cell surface transiently induces PI3K signaling [186]. In the later phase, PI3K is 
activated by NS1 and the influenza viral RNA through the stimulation of the cytosolic 
receptor RIG-I, promoting the production of type I IFN [186,187]. NS1 activates PI3K 
signaling by directly binding to the inter-HS2 (iSH2) domain of the regulatory subunit 
p85" of PI3K to prevent the premature apoptosis of the infected cell and facilitate the 
viral replication [188,189]. It’s reported that NS1 can preferentially interact with 
phosphorylated Akt in the nucleus and changes the Akt anti-apoptotic activity[190]. 
Infection with the influenza A virus activates the NF-!B pathway, and leads to the 
antiviral response of the host cells. However, NS1 directly interacts with IKK-" and 
IKK-# and impairs their phosporylation in both the cytoplasm and nucleus, and 
subsequently inhibits the NF-!B-mediated innate immune response [333].  
NS1 from the 2009 swine-origin pandemic H1N1 virus cannot inhibit the host 
gene expression as in other human-adapted influenza A viruses. This feature could be 
restored in 2009/NS1 by introducing the substitutions R108K, E125D and G189D. The 




more efficiently blocked the innate immune response than the wild-type virus. However, 
this mutant virus caused less morbidity in mice, and showed a decreased titer in the URT 
of ferrets when compared to the wild-type virus. The data showed that the NS1 from the 
2009 pandemic H1N1 virus seems lack the potential to function more efficiently in 
human cells [334]. 
Escaping adaptive immune response by influenza virus 
Antigenic drift and antigenic shift are the two main mechanisms causing the 
antigenic variability of influenza viruses, allowing pathogens to overcome the host 
adaptive immune responses. Antigenic drift occurs frequently, which enables the virus to 
cause influenza epidemics by evading the pre-existing immunity in humans. Antigenic 
shift occurs as gene mixing, or reassortment from different influenza A virus subtypes, 
such as the 2009 triple-reassortant swine-origin H1N1 [312]. Antigenic shift may cause a 
human pandemic if the population is immunologically naïve to the new reassortant strains 
at large [248]. 
The selective pressure of neutralizing antibodies, mainly against influenza HA, is 
critical for antigenic shift [322]. For example, a recent study found that the glycosylation 
residues on HA increased (ranging from 5 to 11 glycosylations) in the past 30 years from 
the H3N2 isolates [103]. Both HA and NA process post-transcriptional modifications of 
glycosylation and gain the proper functions in their life cycles. The glycosylation of the 
globular head region of HA may result in the immune escape from the neutralizing 




In the cell-mediated immune response, influenza viruses avoided the recognition 
by virus specific T cells with mutations inside the CTL epitope regions, or at the TCR 
contact residues [322]. For example, the variations in the CTL epitopes were analyzed in 
the seasonal H3N2 isolates. The substitution R384G in the NP (383-391) epitope is an 
anchor residue which greatly reduces the peptide-MHC I affinity, resulting in the loss of 







Chapter 4: Improved hatchability and efficient 
protection after in ovo vaccination with live-
attenuated H7N2 and H9N2 avian influenza viruses 
 
Adapted from: Cai Y, Song H, Ye J, Shao H, Padmanabhan R, Sutton TC, Perez DR. 
Improved hatchability and efficient protection after in ovo vaccination with live-
attenuated H7N2 and H9N2 avian influenza viruses. Virol J. 2011 Jan 21;8:31. 
Abstract 
Mass in ovo vaccination with live attenuated viruses is widely used in the poultry 
industry to protect against various infectious diseases. The worldwide outbreaks of low 
pathogenic and highly pathogenic avian influenza highlight the pressing need for the 
development of similar mass vaccination strategies against avian influenza viruses. We 
have previously shown that a genetically modified live attenuated avian influenza virus 
(LAIV) was amenable for in ovo vaccination and provided optimal protection against H5 
HPAI viruses. However, in ovo vaccination against other subtypes resulted in poor 
hatchability and, therefore, seemed impractical. In this study, we modified the H7 and H9 
hemagglutinin (HA) proteins by substituting the amino acids at the cleavage site for those 
found in the H6 HA subtype. We found that with this modification, a single dose in ovo 
vaccination of 18-day old eggs provided complete protection against homologous 
challenge with low pathogenic virus in !70% of chickens at 2 or 6 weeks post-hatching. 
Further, inoculation of 19-day old egg embryos with 106 EID50 of LAIVs improved 
hatchability to !90% (equivalent to unvaccinated controls) with similar levels of 
protection. Our findings indicate that the strategy of modifying the HA cleavage site 
combined with the LAIV backbone could be used for in ovo vaccination against avian 




this strategy birds would be protected prior to or at the time of delivery to a farm or 
commercial operation. 
Introduction 
Although depopulation of infected flocks is the method of choice to control the 
spread of avian Influenza virus (AIV) in poultry, vaccination has become an alternative 
strategy in order to provide protection to high-risk birds and reduce the possibility of 
transmission among birds and/or to mammals [253,254]. Thus, in many countries in 
which avian influenza outbreaks particularly of low pathogenicity have occurred 
recurrently, selective culling followed by vaccination is used as a measure to control the 
disease without major economic disruptions. There are only two types of avian influenza 
vaccines (AIVs) licensed worldwide: inactivated whole AIV vaccine and recombinant 
fowlpox virus-vectored vaccine expressing the HA gene of AIV. However, both types of 
vaccines have major limitations: inactivated vaccines cannot elicit strong mucosal and 
cellular immunity; and previous exposure to fowlpox virus inhibits the host response to 
the fowl-pox vectored vaccine inhibiting anti-influenza immunity [254,271,272]. In 
addition, both strategies are heavily time-consuming, requiring each bird to be vaccinated 
individually by parenteral inoculation. 
With the advent of reverse genetics, LAIVs have emerged as a potential 
alternative to control avian influenza [284]. Several different strategies have been 
developed to attenuate influenza viruses based on mutations in one or more of the viral 
internal or surface genes [280,281,282,283]. Several studies have shown that LAIV 




mammals. However, field application of these vaccines is difficult due to the inherent 
segmented nature of the influenza genome and the fear that LAIVs could expand the 
plethora of influenza viruses through reassortment. Despite recent reports of the potential 
genomic manipulation of influenza to prevent undesired reassortments, it is unclear how 
these viruses will behave under more natural conditions; either by providing adequate 
protection or reverting to wild type-like viruses. Instead, in ovo vaccination using LAIV 
is an attractive alternative to provide fast and effective protection against influenza while 
avoiding the potential for reassortment (in ovo vaccination is unlikely to produce 
reassortants as other influenza viruses are not present in the egg). 
Several strategies have been developed to generate LAIVs for in ovo vaccination. 
A recombinant LAIV was recently developed that provided immunity against HPAI 
H5N1 influenza and Newcastle Disease Virus (NDV) [280,337]. This recombinant 
influenza virus expressed the HA of H5 with a deleted polybasic cleavage site, and the 
ectodomain of the hemagglutinin-neuraminidase (HN) genes NDV instead of NA gene of 
HPAI H5N1. With this bivalent virus, a single dose in ovo vaccination of 18-day-old eggs 
provided 90% and 80% protection as early as 3 weeks post-hatching, against NDV and 
HPAI, respectively. A second strategy employed a non-replicating human adenovirus 
serotype 5 (Ad5)- vectored vaccine that expressed the HA of a LPAI H5N9 virus. 
Similarly, this vaccine was delivered in ovo and conferred protection in chickens after 
challenge with either HPAI H5N1 (89% HA homology; 68% protection) or HPAI H5N2 
(94% HA homology; 100% protection) viruses. Unfortunately, in both these studies, the 
hatchability efficiency was not addressed in detail [179]. 




LAIV with the internal gene backbone of A/guinea fowl/Hong Kong/WF10/99 (H9N2) 
(WF10att) as a vaccine backbone for H5N1 influenza viruses [254]. The WF10att 
backbone carries mutations in the PB1 (K391E, E581G and A661T) and PB2 (N265S) 
genes. In addition an HA tag was cloned in frame at the C-terminus of PB1, and 
enhanced the att phenotype. This backbone results in virus attenuation in vitro while 
attaining high viral growth properties at the permissive temperatures of 33 and 35°C. We 
also showed that an H5N1 virus carrying the backbone 'H5N1WF10att was amenable 
for in ovo vaccination and provided optimal protection against H5 HPAI virus. More 
specifically, a single low (104 EID50) or high (106 EID50) dose of LAIV resulted in greater 
than 60% protection at 4-week post-hatching and 100% protection at 9 to 12-week post-
hatching. Incorporation of a boost regime with either the low or high virus dose at 2-
weeks post-hatching increased the protection efficiency to 100% in 4-week old chickens. 
The hatchability efficiency of the high-dose (106 EID50) in ovo vaccination was 85%, 
compared with 90% in low-dose (104 EID50) and mock groups [254,285]. 
In ovo vaccination with live attenuated viruses is widely used in commercial 
poultry against various infectious diseases. In ovo vaccination was initially introduced 
into the poultry market to protect against Marek's disease virus (MD) [338,339]. 
Currently, over 80% of US broilers are immunized in ovo with MD vaccine. In ovo 
vaccination is also effective and used commercially to protect poultry from infectious 
bursal disease virus (IBDV) [340]. Compared with field vaccination, in ovo vaccination 
provides uniform and fast delivery (50,000 egg/h), reduced labor costs, decreased stress 
to the birds; and most importantly, elicits early immune responses, as soon as 2-week 




only has to be effective in providing protection but also has to maintain high hatchability 
levels (!90%). In this report, we investigated the effects of changing the H7 and H9 
cleavage site to that of the LPAI H6 subtype and the timing of vaccination on levels of 
protection and hatchability after in ovo vaccination with LAIV against H7 and H9 LPAI 
viruses. Our results indicate that in ovo vaccination can result in significant protection 
against the H7 and H9 virus subtypes while maintaining high hatchability (>90%) when 
the vaccine is administered in 19-day old chicken embryos. 
Materials and methods 
Virus, cells and Animals 
The influenza virus A/Guinea Fowl/Hong Kong/WF10/99 (H9N2) (WF10) was 
kindly provided by Robert Webster from the repository at St. Jude's Children's Research 
Hospital, Memphis, Tennessee; influenza virus A/Chicken/Delaware/VIVA/04 (H7N2) 
(CK/04) was kindly obtained from Dennis Senne at the National Veterinary Laboratory 
Services, USDA, Ames, Iowa. The viruses were propagated in 10-day-old embryonated 
specific-pathogen-free chicken eggs at 35°C and stored at -70°C. The viruses were 
titrated by the Reed and Muench method to determine the 50% egg infectious dose 
(EID50). 293T human embryonic kidney and Madin-Darby canine kidney (MDCK) cells 
were maintained as described previously [254]. White leghorn chickens (Charles River 
Laboratories, MA) and Japanese quail (Murray McMurray Hatchery, Webster, IA) were 
hatched at 100°F in a circulating air incubator (G.Q.F. Manufacturing co. Savannah, GA) 
and maintained under BSL2 conditions. 




The 6 internal genes of WF10att were described previously and were used to 
recover viruses carrying the surface genes of Ck/04 or WF10 [254]. The cloning of the 
Ck/04 surface genes has been previously described [254]. The H7 HA cleavage site, 
PEKPKPRG, was substituted with an alternative cleavage site sequence, PQIETRG, from 
the H6 HA subtype using a two-step PCR reaction and the plasmid pDP2002-H7 (Ck/04) 
as the template (Figure 4.1A). In brief, two PCR fragments were produced by using 
primers EcoR I 550-F (5'-CTGTCGAATTCAGATAATTCAGC-3') and H7-H6 CVS-R 
(5'-GGTCTCCCGCTGTGGAACATTTCTC-3'), and primers H7-H6 CVS-F (5'-
CACAGCGGGAGACCAGAGGCCTTTTTG-3') and Pst I 1150-R (5'-
GTCAGCTGCAGTTCCCTCCCCTTGT-3'). These two fragments were then used as 
templates for a new PCR product using primers EcoR I 550-F and Pst I 1150-R. The 
fragment was digested with EcoR I and Pst I, and cloned into pDP-2002-H7 (VIVA/04), 
to obtain pDP2002-mH7. 
The H9 HA cleavage site, PARSSRG, was substituted with the alternative 
cleavage site sequence PQIETRG (Figure 4.1B) using pDPH9WF10 as the template. Two 
PCR fragments were produced by using primers: Xbal I 285-F (5'-
CCTCATTCTAGACACATGCAC-3') and H9-H6 CVS-R (5'-
CCAAATAGTCCTCTAGTTTCGATCTGAGGCACGTTC-3'), and primers H9-H6 
CVS-F (5'-GAACGTGCCTCAGATCGAAACTAGAGGACTATTTGG-3') and EcoN I 
1297-R (5'-CCTCATTCTAGACACATGCAC-3'). These two fragments were then used 
as templates to generate a new PCR fragment using primers Xbal I 285-F and EcoN I 
1297-R. The fragment was digested with Xbal I and EcoN I, and cloned into 




Recombinant viruses were generated using the 8-plasmid system in co-cultured 
293T and MDCK cells as described previously [254]. The recombinant viruses (Table 
4.1) were propagated in 10-day-old embryonated eggs, titrated by EID50, and stored at -
70°C until use. 2mH7N2:6WF10att and 2mH9N2:6WF10att viruses were sequenced 
using specific primers, the Big Dye Terminator v3.1 Cycle Sequencing kit (Applied 
Biosystems, Foster City, CA), and a 3100 Genetic Analyzer (Applied Biosystems, Foster 
City, CA), according to the manufacturer's instructions. The genetic stability of mutations 
on HA, PB1 and PB2 were evaluated by serial passage of virus stocks at a 1:10,000 
dilution for 10 passages in triplicate samples in 10-day-old embryonated eggs. Viruses 
obtained after ten passages were sequenced as described above. 
Hatchability in embryonated chicken eggs 
18 or 19-day-old embryonated specific-pathogen-free chicken eggs were 
inoculated with either 106 or 107 EID50 of virus in 0.1 ml inoculum according to the 
scheme presented in Table 2. Eggs in the mock group were inoculated with 0.1 ml of 
PBS. The egg inoculation was performed as described previously [254]. Briefly, eggs 
were candled, and a small hole was made through the air cell with an electric drill. Next, 
0.1 ml of virus dilution or PBS was injected into the allantoic cavity using a 21-gauge 
needle at a depth of 2.5 cm. The percent hatchability was calculated using the total 
number of inoculated eggs versus the number of 21-day old eggs that hatched in each 
group. This experiment was performed under BSL-2 conditions according to protocols 




Plaque assay in chicken embryonic kidney (CEK) cells and 
immunostaining 
To investigate if the replacement of amino acids at the HA cleavage site affected 
the temperature sensitive phenotype of the new live-attenuated viruses, plaque assays 
were performed in CEK cells at 37°C, 39°C, and 41°C. Confluent CEK cell monolayers 
in six-well plates were infected with 0.5 ml of 10-fold dilutions of virus 
2mH7N2:6WF10att or 2H7N2:6WF10att in M199 medium. The cells were incubated 
with the virus dilutions for 1 h at 37°C, washed, and overlaid with M199 medium 
containing 0.9% agar and 0.1 µg/ml TPCK-trypsin. The plates were then incubated at 
37°C, 39°C, and 41°C with 5% CO2. At 4 days post-inoculation (dpi) the overlay was 
removed and immunostaining was performed as described previously [254]. In brief, the 
cells were fixed, permeabilized, and blocked with bovine serum albumin (BSA) in PBS. 
The cells were then incubated with mouse anti-WF10 monoclonal NP antibody prepared 
in our laboratory, followed by incubation with peroxidase-conjugated goat anti-mouse 
IgG (Jackson Immuno Research, West Grove, PA). The presence of viral antigen was 
revealed by adding several drops of aminoethylcarbazol (BD Biosciences, San Diego, 
CA). The size and number of plaques at each temperature were compared to determine 
the temperature sensitive phenotype of the new recombinant virus. 
Viral replication in MDCK cells 
Viral replication was studied to examine the temperature sensitive phenotype of 
the new recombinant viruses in MDCK cells. Confluent monolayers of MDCK cells in 6-
well plates were infected with 2m2H7N2:6WF10att or 2H7N2:6WF10att at a MOI = 




12, 24, 48, 72, 96 and 120 h post-inoculation, and the viral titer of these samples was 
determined by TCID50 in MDCK cells[254]. 
Virus replication and transmission in quail 
To evaluate the vaccine's attenuated phenotype in vivo, 2mH7N2:6WF10att was 
compared to the recombinant virus 2H7N2:6WF10att. Six 4-week-old Japanese quail 
were inoculated by the ocular, intranasal, and intratracheal routes with 106 EID50/0.5 ml 
of either 2mH7N2:6WF10att or 2H7N2:6WF10att vaccine viruses. Two control quail 
were inoculated with 0.5 ml of PBS. At 1 dpi, 3 naïve quail were introduced into the 
same isolators, and placed in direct contact with the inoculated quail to assess virus 
transmission. At 3 dpi, 3 inoculated quail per group were sacrificed, lungs were 
homogenized and virus titers were determined by EID50. For the remaining quail, tracheal 
and cloacal swabs were collected from both the inoculated and direct contact birds at 1, 3, 
5, 7, and 9 dpi. The swab samples were stored in glass vials in 1.0 ml freezing Brain 
Heart Infusion (BHI) medium (BD, Sparks, MD) and titrated for infectivity in 10-day-old 
embryonated chicken eggs and MDCK cells. Sera were collected 2 weeks post-infection 
and HA inhibition tests (HI) were performed to quantify antibodies against HA [254]. 
Challenge studies 
Chickens that hatched after in ovo vaccination were randomly divided into two 
groups with the same number of individuals. Early protection was assessed in the first 
group of chickens by challenge at 2-weeks post-hatching. Challenge virus consisted of 5 
( 105 EID50 of virus (equal to 500 chicken infectious dose 50 (CID50)) and was delivered 




following the strategy described above, but in chickens that were 6 weeks old. Tracheal 
and cloacal swab samples were collected at 3, 5, and 7 days post-challenge (dpc). Virus 
shedding was titrated in MDCK cells by TCID50. Sera samples were collected at 2-weeks 
post-hatching pre-challenge, and 2 weeks post-challenge. HI titers were determined as 
previously described. Animal studies were conducted under BSL-2 conditions, and 
performed according to protocols approved by the Animal Care and Use Committee of 
the University of Maryland. 
Results 
Chicken hatchability is impaired after in ovo  vaccination with 
H7N2 and H9N2 WF10att viruses 
Our previous studies showed that in ovo vaccination with 106 EID50 of the 
'H5N1:6WF10att virus resulted in effective protection against HPAI H5N1 virus [254]. 
We wanted to determine whether similar levels of protection could be obtained against 
other HA subtypes following the same strategy. We were particularly interested in the H7 
and the H9 subtypes because they have been responsible for recurrent outbreaks, 
particularly in Eurasia (although in our studies a H7 virus of the North American lineage 
was used). Thus, 18-day-old egg embryos were inoculated with 106 EID50 of either 
2H7N2:6WF10att or 2H9N2:6WF10att vaccine viruses (Tables 4.1 and 4.2). 
Unfortunately, the hatchability of vaccinated eggs was poor, 30% and 37% in eggs 
vaccinated with 2H7N2:6WF10att and 2H9N2:6WF10att, respectively (Table 4.2) 





Chicken hatchability after modification of the HA cleavage site 
in H7N2 and H9N2 WF10att viruses 
The 2'H5N1:6WF10att virus carries the H5 HA protein from 
A/Vietnam/1203/04 (H5N1) but its polybasic cleavage site, characteristic of HPAI 
viruses, has been replaced with that from the LPAI H6 HA virus subtype, as described in 
previous reports [342]. In order to determine if incorporation of the H6 HA cleavage site 
in the H7 and H9 subtypes would result in more attenuated vaccine viruses and improved 
hatchability, we generated the recombinant viruses 2mH7N2:6WF10att and 
2mH9N2:6WF10att. Modifications at the cleavage site in these viruses did not have 
major effects on the in vitro properties of these viruses. Both recombinant viruses reached 
titers of 106 TCID50/ml at 120 h post-infection in MDCK cells inoculated at an MOI = 
0.001 and cultured at 35°C (Figure 4.2 and data not shown). In contrast, viral replication 
at 39°C was severely restricted, with viral titers reduced more than 1000-fold relative to 
those at 35°C (Figure 4.2 and data not shown). This indicates that modifications in the 
HA cleavage site did not change the temperature sensitive phenotype of these viruses in 
MDCK cells. Likewise, plaque assays, performed using CEK cells (Figure 4.3), showed 
that 2mH7N2:6WF10att formed significantly smaller plaques than 2H7N2:6WF10att at 
37° and 39°C. As expected, these viruses were highly restricted at 41°C (yields of <103 
PFU/ml) consistent with their att phenotype. Interestingly, the lower virus titers and 
smaller plaque sizes of 2mH7N2:6WF10att compared to 2H7N2:6WF10att indicate an 
additive effect on attenuation provided by the modified HA cleavage site. Similar results 
were obtained when we compared the 2mH9N2:6WF10att to 2H9N2:6WF10att (not 




hatchability (50% and 63%) was observed when 18-day-old egg embryos were inoculated 
with 106 EID50 of the 2mH7N2:6WF10att and 2mH9N2:6WF10att vaccine viruses, 
respectively (Table 4.2). 
Stability of new recombinant viruses 
The genetic stability of the mutations on HA, PB1, and PB2, was verified by 
serial passage of the 2mH7N2:6WF10att and 2mH9N2:6WF10att viruses in 10-day-old 
embryonated eggs. Amino acids 391E, 581G, 661T and the HA tag on PB1, and 265S on 
PB2 remained unchanged after serial propagation in eggs. More importantly, the amino 
acids at the HA cleavage site remained unchanged and corresponded to the H6 HA 
cleavage sequence (PQIETRG). 
Modification of the HA cleavage site reduces replication of 
2mH7N2:6WF10att virus in quail 
We have previously shown that quail are more susceptible than chickens to avian 
influenza viruses. Thus quail represent a better host to test whether modifications in our 
vaccine viruses would have any effect on replication and transmissibility. To investigate 
if modification of the HA cleavage site altered the degree of attenuation and 
transmissibility in quail, 2 groups of quail (n = 6) were inoculated with either the 
2mH7N2:6WF10att virus or the 2H7N2: 6WF10att virus. At 24 h after infection, 3-naïve 
quail/group were brought in direct contact with inoculated quail to monitor for 
transmission (Table 4.3). At 3 dpi, 3 inoculated quail from each group were sacrificed to 
determine virus load in the lungs. No virus was detected in the lungs of inoculated quail 




that the WF10att backbone prevents the virus from replicating in the lower respiratory 
tract (not shown and [254,285]). In addition, no virus was detected in cloacal swabs for 
any of the quail in the study (not shown). In contrast, tracheal swabs showed the presence 
of virus in the 2H7N2:6WF10att group, with peak virus titers of 102.9 (at 1 dpi) and 101.6 
TCID50/ml (at 3 dpi) in the inoculated and direct contact quail, respectively. Inoculated 
quail remained positive until 5 dpi but were negative by 7 dpi. Only 2 out of the 3 direct 
contact quail showed trace amounts of 2H7N2:6WF10att and were negative by 9 dpi. 
With respect to the 2mH7N2: 6WF10att inoculated group, only trace amounts of virus 
were observed, and just 1 of 3 quail remained positive by 7 dpi and it became negative by 
9 dpi. Direct contacts in the 2mH7N2: 6WF10att virus group were negative except for 
trace amounts of virus on a single day, 7 dpi, in 2 of the 3 quail. The levels of virus 
replication in the different groups corresponded with the levels of seroconversion 
observed. Thus, inoculated quail in the 2H7N2:6WF10att group had the highest 
neutralizing antibody response, followed by inoculated quail in the 2mH7N2: 6WF10att 
group, whereas the direct contacts in the 2H7N2:6WF10att showed low, but significant 
seroconversion. Also consistent with the transient presence of the 2mH7N2: 6WF10att 
virus in the direct contact group, very low seroconversion was observed. These studies 
suggest that alterations in the HA cleavage site have an effect on replication in vivo 
further attenuating these viruses and limiting the ability to replicate after transmission 
(Table 4.3). We did not perform similar studies in quail with the H9N2 vaccine viruses. 
However, we must note that similar studies in white leghorn chickens did not result in 
detectable transmission, when the viruses carry the att backbone in the context of H7N2 




Single dose in ovo vaccination provides protection in chickens 
from homologous challenge with H7 and H9 LPAI viruses at 2 
and 6 weeks post-hatching 
To further evaluate whether in ovo immunization would result in protection 
against H7 or H9 viruses, vaccinated chickens were divided into two groups, and 
subsequently challenged with homologous virus at either 2 or 6 weeks post-hatching 
(Tables 4.4 and 4.5). 
Pre-challenge sera collected at 2 weeks post-hatching showed limited 
seroconversion in chickens that received the 2mH7N2:6WF10att (Table 4.4), both in 
terms of the number of seropositive chickens as well as the level of HI responses. 
However, sera collected at 6 weeks post-hatching showed increased numbers of 
seropositive chickens and increased HI titers (Table 4.4). Relative to 2mH7N2:6WF10att, 
improved and more consistent antibody responses were obtained in chickens that were 
vaccinated with 2mH9N2:6WF10att (Table 4.5). In terms of protection, significant 
protection was observed in chickens challenged with 500 CID50 of Ck/04 (H7N2) at 2 or 
6 weeks post-hatching but only in the 19-day old embryo vaccinated groups. Tracheal 
virus shedding was detected in only 2 out 8 and 1 out of 5 chickens in the 19-day old 
embryo groups that received 106 or 107 EID50, respectively, of 2mH7N2:6WF10att. There 
was also a sharp decrease in cloacal virus shedding in these groups, with just 1 out 8 (106 
EID50 group) and 1 out 5 (107 EID50 group) virus positive chickens and only at 7 dpc 
(Table 4.4). In contrast, in the 18-day old embryo vaccinated group only 1 out 4 and 2 out 
4, at 2 and 6 weeks post-hatching, respectively, showed protection and no detectable 




challenged chickens. Chickens in the 19-day old embryo vaccinated groups showing the 
best protection, and those in the 18-day old embryo vaccinated groups showed the 
decreased protection (Table 4.5). Significant seroconversion in all the groups at 14 dpc 
indicated that lack of virus shedding in protected chickens was not due to a failure in our 
challenge approach. Considering the 106 EID50 vaccine dose in the 19-day old embryo 
vaccinated groups for both att vaccines, there was between 70 and 80% protection 
efficiency in chickens challenge at 2 or 6 weeks post-hatching, respectively. Slightly 
better protection efficiency (82%) was observed in the 107 EID50 vaccine dose groups; 
however, it was achieved at the expense of lower hatchability rates (~91% for the 106 
EID50 versus ~80% for the 107 EID50 groups). In contrast, an average of only 55% 
protection efficiency was observed in the groups vaccinated with a dose 106 EID50 in 18-
day old embryos. 
Discussion 
The HA is perhaps the most important protein in influenza viruses, as it is a 
critical determinant of host range and virulence [50,51]. The HA protein, encoded in 
segment 4, is expressed on the virus surface as homotrimers. It is initially produced as a 
precursor, HA0, that requires post-translational modifications, including cleavage and 
glycosylation in order to become fully active [57]. Cleavage of the HA0 precursor leads 
to two subunits, HA1 - N-proximal - and HA2 - C-proximal -, which are maintained 
covalently linked via disulfide bonds. Trypsin-like host proteases found in the lumen of 
the respiratory and intestinal tracts are involved in the cleavage of the HA of low 
pathogenic avian influenza viruses - LPAIV - (and mammalian influenza viruses) [57]. 




highly pathogenic avian influenza viruses - HPAIV [57]. The number of basic amino acid 
residues preceding the cleavage site determines recognition by either trypsin-like or 
furin-like proteases, with a string of basic amino acids allowing the latter to cause 
intracellular maturation of the HA at the level of the endoplasmic reticulum [343]. Furin-
like protease cleavage produces mature virions that can spread cell to cell without having 
to reach the lumen of the respiratory or intestinal tracts. This permits the development of 
a fatal systemic infection, hence the so-called highly pathogenic influenza. Therefore, the 
cleavability of HA is one of the critical factors for viral tissue tropism and pathogenicity 
[344,345]. In this study, we modified the cleavage site of the influenza virus H7 and H9 
HA protein genes to encode sequences corresponding to the H6 HA cleavage site (mH7 
and mH9) in order to improve hatchability after in ovo vaccination. It has been previously 
shown that the H6 HA cleavage site can transform a HPAIV of the H5N1 subtype into a 
LPAIV [342]. We have previously shown that a LPAI H5N1 virus carrying att mutations 
is amenable for in ovo vaccination resulting in !60% protection while maintaining at 
least 85% hatchability [254]. In this study we sought to examine whether the mH7 and 
mH9 att viruses showed similar replication yields as unmodified H7 and H9 att viruses, 
and if these modified viruses were more amenable for in ovo vaccination without 
decreased immunogenicity. Growth kinetic studies in tissue culture cells showed similar 
yields for the mH7 compared to the unmodified H7 viruses (Figure 4.2) and similar 
results were obtained comparing the mH9 with the unmodified H9 pairs (not shown). As 
the safe "window" for in ovo vaccination of chicken embryos is between day 17 at 12-14 
hours to day 19 at 2-4 hours [341], we chose days 18 and 19 for vaccination to test the 




the mH7 and mH9 att viruses allowed for hatchability (90-93%, 19-day old embryos) 
similar to the PBS inoculated controls (93-96%), which were much higher than those 
obtained with the unmodified H7 or H9 att viruses (43-60%, 19-day old embryos). We 
found that the combination of the modified HA cleavage site, vaccine dose, and time of 
vaccine delivery, had a significant impact on hatchability rates. Thus, 18-day old chicken 
embryos vaccinated with the mH7 or the mH9 att viruses showed improved hatchability 
rates compared to the unmodified HA att counterparts, but they were significantly lower 
than the rates obtained after vaccinating 19-day old embryos (Table 4.2). Likewise, 
increasing the dose to 107 EID50 of either mH7 or mH9 att viruses resulted in 10% 
hatchability loss compared to the same age embryos inoculated with 106 EID50 of the 
same viruses. 
We speculate that the introduction of the alternative H6 HA cleavage site in the 
mH7 and mH9 att viruses (and perhaps in the 'H5 att virus) leads to reduced HA 
cleavage efficiency and, thus, these viruses exhibit growth restrictions at higher 
temperatures in vitro (Figure 4.3) and in vivo in 18-19-day old chicken embryos (Table 
4.2). However, these viruses showed no defects in terms of virus yield at the permissive 
temperatures of 33 and 35°C in tissue culture (Figure 4.2) or in 10-day old chicken 
embryos. These characteristics are important because efficient immunogenicity was 
maintained without sacrificing virus yield. In fact, 2mH7N2:6WF10att and 
2mH9N2:6WF10att viruses can easily achieve titers on the order of 108 EID50/ml when 
grown in 10-day old embryonated chicken eggs (data not show), thus making them ideal 




In ovo vaccination is an attractive approach for vaccination of chickens, 
particularly broilers [341,346]. It helps to 'close the window' of susceptibility between 
vaccination and early exposure to infectious agents compared with post-hatch vaccination 
[346]. Because chickens already develop certain immunologic functions before hatching, 
in ovo vaccination stimulates both the innate and adaptive immune responses. Thus, in 
ovo vaccinated chicks develop an appreciable degree of protection by the time of 
hatching [346]. This indeed appears to be the case since in our approach chickens showed 
significant protection (! 70%) when challenged as early as 2 weeks post-hatching. It is 
tempting to speculate that under industrial settings higher protection efficiencies could be 
obtained since automated systems would result in more accurate, controlled and efficient 
administration of the vaccine compared to our manual approach. In addition, because the 
mH7 and mH9 att viruses are more attenuated in vivo than the unmodified att 
counterparts, we further speculate that these HA genes are not likely to outcompete wild 
type influenza viruses through reassortment, and thus, should be safe to use in the field. 
The unprecedented spread of low pathogenic H7 and H9 influenza viruses in commercial 
settings, calls for the implementation of alternative prevention and control strategies. Our 














Table 4.1. The gene constellations of the recombinant viruses. 
Virus HA NA Internal genes (PB1, PB2, PA, NP, M and NS) 
2m2H7N2:6WF10att mH7 (VIVA/04) N2 (VIVA/04) WF10att 
2H7N2:6WF10att H7 (VIVA/04) N2 (VIVA/04) WF10att 
2mH9N2:6WF10att mH9 (WF10) N2 (WF10) WF10att 




Table 4.2. Comparison of the hatchability of new recombinant viruses in embryonated 
chicken eggs vs. the viruses with wild type HAs and the optimization of the dose and 

























106 18 30%  (9/30) 
106 19 43%  (13/30) 

















106 18 37%  (11/30) 
106 19 60%  (18/30) 
107 19 37%  (11/30) 
PBS (Mock) 
0 18 93%  (28/30) 
0 19 96%  (43/45) 






Table 4.3.  Replication and transmission study of recombinant virus 2H7N2:6WF10att 
and 2mH7N2:6WF10att in quail 
 
 












Virus Quail group 





/ml± SD) at peak viral shedding 
# of seroconverted/total # 
(Average HI titer at 14 dpi) 









3/3 2/3 0/3 3/3 (47) 
2mH7N2:6WF10att 
Inoculated 6/6 (<0.7) 6/6* 1/3 1/3 0/3 3/3 (87) 




Table 4.4.  Single-dose 2mH7N2:6WF10att in ovo vaccination study in chickens 





















at 14 dpi 
Tracheal Cloacal 
3 dpc 5 dpc 7 dpc 3 dpc 5 dpc 7 dpc 





















































3/5 (5) 2 
1/5 
(2.7) 




































































Table 4.5.  Single-dose 2mH9N2:6WF10att in ovo vaccination study in chickens 



















Tracheal # positive 
HI/total # at 14 
dpi 3 dpc 5 dpc 7 dpc 
























6/7 (32) 2 
1/7 
(2.5) 







3/4 (32) 2 
1/4 
(2.3) 
0/4 0/4 4/4 (260) 
























5/7 (71) 6 
2/7 
(2.4±0.5) 




















Figure 4.1.  Strategy of modifying the HA cleavage site. (A). The substitution of 
H7N2 (VIVA/04) HA amino acid cleavage site with alternative cleavage site sequences 
of H6's. (B). The substitution of H9N2 (WF10) HA amino acid cleavage site with 












Figure 4.2. Viral replication kinetics of the live-attenuated viruses in MDCK cells at 
(A) 35°C and (B) 39°C using MOI of 0.001. Viral titers at different time points were 






Figure 4.3. Plaque morphology of the live-attenuated viruses in CEK cell at different 
temperatures. Confluent CEK cells in six-well plates were infected with 
2mH7N2:6WF10att or 2H7N2:6WF10att. The numbers 10-6, 10-5, and 10-3 on the plaque 
pictures indicate the virus dilution used to infect cells at the indicated temperature. The 
cells incubated at 37°C, 39°C, or 41°C, respectively, for 4 days post infection and then 
fixed and the viral antigen was visualized by immunostaining as described in Materials 
and Methods. The plaques sizes were observed and the plaque numbers were counted and 
calculated as the log10 PFU/ml, as indicated below the individual plaque picture. A titer of 




Chapter 5: Glutamic acid to valine substitution at 
position 59 in PA enhances growth of live-
attenuated influenza vaccines in eggs and 
mammalian cells 
Abstract 
During the emergence of the 2009 pandemic H1N1 (pH1N1) influenza virus, a live 
attenuated vaccine candidate was produced by reverse genetics in the background of 
an experimental alternative live attenuated influenza strain, WF10att.  However, the 
recombiant virus 2ma-Ca/04:6WF10att yielded low hemagglutination (HA) titer after 
amplification in 10-day-old egg embryos.  In order to improve virus yield, the first 
passage virus (P1) was serially propagated in eggs for eight total passages (P8).  The 
P8 virus showed significant increased in HA titer (>30-fold) compared to the P1 
virus.  Sequence analysis of the entire 2ma-Ca/04:6WF10att viral genome revealed a 
single amino acid mutation in the PA gene, at position 59, in which glutamic acid was 
substituted to valine (PA E59V). Inoculation of this virus into eggs resulted in 20-fold 
increase in HA titer and a 4.6-fold increase in viral titer relative to the wild-type (wt) 
PA virus.  Upon culture in MDCK cells, the PA E59V virus had an HA and viral titer 
that increased 16 and 3.9-fold, respectively, compared to wt. Western blot analysis 
and quantitative analysis of viral mRNA showed that the PA E59V virus led to earlier 
and higher production of viral protein and viral mRNAs compared to the wt virus. 
The PA E59V mutation did not impair the temperature sensitive phenotype of 
WF10att. The PA E59V mutation moderately enhanced the HA and viral titer of wt 
WF10 and another alternative live-attenuated backbone, Ty/04att. However, it had no 




cold-adapted (ca) Ann Arbor/60. Interestingly, although the E59V had no significant 
effect on increasing HA/NP ratio of the wt WF10 or WF10att based live-attenuate 
vaccine; both of these backbones resulted in higher antigenic content (higher HA/NP 
ratio) on viral particles than PR/8- or ca Ann Arbor/60-based virus particles. 
Introduction 
In April 2009, a novel swine-origin pandemic influenza virus (pH1N1) rapidly 
spread around the world. By August 2010, human cases of pH1N1 had been reported 
from more than 214 countries, and caused more than 18,000 deaths worldwide [7]. 
  The available seasonal H1N1 vaccines provided little to no protection against 
the novel pH1N1 virus [26]. Both classical reassortment and reverse genetics methods 
were applied to readily generate the vaccine candidates against the pH1N1 virus, such 
as: X-179A (New York Medical School (NYMC)(US)), IVR-153 (Commonwealth 
Serum Laboratories (CSL) Ltd (AU)), NIBRG-121 (National Institute for Biological 
Standards and Control (NIBSC)(UK)) and IDCDC-RG15 (Centers for Disease 
Control and Prevention (CDC)(US)) [262]. Due to the low viral protein yield of those 
vaccine strains in chicken egg embryos, more efforts were carried out to achieve 
higher protein yield and functional HA yield resulting in strains NIBRG-121 xp and 
X-181[262].  
In order to generate live attenuated influenza vaccine (LAIV) against pH1N1, 
Chen et al. generated several reassortants with 6:2 gene constellation (2 surface genes 
from A/California/4/09 or A/ California /7/09, and 6 internal genes from cold-adapted 




replication in egg embryos and MDCK cells, those reassortant vaccines were 
propagated two times in MDCK cells and the large plaques were isolated for the 
sequence analysis. The mutations in the HA gene contributed to the improved viral 
replication in eggs were identified. The reassortant variants carrying those mutations 
were further detected in receptor binding assay and animal study. And the results 
demonstrated that the mutations on residue 119 and 186 may largely improve the 
viral growth in eggs without affecting the antigenicity and immunogenic of the 
vaccines [347]. 
 Other strategies were also applied to develop LAIV to protect against pH1N1. 
Additional experimental vaccines were developed, such as a mutant pH1N1 virus 
with the M2 protein lacking 11 amino acids at the cytoplasmic tail could protect mice 
from infection [348]; an engineering temperature sensitive LAIV was successfully 
developed by directly introducing point mutations into PB1 and PB2 genes of a 
pH1N1 like-virus [349]. 
Previsouly, we reported the development of alternative LAIVs based on 
introduction of amino acid mutations on the PB1 (K391E, E581G, and A661T) and 
PB2 (N265S) genes and an additional HA-tag at the C-terminus of the PB1 gene in 
the background of  influenza viruses A/Guinea Fowl/Hong Kong/WF10/99 (H9N2) 
and A/turkey/Ohio/313035/2004 (H3N2), herein referred to as WF10att and Ty/04att, 
respectively. Using the WF10att background we generated a LAIV for the pH1N1 
virus based on the surface HA and NA genes from A/California/04/2009 (H1N1) 
(Ca/04). The new virus, 2Ca/04:6WF10att, produced low HA titers (4.4 ±0.4) when 




improved the HA titer (10.0 ±0.38). Sequencing results revealed no changes on the 
surface genes but instead a single amino acid mutation in the PA gene: the codon 
encoding residue 59 changed from glutamic acid to valine. 
PA, a subunit of the influenza virus RNA-dependent RNA polymerase 
(RdRP), contains an N-terminal domian with endonuclease and protease activities and 
a C-terminal domain that interacts with the RdRP’s PB1 subunit. The N-terminal 209 
amino acids of PA posses a type II restriction endonuclease activity, with active site 
that coordinated with two manganese ions (Mn+), similar to other two-metal-
dependent endonuleases. Chelation of Mn2+ by PA involves participation of two sites: 
Mn2+ site 1 involves amino acids Glu80 and Asp108; whereas Mn2+ site 2 binding 
involves His40, Asp108 and Glu109 [134,135,136,137]. The endonuclease activity of 
PA complements the process of binding and snatching of host-derived capped mRNA 
10-13 nt long primers used for the synthesis of viral mRNAs [134,138,139,140].  
In this study, the animo acid substitution E59V in PA is demonstrated to be 
responsible for the enhanced HA titer and viral yeild in eggs and MDCK cell on the 
live attenuated vaccine WF10att background. PA E59V virus resulted in earlier and 
higher production of viral protein and viral mRNAs compared to the wt virus. 
Introduction of this substitution could also moderately enhance the HA and viral titer 
of the wild-type WF10 backbone and another alternative LAIV backbone, Ty/04att; 
however, it had no significant effect on two licensed influenza vaccine internal 
backbones PR/8 and ca Ann Arbor/60. Interestingly, although the PA E59V mutation 




attenuated background; both of these backbones led to more antigenic content on the 
viral particles (higher HA/NP) than PR/8 or ca Ann Arbor/60 backgrounds. 
Materials and methods 
Virus, plasmid and cells 
The pH1N1 virus (Ca/04), wt-WF10, WF10att, wt-ty/04, and Ty/04att viruses 
have been previously described [254,350,351]. Virus stocks were prepared in specific 
pathogen free 9-day old embryonated chickens eggs following standard techniques 
for growth of influenza viruses. Madin-Darby canine kidney (MDCK) cells were 
maintained in Modified Eagle's medium (MEM) (Sigma-Aldrich, St. Louis, MO) 
containing 5% fetal bovine serum (FBS) (Sigma-Aldrich). Human embryonic kidney 
293T cells were cultured in Opti-MEM I (GIBCO, Grand Island, NY) containing 5% 
FBS. The reverse genetics 8-plasmid system for influenza A/Puerto Rico/8/1934 
(H1N1) (PR8) virus was a gift from Peter Palese, Mount Sinai School of Medicine, 
New York, NY. The RG system for the ca A/Ann Arbor/6/60 (H2N2) virus was 
produced from the homologous strain provided by Ruben Donis, CDC, Atlanta, GA, 
and cloned into the pDP2002 vector (Sutton et al, unpublished). The E59V mutation 
in PA genes from various virus backgrounds was introduced using the QuickChange 
II site-directed mutagenesis kit (Stratagene, Inc., La Jolla, CA) according to 





Generation of recombinant virus by reverse genetics 
The recombinant viruses were generated using the 8-plasmid system in co-
cultured 293T and MDCK cells as described previously [254]. 10 )l of pDP-2002 
plasmids (100 ng/ml) carrying the cDNA from each of 8 RNA segments were 
incubate with 18 )l TransIT LT-1 (Mirus, Madison, WI)  at room temperature for 45 
min, and then the mixture was transfected into co-cultured 293T and MDCK cells. 8 h 
later, the DNA-transfection mixture was replaced by Opti-MEM I. 24 h after 
transfection, 1 ml of Opti-MEM I containing TPCK-trypsin of 1.0 )g /ml was added 
to the cells. All recombinant viruses were propagated in 10-day-old embryonated 
eggs, titrated by TCID50, and stored at -70°C until use. All viruses were sequenced 
using specific primers. 
Sequence analysis 
The cDNA of the virus was prepared as previously described [254]. The total 
RNA of each sample was extracted using RNeasy Mini Kit (Qiagen, Gaithersburg, 
MD), and RNAs were eluted in 40 )l RNase-free water. The reverse trancription (RT) 
was peformed with the 4 )l of RNA sample and 1 )l Uni12 priemer using AMV 
Reverse Transcriptase (Promega, Madison, WI) at 42°C for 2 h and then 70°C for 10 
min. The specific fragment was amplified and sequenced using a combination of 
universal and custom made primers (available upon request, see Appendices). 
Sequencing was performed using the Big Dye Terminator v3.1 Cycle Sequencing kit 
(Applied Biosystems, Foster City, CA) on a 3100 Genetic Analyzer (Applied 
Biosystems, Foster City, CA) according to the manufacturer's instructions. The 




primer, 2.0 )l of RR-100 (Life technologies, Grand Island, NY) and 3.0 )l of 5x 
Sequencing buffer  (Life technologies, Grand Island, NY). The cycle conditions of 
sequencing were 96 °C 4 min, followed by 60 cycles of 96 °C 30 s, 56 °C 10s, and 60 
°C for 4 min. The reaction products were precipitated with 5)l EDTA (0.125 mM) 
and 60 )l 100% ethanol, and spin down at 3000xg for 15 min, following a wash with 
80 )l of 70% ethanol, and spin down at 3000xg for 15 min. The pellet was dried and 
dissolved in 10 )l of Hi Diformamide (HiDi, Fisher Scientific, Waltham, MA) for 
sequencing. 
Viral replication study in eggs and mammalian cells 
10-day-old embryonated eggs were inoculated with 100 or 1000 TCID50 virus 
in 0.1 ml PBS. The allantoic fluids were collected at 24, 48, 72 and 96 h post 
inoculation from 3 egg embryos. For the MDCK cells infection. The cells were 
washed with PBS for 3 times.  Confluent monolayers of MDCK cells (106 cell/well) 
in 6-well plates were infected with 1000 TCID50 of the viruses in 1.0 ml of Opti-
MEM I (MOI = 0.001). The plate was put in 4 °C for 15 min, and then transferred to 
37°C incubator for 45 min. The cells were washed with PBS for 3 times, and then 1.0 
ml of Opti-MEM I containing TPCK-trypsin of 1.0 )g /ml was added to each well. 
The viral supernatants were collected at 12, 24, 48, 72, 96 and 120 h post-inoculation. 
TCID50 from egg embryos and MDCK cells were detected as described previously 
[254].  
The inoculation of the egg embryos was carried out in triplicate; the infection 
of MDCK cells was performed in duplicate. All experiment results were confirmed 





MDCK cells were seeded in 6-well plate overnight, and then infected with 
viruses at MOI=0.1. The cells were harvested every 4 h after infection up to 24 h with 
250 )l of 2x Laemmli Sample Buffer (Bio-Rad, Hercules, CA) containing 50 )l "-
mercaptoethanol (Fisher Scientific, Waltham, MA)/ml. The samples were heated at 
100°C for 5 min and sonicated for 20 seconds, and then 20 )l  of the samples were 
loaded into a Mini-PROTEAN TGX Precast Gel (Bio-Rad, Hercules, CA). The gel 
was run for 60 min at 150 V using PowerPac basic power supply (Bio-Rad, Hercules, 
CA). Then the protein samples were transferred into supported nitrocellulose 
membrane (Bio-Rad, Hercules, CA) at 18 V for 45 min using Trans-Blot SD System 
and PowerPac HC Power Supply System (Bio-Rad, Hercules, CA). The viral protein 
HA and NS1 were detected with the monoclonal antibodies S-OIV-3B2 (prepared in 
the lab (1:500)) and Clone NS1-1A7 (from NIH (1:500)) as the primary antibody, 
rspectively; and then with HRP-conjugated goat anti-mouse IgG (SouthernBiotech, 
Birmingham, Alabama (1:5000)) as the secondary antibody. The image was 
developed using SuperSignal West Pico chemiluminescent substrate (Fisher 
Scientific, Waltham, MA). The image was scanned and the optical density of each 
sample was quatitatived using densitometry software Quantity One version 4.6.5 
(Bio-Rad, Hercules, CA), and then the relative amount of the proteins were further 
calculated. GAPDH was taken as the cellular internal control.  
This experiment has been repeated 2 times. However, quantitative 




Reverse transcription and real-time PCR 
MDCK cells were seeded in 6-well plate overnight, and then infected with 
viruses at MOI=0.1. The cells were collected at the early phase of infection at 1, 5, 9 
and 13 h.p.i. using Trypsin-EDTA solution (Sigma-Aldrich, St. Louis, MO). The total 
RNA of each sample was extracted using RNeasy Mini Kit (Qiagen, Gaithersburg, 
MD), and RNAs were eluted in 40 )l RNase-free water. The reverse trancription (RT) 
was peformed with the 4 )l of RNA sample and 1 )l specific tagged RT priemers as 
listed in Table 5.3 using AMV Reverse Transcriptase (Promega, Madison, WI) at 
42°C for 2 h and 70°C for 10 min. The reverse transcription of the internal control 
MDCK 18s rRNA was performed with a random 15- oligomer (Sigma-Aldrich, St. 
Louis, MO). 
Quantitative real-time PCR (qPCR) was performed with Lightcycler 480 
SYBR Green I Master (Roche Applied Science, Indianapolis, IN), on a CFX96 Real-
time System (Bio-Rad, Hercules, CA). 2 )l of 10-fold dilution of the cDNA was 
added to the qPCR reaction mixture (10 )l Lightcycler 480 SYBR Green I Master 
(2(), 1.5 )l forward primer (10 )M), 1.5 )l reverse primer (10 )M), and 5 )l 
millipore water). The cycle conditions of qPCR were 95 °C 10 min, followed by 40 
cycles of 95 °C 15 s and 63 °C for 1 min. The internal control MDCK 18s rRNA was 
used for normalization, the real-time PCR of the virus samples was performed with 
specific primers as listed in Table 5.3. Data were analyzed using the Bio-Rad iQ5 
software version 2.1 (Bio-Rad, Hercules, CA). The relative level of mRNA, vRNA 




This experiment has been performed once in triplicate. “Relative Quantity 
(mean)” and “Relative Quantity SD (standard deviation) ” produced by Bio-Rad iQ5 
software version 2.1(Bio-Rad, Hercules, CA).  “2-sample t-test” was performed for 
the t-statistic of the RNA samples:  
 
Here: SD1=(3/2) + * S1; SD2=(3/2) + * S2. n1= n2=3. Therefore, t= (MeanmPA-
MeanPA)/(( SDmPA2/2)+ ( SDPA2/2))1/2. Df=n1+n2-2=4. 
I calculated the t-statistic for each RNA sample at different time points with t= 
(MeanmPA-MeanPA)/(( SDmPA2/2)+ ( SDPA2/2))1/2 using Microsoft EXCEL (All Means 
and SDs have been already determined by Bio-Rad iQ5 software version 2.1).  With 
degrees of freedom =4, I compared the t-value of mRNA, vRNA and cRNA at 1, 5, 9 
and 13 h.p.i. I calculated from above to the “t distribution table” at the chosen 
confidence level and decide whether to accept or reject the null hypothesis. 
The comparison of HA/NP ratio of the purified viruses using 
ELISA 
1000 TCID50 virus was inoculated into thirty 10-day-old embryonated eggs. 
200 ml of the allontoic fluid of each virus was harvested at 3 d.p.i., and then purified 
using sucrose cushion centrifugation with Ultra-Clear centrifuge tubes (Beckman 
Coulter, Sykesville, Maryland) and L-90K Ultracentrifuge (Beckman Coulter, 
Sykesville, Maryland) at 25,000(g for 2h. The concentrated pellet was dissolved in 8 




In the ELISA, the purified virus was lysed with lysis buffer (0.5% Tween-20 
in PBS). The lysed virus was used as coating antigen, the mouse monoclonal antibody 
against HA: S-OIV-3B2 (prepared in the lab, specific to HA of A/California/04/2009 
(H1N1)) or NP: 2F4 (prepared in the lab, specific to NP of influenza virus) was used 
as first antibody, and the HRP-conjugated goat anti-mouse IgG (Southern biotech, 
Birmingham, AL) was used as detection antibody. The virus (diluted in 
carbonate/bicarbonate buffer, pH 9.6) was coated to 96-well plates for 12h at 4°C. 
After one wash with PBST (0.05%Tween-20 in PBS), the plate was blocked with 5% 
(w/v) non-fat milk in PBS for 1h at 37°C. After one wash with PBST, the first 
antibody was diluted (1:5000) in dilution buffer (0.5%BSA in PBS) and added to the 
wells (100)l/well). The mixture was incubated at 37°C for 1 h. After wash three 
times with PBST, 100)l HRP-conjugated goat anti-mouse IgG (1:10000) diluted in 
dilution buffer was added to well and the mixture was incubated for 1 h at 37°C. 
After five washes with PBST, the development was performed using the TMB 
substrate system (KPL, Gaithersburg, Maryland) for 15 min. The ratio of the OD650 
value of the sample wells (S) to that of the negative control wells (N) was determined, 
and the ratio of HA to NP from the same sample was calculated. However, this 
experiment was performed only once. 
Statistical analysis 
All figures were generated and all statistical analyses were performed with 
GraphPad Prism software version 5.0c (GraphPad Software Inc., San Diego, CA).  
Comparison between the means of two groups was carried out with a paired two-




variance (ANOVA) with Tukey’s multiple comparison test, unless otherwise 
specified. P values of <0.05 were considered significant difference. The statistical 
analysis of the “real-time PCR” was performed with “2-sample t-test” using 
Microsoft EXCEL, and compared with “t distribution table”. 
Results 
Preparation of an alternative pH1N1 live attenuated 
influenza virus (LAIV) based on the WF10att background 
(pH1N1 WF10att) 
During the emergence of pH1N1, a LAIV was produced carrying the two 
surface genes from A/California/04/2009 (pH1N1) (Ca/04) in the WF10att 
background (2 Ca/04:6 WF10att) (Table 5.1). The amplification of virus in 10-day-
old eggs, however, resulted in low HA titer (4.4 ±0.4). To enhance the viral growth, 
the first passage virus (P1) was further serially propagated in eggs for a total of eight 
passages (P8). The results showed the viral HA titer of the P8 (10 ±0.38) virus 
increased at least 30 fold compared to P1 (Table 5.2). 
Cooperated with Hongjun Chen, I finished the whole genome sequecing of P1 
and P8 viruses at 3x coverage. Five nucleotide substitutions were found in the PA and 
PB2 segments in P8 virus. However, only one nucleotide substitution in PA is non-
synonymous, and rest four nucleotide substitutions caused no amino acid change 
(Table 5.3). Generally during egg adapation of influenza viruses amino acid 
substitutions on the surface of HA and NA proteins are expected,  which can enhance 




Interestingly, full-length genome sequencing of the P8 virus revealed no mutations 
resulting in amino acid changes on HA and NA. Instead, a single amino acid mutation 
was detected in the PA gene: amino acid 59 changed from glutamic acid to valine 
(E59V).  
The enhanced HA and viral titer of live-attenuated virus was 
confirmed in egg embryos and MDCK cells using reverse 
genetics 
To investigate if PA E59V is responsible for the enhanced HA titer, we 
generated the viruses containing either mutated PA (E59V) or wild-type (wt) PA 
using reverse genetics (Table 5.1). The viruses were inoculated into 10-day-old egg 
embryos, and HA and viral titer were detected at 3 d.p.i. The HA  titer of virus 2ma 
Ca/04:mPA(E59V):5WF10att increased at least 20-fold compared with that of the 
recombinant virus with the wt PA (Figure 5.1A and E); and the viral titer increased 
4.6-fold than that of the recombinant virus with the wild-type PA at HA peak (Figure 
5.1B and F). Similarly, when infected MDCK cells, the HA titer and the viral titer of 
2 ma Ca/04:mPA(E59V):5WF10att increased 16 and 3.9-fold, respectively, compared 
with those of the virus with the wild-type PA (Figures 5.1C and G, and Figures5.1 D 
and H). 
We further confirmed the role of PA E59V on viral HA synthesis using 
western blot. MDCK cells were infected with either E59V or wt PA virus at 
MOI=0.1; the viral supernatants were collected every 4 h after infection up to 24 h. 
The expression level of HA (CA/04) and NS1 (WF10) were detected using western 




early as 8 h.p.i. in E59V samples; while no signals could be detected from the wt PA 
samples at the same time point (Figure 5.2D and E). The strong HA signal could be 
detected in the E59V infected cell lysate from 12 h.p.i. (Figures 5.2C and D). The 
results suggested HA expression level was greatly up-regulated by PA E59V during 
the infection with live-attenuated virus. 
The substitution of PA E59V increased mRNA, cRNA and 
vRNA level during early phase of infection in MDCK cells 
using strand-specific real-time RT-PCR 
To investigate the role of PA E59V on viral RNA transcription and 
replication, we applied strand-specific real-time RT-PCR to evaluate the mRNA, 
cRNA and vRNA levels during early phase of infection; and selected HA and NP as 
the target genes for detection. The reverse trancription of HA (ma Ca/04) and NP 
(WF10) genes were peformed with specific tagged priemers “RT mRNAtag”, “RT 
vRNAtag” or “RT cRNAtag” (Table 5.4). The quantitative real-time PCR performed 
with specific primers “mRNAtag”, “vRNAtag” or “cRNAtag” which was reverse 
complement to the partial sequence of the tagged primer in the RT process, and the 
internal primers as listed (Table 5.4). The result showed: for HA gene, 2ma 
Ca/04:mPA(E59V):5WF10att increased the mRNA level 8- and 2.5-fold, and 
increased the vRNA level 9- and 4.3-fold at 9 and 13 h.p.i., respectively, compared to 
those of wt-PA virus at 9 and 13 h.p.i. (Figures 5.3A and B). Similarly, for the NP 
gene, at 9 and 13 h.p.i., 2ma Ca/04:mPA(E59V):5WF10att increased the mRNA level 
6.5- and 2.5-fold and increased vRNA level 7.9 and 7.1-fold, respectively, compared 




The substitution of PA E59V did not impair the temperature 
sensitive phonotype of the live-attenuated backbone 
To study if PA E59V affects the temperature sensitive phenotype of WF10att, 
MDCK cells were infected with PA E59V or wt PA virus, and cultured at 35°C and 
39°C. The kinetic curve of the viral replication suggested that the viral replication at 
39°C was severely restricted, with viral titers reduced more than 1000-fold relative to 
those at 35°C (Figure 5.4), which indicated that the substitution E59V did not impair 
the temperature sensitive phenotype of the backbone. 
The substitution of PA E59A had no effect on the viral 
replication of live-attenuated virus in egg embryos and 
MDCK cells 
To investigate if position 59 on PA gene is critical to the viral replication in 
the live-attenuated viruses, we substituted this amino acid to alanine, and generated 
2ma Ca/04:mPA(E59A):5WF10att (Table 5.1) using reverse genetics. The viral 
kinetics of live-attenuated viruses carrying PA 59V, 59E and 59A were compared in 
egg embryos and MDCK cells. However, no significant difference in HA or viral titer 
has been detected between the viruses with PA 59E and 59A during infection (Figure 
5.5), which indicated that PA position 59 may not be the critical amino acid 
responsible for the viral RNA-dependent polymerase activity in the live-attenuated 
influenza viruses. Take together, PA 59V may contribute to a regulation mechanism 





The substitution of PA E59V moderate enhanced the HA titer 
of vaccines with WF10 and Ty/04att backbones; but had no 
effect in PR/8 and Ann Arbor backbones 
To investigate if PA E59V has the effect of enhancing the HA and viral titers 
in other live-attenuated and inactivated influenza vaccine systems, we introduced this 
substitution into PA of wild-type WF10, PR8, ca Ann Arbor/60 and Ty/04att 
backbones (Table 5.1); and inoculated egg embryos and MDCK cells with the 
recombinant viruses. However, amongst those four systems, only wild-type WF10 
and Ty/04att backbones with PA E59V displayed moderately enhanced HA and viral 
titers in egg embryos and MDCK cells (Figures 5.6A-D, and Figures 5.6E-H); while 
introducing of this substitution did not affect the HA titer of virus with PR8 or ca Ann 
Arbor/60 backbone in egg embryos (Figures 5.6I and K, and Figures 5.6J and L). 
WF10att  and wild-type WF10 backbones have higher HA/NP 
ratio than that of PR8 and Ann Arbor/60 
To investigate if substitution PA E59V can cause the particles to incorporate 
more HA proteins into the live-attenuated virus, and to compare which vaccine 
backbone may include more HA content, we detected the HA and NP level of 
purified live-attenuated and inactivated viruses, and compared the HA/NP ratio of 
each virus. However, in the WF10att and wt-WF10 system, the result revealed that 
the introduction of E59V did not significantly increase the HA/NP ratio (Table 5.5). 
As the amount of NP is generally taken as a constant in a viral particle, the result 
indicated that E59V could not increase the number of HA molecules on the surface of 




Interestingly, compared with HA/NP ratio of PR8 (3.27) and ca Ann Arbor/60 
(3.86) system, WF10att and wt-WF10 has the HA/NP ratio more than 5.0 (Table 5.5), 
which suggested that these two system may incorporate more HA content than other 
two systems when produce recombinant vaccines. However, this experiment has been 
performed only once, and repeating is needed to confirm the result. 
Discussion 
The embryonated chicken eggs have been widely used for influenza vaccines 
production. However, the amplification of the human-like virus isolates, especially 
H1N1 and H3N2 subtype, generally showed low viral protein yield in eggs 
[262,353,354,355]. Several approaches are employed to improve the virus growth in 
eggs. To further serially pass in eggs is the most straightforward method to improve 
the viral growth [262,353,356,357].  For example, a live-attenuated vaccine strain 
against seasonal influenza H3N2 A/Fujian/411/02 was generated by reassorting the 
HA and NA segments of H3N2 virus with the internal segments of ca A/Ann 
Arbor/6/60. Inoculation of reassortant vaccine in chicken eggs resulted in poor 
replication. Three more passages in eggs dramatically increased the virus titer from 
1.5 log10 PFU/ml to 8.2 log10 PFU/ml. Two amino acid substitutions in the HA 
(H183L and V226A) contribute to the improved virus replication in eggs, as well as 
the enhanced receptor-binding activity [357]. The first available candidate vaccine 
viruses against an A/California/7/2009-like virus, such as NIBRG-121 showed 
disappointingly low virus protein yield in eggs. The protein yield was greatly 
improved by serial passage of NIBRG-121 for ten more times. The substitution 




yield observed in the egg-adapted vaccine [353]. Propagating the virus in mammalian 
cells, isolating the large-morphology for the test of viral replication in eggs is also 
been applied to improve the vaccine virus replication in eggs. A live attenuated 
influenza virus A/California/7/9 (H1N1) vaccine strain carrying the HA and NA gene 
segments of the 2009 pandemic virus and the six internal gene segments of ca A/Ann 
Arbor/6/60 (H2N2) replicated poorly in chicken eggs. The reassortant viruses were 
propagated twice in MDCK cells with different MOI, and the supernatants were 
detected by plaque assay. The HA segments from the MDCK-passaged viruses with 
much larger size of the plaques were further sequenced. The results revealed that 
several amino acid substitutions were responsible for the enhanced viral replication in 
MDCK cells and eggs. However, only the substitutions at residues 119 and 186 did 
not change the antigenicity or immunogenicity of the virus [347].  
The previously identified amino acid substitutions in HA which are 
responsible for the improved the viral growth in eggs can also be a good reference for 
the novel vaccine strain with the same subtype [347,356]. For example, the 
substitutions G186V and V226I or H183L and V226A in the HA have been 
discovered to contribute to the improved virus replication of live attenuated vaccine 
against seasonal influenza H3N2 A/Fujian/411/02 in eggs. Those substitutions were 
introduced into the HA of another H3N2 virus A/Singapore/21/04 by reverse 
genetics. The results showed that G186V also has the effect on enhancing the virus 
replication of this strain in eggs [356]. However, the vaccine strains needs to be 




the HA antigenic site or/and receptor binding site, affect the antigenicity and 
immunogenic of the vaccine, and protection efficacy [358,359]. 
In order to evaluate the live attenuated Influenza virus as a candidate to 
protect human and animals from the infection of newly emergent pH1N1 2009, our 
lab selected ma Ca/04 strain as an alternative to A/California//04/2009. This strain 
contains two mutations D131E and S186P on HA, which are responsible for the 
increased virulence for mice; and these two mutations were also found in increased 
human cases after 2009 ([350] and Ye et al, unpublished).  
Our lab generated live attenuated influenza virus 2ma-Ca/04:6WF10att 
against pH1N1 2009 replicated poorly in eggs firstly. After passed the virus 7 more 
times in eggs, the virus had dramatic increased in HA titer. Interestingly, the whole 
genome sequencing result of the egg-adapted virus showed that the amino acid 
substitution did not appearred on the surface glycoprotein HA or NA, but on the 
internal gene PA: residue 59 mutated from glutamic acid to valine. We obtained the 
live attenuated WF10att virus contained this amino acid substitution using reverse 
genetics, and confirmed the effect of E59V on incraesing the HA yeild and viral 
growth.  
PA is the subunit of influenza virus RdRP heterotrimer, and characterized to 
be a type II restriction endonulease in the crystal structure study. The function of PA 
residue 59 is unclear, but according to the crystal structure of PAN, E59 is also 
coordinated with Mn1 and Mn2 from close molecule, which suggest that amino acid 




The kinetic study in 35 and 39°C showed that PA E59V did not impair the 
temperature sensitive phenotype of live attenuated WF10att backbone. As the single 
mutation is on the internal gene, this mutation is not likely to affect the antigenicity 
and immunogenic. 
The conventional real-time RT-PCR approach performed with the strand-
specific primers, and generally showed low specificity. In contrast, the novel strand-
specific reverse transcription method developed recently greatly improved the 
product specificity using tagged primers to add a 18-20 nucleotides “tag” on the 5’-
end which is not related to influenza sequences [360]. We selected canine18S rRNA 
as the reference gene (internal control) for the normalization of real-time RT PCR 
data, as compared with other tested housekeeping genes, 18S rRNA was the most 
stable in the influenza virus infected cells [361]. To generate the viral RNA synthesis 
profiles during infection, we applied this tagged primer strand-specific real-time PCR 
method. The results showed, both viral mRNA transcription level and vRNA 
replication level were significantly up-regulated in HA and NP genes by the 
substitution of PA E59V at the early phase of infection; which indicated that this 
mutation enhanced RdRP activity of the live attenuate WF10att vaccine when 
carrying the pH1N1 2009 surface glycoprotein.  
However, the alignment of PA genes from different subtypes of Influenza 
viruses displayed that glutamic acid at residue 59 is highly conserved in most of the 
virus strains, and PA E59V substitution did not enhance the HA and viral titers in 
PR8 and ca Ann Arbor/60 backbones. In another experimet, the replacement of PA 




and MDCK cells. All together, the amino acid substitution of E59V on PA gene is the 
result of viral adaptation under the selestion stress of embryonated chicken eggs; this 
substitution could be backbone-specific, not critical to the RdRP activity, but confer 
the live attenuated system enhanced HA yeild and better viral growth without 
imparing the temperature sensitive phenotype of WF10att. The substitution PA E59V 
also confer WF10att backbone higher capbility to replicate better in eggs with the 
glycoprotein derived from human-like influenza virus. 
To compare the HA yield and viral growth of pH1N1 2009 vaccines with 
different backbone systems, as well as to investigate if the substitution of PA E59V 
could cause the viral particle to incorporate more HA molecules on the surface, we 
purified and concentrated the viruses in this study and then determined the HA titer, 
viral titer and HA/NP ratio of each virus. In the live attenuated vaccine group, 
WF10att backbone with PA E59V mutation achieved the best HA titer (4096) and 
viral titer (5.6x109); while in the inactivated vaccine group, PR8 system obtained the 
highest HA titer (4096) and viral titer (1.8x1010) (Table 5.5). Unlike our hypothesis, 
PA E59V did not provide higher HA/NP ratio in either WF10att or wt WF10 systems, 
which indicated E59V could not increase the number of HA molecules on the surface 
since the amount of NP is generally unchanged in a viral particle. Interestingly, we 
found the HA/NP ratios of WF10att wt WF10 are more than 5.0, which are much 
higher than that of PR8 or ca Ann Arbor/60 systems (Table 5.5). HA is the most 
important antigen to elicit the neutralization antibody in the host immune response. 




proved to be valuable to contain more antigen content from embryonated chicken 
eggs and mammalian cells.  
I also planned to study the mechanism of PA E59V on HA and viral titer 
promotion using the endonuclease activity assay. I cloned N-terminal 210 amino 
acids of WF10 mPA (E59V) and wt-PA into pET-15b vector. However, the 
expression of PA-Nter in BL-21 E.coli was not successful.  After pre-culture, the 
bacteria strains were inoculated 1:50 into 5 ml of LB media. I tried culture at 37°C for 
5-8 h or at room temperature (around 25°C) for overnight until the OD600 was 
0.4~0.7. The induction of protein express was carried out by the addition of 0.2, 0.5 
or 1.0 mM Isopropyl !-D-1-thiogalactopyranoside (IPTG) into the media. The 
bacteria were harvested at 6 and 12 h after induction, and the expression of the 
protein was detected using SDS-PAGE gel. However, compared with blank plasmid, 
no extra band has been found around the molecular weight 33 kDa (PA-Nter). Other 
conditions, such as culturing at 16°C or inducing with 2.0 mM IPTG should be try to 
















Virus HA and NA Internal Genes (PB1, 
PB2, NP, M and NS) 
PA 
2ma Ca/04: 6WF10att mouse-adapted Ca/04 H1and N1 WF10att PA ( WF10att) 
2ma Ca/04:mPA(E59V):5WF10att mouse-adapted Ca/04 H1and N1 WF10att PA E59V ( WF10att) 
2ma Ca/04: 6WF10 mouse-adapted Ca/04 H1and N1 WF10 PA (WF10) 
2ma Ca/04:mPA(E59V):5WF10 mouse-adapted Ca/04 H1and N1 WF10 PA E59V (WF10) 
2ma Ca/04: 6PR8 mouse-adapted Ca/04 H1and N1 PR8 PA (PR8) 
2ma Ca/04:mPA(E59V):5PR8 mouse-adapted Ca/04 H1and N1 PR8 PA E59V (PR8) 
2ma Ca/04: 6ca Ann Arbor mouse-adapted Ca/04 H1and N1 ca Ann Arbor PA ( ca Ann Arbor) 
2ma Ca/04:mPA(E59V):5ca Ann 
Arbor 
mouse-adapted Ca/04 H1and N1 ca Ann Arbor PA E59V ( ca Ann Arbor) 
2ma Ca/04: 6Ty/04att mouse-adapted Ca/04 H1and N1 Ty/04att PA (Ty/04att) 
2ma Ca/04:mPA(E59V):5Ty/04att   mouse-adapted Ca/04 H1and N1 Ty/04att PA E59V (Ty/04att) 






Table 5.2. Enhanced HA titers after serially propagated recombinant influenza virus ma-CA/04 
H1N1:6WF10att in egg embryos. 
 
Passage HA Titer (log2) Mean±standard error of 
the mean 
1 5, 4, 3, 5, 5  4.40 ±0.40 
2 5, 5, 5, 5, 6 5.20±0.20 
3 6, 3, 7, 8, 7, 7 6.33±0.72 
4 9, 6, 7, 7, 6 7.00±0.55 
5 8, 9, 9, 9, 8 8.60±0.25 
6 9, 9, 8, 11, 9, 6, 8 8.57±0.57 
7 11, 9, 11, 9 10.00±0.58 







Table 5.3. The nucleotide changes in the genes of P8 virus. 
 
 
Gene Nucleotide position 
Nucleotide 
change Amino acid 
Synonymous or non-
synonymous mutations  
PA 
215 A ! T/A Glu ! Val/Glu Non-synonymous 
495 A ! A/T/C Gly ! Gly Synonymous 
2061 A!A/T Leu ! Leu Synonymous 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 5.5. The comparison of HA to NP ratios of the pH1N1 vaccines with 












4096 5.0x107 5.6x109 5.29 
ma-Ca/04 H1N1: 
6WF10att 
256 2.3x106 3.2x108 5.15 
ma-Ca/04 H1N1: 
6ca Ann Arbor 





4096 5.0x107 5.6x109 5.22 
ma-Ca/04 H1N1: 
6WF10 
2048 2.3x107 3.2x109 5.18 
ma-Ca/04 H1N1: 
6PR/8 




















































































































































































































Figure 5.1. Comparison of the HA and viral titers of mPA (E59V) and wt-PA viruses in 
10-day-old embryonated eggs and MDCK cells. 100 TCID50 of the viruses were inoculated 
in 10-day-old embryonated eggs and the HA titers of the allantoic fluid were detected every 
24 hpi (A), or (E) at 4 d.p.i., and the viral titers of the samples were detected using TCID50 
method in MDCK cells (B and F). MDCK cells were infected with the viruses at MOI=0.005. 
T he HA titers of the supernatants were detected at 24, 48, 72, 96 and 120 hpi (C) or at 96 
h.p.i (G), and the viral titers of the samples were detected using TCID50 method in MDCK 














































































Figure 5.2. Comparison of the viral protein: HA and NS1 synthesis level in 
MDCK cells during infection. MDCK cell were infected with 2ma-Ca/04 
H1N1:mPA (E59V):5WF10att (m) or 2ma-Ca/04 H1N1:6WF10att (wt) at 
MOI=0.1.  The protein synthesis levels of HA and NS1 were detected (A) at 4, 8, 
24 and 48 h.p.i; (B) at 9, 11, 13, and 24 h.p.i; and (C) at 4,8,12,16,20 and 24 h.p.i. 
using western blot. Cells were mock (M) infected with PBS. The protein synthesis 
levels of the HA (D) and NS1 (E) in (C) were quantitative by densitometry, and 










* indicates a P-value<0.05, ** indicates a P-value<0.005. 
 
Figure 5.3. Evaluation of HA and NP viral mRNA, cRNA and vRNA level at 
early phase of infection in MDCK cells at different time points using RT real-
time PCR. MDCK cells were infected with 2ma-Ca/04 H1N1:mPA 
(E59V):5WF10att and 2ma-Ca/04 H1N1:6WF10att. The cell samples were 
harvested at 1, 5, 9 and 13 h.p.i. The viral RNA expression levels of HA and NP 
were detected by using influenza virus segment specific tagged primers. The relative 
mRNA (A), vRNA (B) and cRNA (C) levels of the HA, and the relative mRNA (D), 
vRNA (E) and cRNA (F) levels of the NP were calculated by comparing the 






Figure 5.4. Viral replication kinetics of the live-attenuated viruses in MDCK 
cells at 35°C and 39°C using MOI of 0.001. Viral titers at different time points 
























































































HA titers in MDCK cells






















Viral titers in MDCK cells 



















































Figure 5.5. The comparison of live-attenuated viruses of PA 59A with 59E and 
59V in egg embryos and MDCK cells. 100 TCID50 of the viruses were inoculated in 
10-day-old eggs and the HA titers of the allantoic fluid were detected at 3 d.p.i. (A), 
and the viral titers were detected using TCID50 method in MDCK cells (B). MDCK 
cells were infected with the viruses at MOI=0.01. The HA titers of the supernatants 
were detected at 24, 48, 72, 96 and 120 h.p.i. (C), and the viral titers were detected 
using TCID50 method in MDCK cells (D). The virus replications of PA 59E and 59A 
were also compared (E) in eggs by inoculated with 100 TCID50 of the virus and (F) in 
MDCK cells by infected with the virus at MOI=0.01. The peak HA titers of the viruses 




WF10 backbone in eggs 






















WF10 backbone in MDCK cells









































WF10 backbone in MDCK 





















Ty/04 att backbone in eggs




















Ty/04 att backbone in MDCK cells




















Ty/04 backbone in egg embryos 





















Ty/04 backbone in MDCK cells 

















































































































Figure 5.6. Evaluation of the effect of PA amino acid 59 substitution on WF10, Ty/04att , 
PR8 and ca Ann Arbor/60 internal backbones. (A) and (C) 100 TCID50 of the viruse 2ma 
Ca/04 H1N1:mPA(E59V):5WF10 or 2ma Ca/04 H1N1: 6WF10, or (E) and (G) 2ma Ca/04 
H1N1: 6Ty/04att or 2ma Ca/04 H1N1:mPA(E59V):5Ty/04att were inoculated in 10-day-old eggs 
and the HA titers of the allantoic fluid were detected every 24 h.p.i. MDCK cells were infected 
with the viruses of (B) and (D) WF10 or (F) and (H) Ty/04att backbones at MOI=0.005 and the 
HA titers of the supernatants were detected at 24, 48, 72, 96 and 120 h.p.i. (I) and (K) 100 
TCID50 of the virus 2ma Ca/04 H1N1:mPA(E59V):5PR8 or 2ma Ca/04 H1N1: 6PR8, and (J) 
and (L) 2maCa/04 H1N1:mPA(E59V):5ca Ann Arbor/60 or 2maCa/04 H1N1: 6ca Ann Arbor/60 





Chapter 6: Cytoplasmic Accumulation of NS1 
Enhances the Viral Replication and Anti-apoptotic 
activity of an Avian Influenza Virus (H9N2)  
 
Abstract 
To better understand the molecular mechanism of the adaptation and interspecies 
transmission of influenza viruses, our lab previously generated two adapted 
viruses from wildtype duck H9N2, A/duck/Hong Kong/702/79 (WT702) virus, 
through 23 serial passages in lung of quail, and followed by 10 serial passages in 
the chickens. The quail-adapted virus is named as QA23, and the virus further 
adapted in chickens is named as QA23CkA10.  QA23CkA10 gained the new 
phenotype of replicating and transmitting efficiently in both chickens and quail. 
And more importantly, both QA23 and QA23Ck10, unlike WT702, were able to 
infect mice without any further adaptation. We were particularly interested in the 
mutated NS1 gene of QA23, as NS1 has multiple functions, such as antagonizing 
host immune responses during viral infection. Three amino acid substitutions 
M106T, K217E and K219E were identified in QA23 NS1 as well as QA23Ck10 
NS1. The localization study and the nuclear and cytoplasmic protein distribution 
assay demonstrated that QA23 NS1 mainly accumulated in the cytoplasm; in 
contrast, WT702 NS1 predominantly accumulated in the nucleus. In this H9N2 
influenza virus strain, residue 219 played the critical role on the nucleus 




signal instead of NLS1. Minigenome assay in DF1 cells demonstrated that QA23 
NS1 up-regulated the viral protein synthesis. The enhanced cytoplasmic 
accumulation of QA23 NS1 did not affect the inhibition of IFN- !, while the 
apoptotic activity level of the cell was greatly reduced during the infection. 
However, the mutated NS1 did not affect the virus replication and transmission in 
Japanese quail. Take together, the increased cytoplasmic accumulation of NS1 
may enhance the viral replication and reduce apoptotic activity in the host cells. 
Introduction 
NS1 protein contains 230-237 amino acids, depending on the strains, and 
has a molecular weight around 26 kDa. According to the biological function, NS1 
can be divided into the N-terminal (residues 1-73) RNA-binding domain (RBD) 
and C-terminal (residues 84-207) effector domain (ED), which are connected by a 
linker. The structure of the 20 amino acids on the C-terminal domain may be 
naturally disordered.  
The structures of RBD domain and ED domain, and the locations and key 
residues of NLS1, NLS2, NES and NoLS have been discussed in Chapter 1 and 3.  
 One of the major functions of NS1 is to antagonize the innate immune response 
of the host during influenza infection, especially to limit the production of 
interferon beta (IFN-!) induction by interacting with multiple host factors, such as 
CPSF30, PABPII, RIG I, TRAM25, OSA and PKR (discussed in Chapter 1 and 
3).  
To our notice, several important functions of NS1, such as the PDZ 




Some of those functions are associated with the virulence of the influenza virus. I 
summarized the strain-specific functions of NS1 from the references, and listed in 
Table 1.2. 
The nucleus/cytoplasm accumulation pattern of NS1 may affect its 
interaction with the host factors, because some host factors distribute only in the 
nuclear or cytoplasm. For example, compared to the NS1 of its low pathogenic 
precursor H7N1 (A/chicken/Italy/1082/99), the NS1 of the highly pathogenic 
H7N1 (A/ostrich/Italy/984/00) carried two mutations in NES, and a 6-amino acid 
truncation at the C-terminus resulted from the third mutation. The cytoplasmic 
accumulation of NS1 is responsible for the enhanced pathogenicity of this HP 
H7N1 strain [199]. 
Our lab previously generated two adapted viruses QA23 and QA23CkA10 
from a wildtype duck H9N2 (WT702) virus. Both viruses gained the new 
phenotype of replicating and transmitting efficiently in both chickens and quail, 
and directly infecting mice. These two viruses also showed faster growth kinetics 
in MDCK and CEK cells [98]. The comparison of the deduced amino acid 
sequences from the ORF of QA23, QA23Ck10 and WT702 revealed that 14 and 
17 amino acid substitutions and throughout the viral genome and a 21-amino acid 
deletion in NA in the adapted viruses QA23 and QA23Ck10 compared with 
WT702 [98]. Of particular interest, however, were the amino acid mutations on 
NS1, as NS1 is one of the most important pathogenesis factors and has multiple 
functions during viral infection. Three amino acid substitutions were identified in 




localization study using Immunofluorescence assay and dissociation of nuclear 
and cytoplasmic fractions displayed that QA23 NS1 predominantly accumulated 
in the cytoplasm; in contrast, WT702 NS1 predominantly distributed in the 
nucleus. Residue 219 played the critical role on the nucleus importing of NS1, 
and nuclear localization sequence 2 (NLS2) is the major signal instead of NLS1. 
Minigenome assay in DF1 cells demonstrated that QA23 NS1 up-regulated the 
viral protein synthesis. The enhanced cytoplasmic accumulation of QA23 NS1 did 
not affect the inhibition of IFN- !, while the apoptotic activity level was greatly 
reduced during the early phase of the infection. However, there is no evidence 
showing that QA23 NS1 is associated with the enhanced replication and 
transmission of the virus in quail. Take together, the increased cytoplasmic 
accumulation of NS1 may enhance the viral replication and reduce apoptotic 
activity in the host cells. 
Materials and methods 
Virus, plasmid and cells 
The A/Duck/Hong Kong/702/79 (H9N2) virus (WT702) was kindly 
provided by Dr. Robert G. Webster, St. Jude Children's Research Hospital, 
Memphis, TN. The quail-adapted (QA23) virus was generated and isolated as 
previously described [98]. The virus stocks were prepared in specific pathogen 
free 9-day old embryonated chickens eggs following standard techniques for 
growth of influenza viruses. The RG 8-plasmid system for the WT702 and QA23 




A549 and HeLa cells, as well as DF1 cells, MDCK cells were maintained in 
Modified Eagle's medium (MEM) (Sigma-Aldrich, St. Louis, MO) containing 
10% fetal bovine serum (FBS) (Sigma-Aldrich). Human embryonic kidney cell-
line 293T (HEK293T) were cultured in Opti-MEM I (GIBCO, Grand Island, NY) 
containing 5% FBS.  
The green fluorescence protein eGFP-NS1 fusion plasmids were 
constructed as following: the amplified full-length of WT702 and QA23 NS1 
gene were digested with PstI and BamHI, and cloned into pEGFP-C1 expression 
vector (Clontech, Mountain View, CA) digested with identical enzymes. The C-
terminus of the eGFP protein is connected with the N-terminus of the NS1. 
All mutations were introduced using the QuickChange II site-directed 
mutagenesis kit (Stratagene, Inc., La Jolla, CA) according to manufacturer's 
protocols with the specific primers. The presence of each mutation was confirmed 
by sequencing.  
Generation of recombinant virus by reverse genetics  
The recombinant viruses were generated using the 8-plasmid system in co-
cultured 293T and MDCK cells as described previously [254]. All recombinant 
viruses were propagated in 10-day-old embryonated eggs, titrated by TCID50, and 
stored at -70°C until use. All viruses were sequenced using specific primers. 
Sequence analysis 
The cDNA of the virus was prepared as previously described [254]; the 
specific fragment was amplified and sequenced using a combination of universal 




was performed using the Big Dye Terminator v3.1 Cycle Sequencing kit (Applied 
Biosystems, Foster City, CA) on a 3100 Genetic Analyzer (Applied Biosystems, 
Foster City, CA) according to the manufacturer's instructions. 
Immunofluorescence assay 
For the eGFP-NS1 fusion protein localization, 293T, MDCK, A549 and 
DF1 cells were seeded on glass coverslips overnight. 200ng of eGFP-NS1 
plasmid was incubate with 3.6 !l TransIT LT-1 (Mirus, Madison, WI) at room 
temperature for 45 min, and then the mixture was transfected into the cells. 8 h 
later, the DNA-transfection mixture was replaced by Opti-MEM I. At 24 h post 
transfection, the cells were fixed with 4% paraformaldehyde solution, washed 
with PBS, incubated with 0.2% Triton X-100 in PBS. After further washes with 
PBS, cells were incubated with 4",6-diamidino-2-phenylindole (DAPI ; 1 mg /ml; 
Thermo Scientific, West Palm Beach, FL), and processed for 
immunofluorescence microscopy using a Zeiss SM510 confocal microscope (Carl 
Zeiss Microscopy, Thornwood, NY).  
For the immunostaining assay, DF1 cells were seeded in Nunc Lab-Tek II 
chamber slides (Thermo Scientific, West Palm Beach, FL) overnight, and infected 
with virus WT702 or QA23 NS:7WT702 at MOI=1. At 9 h.p.i., cells were fixed 
with 4% paraformaldehyde solution, washed with PBS, incubated with 0.2% 
Triton X-100 in PBS, and blocked with 5% bovine serum albumin (BSA). 
Incubation with primary mouse NS1 monoclonal antibodies (Clone NS1-1A7 




isothiocyanate (FITC) -labeled secondary antibody (Southern Biotech, 
Birmingham, AL (1:5000)). Cells were visualized using a Zeiss SM510 confocal 
microscope (Carl Zeiss Microscopy, Thornwood, NY).  
Dissociation of nuclear and cytoplasmic fractions 
MDCK cells were seeded in 6-well plate to 80% confluence and infected 
with recombinant virus WT702 or QA23 NS:7WT702 at MOI=1, and harvested 
the cell at 8 and 24 h.p.i. using Trypsin-EDTA solution (Sigma-Aldrich, St. Louis, 
MO). The nuclear and cytoplasmic fractions were separated using the NE-PER 
Nuclear and Cytoplasmic Extraction kit (Thermo Scientific, West Palm Beach, 
FL) according to the manufacturer's protocol. Added 200 !l of ice-cold CER I to 
the cell pellet, and resuspended. Incubated the tube on ice for 10 min. 11 !l of ice-
cold CER II was added to the tube. Vortexed and incubated the tube on ice for 1 
min. The tube was spin down at 16,000xg for 5 min and transferred the 
supernatant (cytoplasmic extract) fraction to a new tube. The insoluble (pellet) 
fraction was resuspended in 100 !l of ice-cold NER. The sample was kept on ice 
and continue vortexed for 15 s every 10 min, for a total of 40 min. Spin down the 
tube at 16,000xg for 10 min, and immediately transfer the supernatant (nuclear 
extract) fraction to a new tube.  
The samples were added 50 !l of 2x Laemmli Sample Buffer (Bio-Rad, 
Hercules, CA) containing 50 !l !-mercaptoethanol (Fisher Scientific, Waltham, 
MA)/ml, heated at 100°C for 5 min, and then loaded into a Mini-PROTEAN TGX 
Precast Gel (Bio-Rad, Hercules, CA). The gel was run for 60 min at 150 V using 




were transferred into supported nitrocellulose membrane (Bio-Rad, Hercules, CA) 
at 18 V for 45 min using Trans-Blot SD System and PowerPac HC Power Supply 
System (Bio-Rad, Hercules, CA). The NS1 expression were detected with the 
Clone NS1-1A7 (from NIH (1:500)) as the primary antibody, and then with HRP-
conjugated goat anti-mouse IgG (SouthernBiotech, Birmingham, Alabama 
(1:5000)) as the secondary antibody. The image was developed using SuperSignal 
West Pico chemiluminescent substrate (Fisher Scientific, Waltham, MA). The 
image was scanned and the optical density of each sample was quatitatived using 
densitometry software Quantity One version 4.6.5 (Bio-Rad, Hercules, CA), and 
then the relative amount of the proteins were further calculated. GAPDH was 
taken as the cellular internal control.  
Minigenome assay 
The minigenome assay was performed as described previously [351]. 200 
ng of the plasmid pMACK-GLuc encoding the influenza virus-like NS vRNA 
carrying the GaussiaLuciferase (GLuc) reporter gene and chicken polymerase I 
promoter (PolI) was transfected in DF1 cells along with 200 ng of plasmids 
encoding WT702 PB1, PB2, PA, NP and QA23 or WT702 NS or NS1 (only) 
using the TransIT-LT1 (Mirus,Madison, WI) reagent. The SEAP plasmid, which 
expresses the secretedalkaline phosphatase, was co-transfected into cells to 
normalize the transfection efficiency. The supernatants were collected at 24, 48 
and 72 h post transfection, and luciferase and secreted alkaline phosphatase 
activities were detected from 25 !l of the samples using the BioLux Gaussia 




Alkaline Phosphatase Reporter Gene Assay System (A&D, FosterCity, CA) 
according to the manufacturers’ instructions. Relative polymerase activity was 
calculated as the ratio of luciferase to SEAP luminescence. Two independent 
experiments were performed in duplicate. The statistical analyses were performed 
with GraphPad Prism software version 5.0c (GraphPad Software Inc., San Diego, 
CA).  The multiple comparisons were performed by analysis of variance 
(ANOVA) with Tukey’s multiple comparison test. 
IFN-!  ELISA 
Beta interferon (IFN-!) expression level in mammalian and avian cells 
were detected using Dog/Canine Interferon Beta INF-Beta ELISA Kit 
(Novateinbio, Woburn, MA), and Chicken Interferon !, IFN-!/IFNB ELISA Kit 
(Novateinbio, Woburn, MA ), respectively, according to the manufacturer's 
protocol. Confluent MDCK and DF1 cells in 12-well plates were infected with the 
recombinant viruses at MOI=0.1, and at 12, 24 and 48 h.p.i., 10 µl of supernatant 
diluted in 40 µl of Sample Diluent or 50 µl standards were added to 96-well 
plates, and then add 50 µl horseradish peroxidase (HRP)-labeled IFN-! antibody 
and incubated for at 37°C 30 min. After 5 washes, the 50 µl chromogenic 
Substrate A and 50 µl chromogenic Substrate B solution were added to develop 
the color, and incubated at 37°C for 15 min. 50 µl of Stop Solution was added 
immediately to each well to stop the reaction. The optical density was measured at 
450 nm (OD450). Cells transfected with Poly(I:C) (InvivoGen, San Diego, 
California) or infected with inactivated virus were taken as the positive control in 





The terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick-
end-labeling (TUNEL) staining for apoptotic nuclei was carried out using the 
DeadEnd colorimetric TUNEL kit (Promega, Madison, WI) according to the 
instructions of the manufacturer. A549 and HeLa cells were infected with 
recombinant virus WT702 or QA23 NS:7WT702 at MOI=1. At 16 h.p.i., the cells 
were fixed in 4% paraformaldehyde and incubated with 0.2% Triton X-100 in 
PBS. Labeling reactions were performed with 100 µl of TdT reaction mix for 1h 
at 37°C in a humidified chamber. After washed with PBS, cells were incubated 
with100 µl Streptavidin HRP at room temperature for 30 min. The Color 
development was accomplished with diaminobenzidine (DAB) for 7 min. The 
image of stained positively apoptotic nuclei was captured using a Zeiss Axiovert 
200M (Carl Zeiss Microscopy, Thornwood, NY, USA). Apoptosis was evaluated 
as the average number of positively stained cells per field at high-power 
magnification (!400). The cells added Staurosporine reagent (0.2 µM; Sigma-
Aldrich, St. Louis, MO) was taken as the positive control. 
To determine the role of QA23 NS1 on regulation the cellular apoptotic 
activity, the Akt and phosphorylated Akt levels were detected in HeLa cells 
infected with the viruses carrying either QA23 or WT702 NS1. HeLa cells were 
seeded in 6-well plate overnight, and then starved the cells by culturing with non-
serum media for 24 h. The cells were infected with viruses QA23 NS:7WT702 or 
WT702 at MOI=0.1. The cells were harvested at 12, 24 and 36 h.p.i by adding 




!-mercaptoethanol (Fisher Scientific, Waltham, MA) and 10 !l sodium fluoride 
(BioLabs, Ipswich, MA) /ml. The samples were heated at 100°C for 5 min and 
sonicated for 20 sec, and then 20 !l  of the samples were loaded into a Mini-
PROTEAN TGX Precast Gel (Bio-Rad, Hercules, CA). The gel was run for 60 
min at 150 V using PowerPac basic power supply (Bio-Rad, Hercules, CA). Then 
the protein samples were transferred into supported nitrocellulose membrane 
(Bio-Rad, Hercules, CA) at 18 V for 45 min using Trans-Blot SD System and 
PowerPac HC Power Supply System (Bio-Rad, Hercules, CA). The total Akt, 
phosphorylated Akt (Pho-Akt) and viral NS1 were detected with the Akt antibody 
(Cell Signaling, Boston, MA (1:500)), Phospho-Akt antibody (Ser473) (Cell 
Signaling, Boston, MA (1:500)), and Clone NS1-1A7 (from NIH (1:500)) as the 
primary antibody, rspectively. Then added HRP-conjugated goat anti-rabbit IgG 
(SouthernBiotech, Birmingham, Alabama (1:5000)) as the secondary antibody for 
Akt and Pho-Akt, and added HRP-conjugated goat anti-rabbit IgG 
(SouthernBiotech, Birmingham, Alabama (1:5000)) as the secondary antibody for 
NS1. The image was developed using SuperSignal West Pico chemiluminescent 
substrate (Fisher Scientific, Waltham, MA). GAPDH was taken as the cellular 
internal control. This experiment has been repeated 2 times.  
Quail study 
Twelve 4-week-old Japanese quail were inoculated by the ocular, 
intranasal, intratracheal and cloacal routes with 106 EID50 viruses in 1.0 ml. At 1 
dpi, 6 naïve quail were introduced into the same isolators, and placed in direct 




inoculated quail per group were sacrificed, lungs were homogenized and virus 
titers were determined by EID50. The tracheal and cloacal swabs were collected 
from both the inoculated and direct contact birds at 1, 3, 5, 7, 9 and 11 dpi. The 
swab samples were stored in glass vials in 1.0 ml freezing Brain Heart Infusion 
(BHI) medium (BD, Sparks, MD) and titrated for infectivity in 10-day-old 
embryonated chicken eggs and MDCK cells. Sera were collected 2 weeks post-
infection and HA inhibition tests (HI) were performed to quantify antibodies 
against HA [254]. 
Statistical analysis 
All figures were generated and all statistical analyses were performed with 
GraphPad Prism software version 5.0c (GraphPad Software Inc., San Diego, CA).  
Comparison between the means of two groups was carried out with a paired two-
tailed Student’s t-test, the multiple comparisons were performed by two-way 
analysis of variance (ANOVA) with Tukey’s multiple comparison test, unless 
otherwise specified. P values of <0.05 were considered significant difference. 
Results 
The mutation K219E enhanced cytoplasmic accumulation 
of NS1 in mammalian and avian cell lines 
After the wildtype duck H9N2 (WT702) virus was serially propagated in 
lung of quail for 23 times, the quail adapted virus QA23 obtained new phenotype 
of replicating and transmitting efficiently in both chickens and quail [98]. Three 




The residue 217 and 219 are located at C-terminal of NS1, and 219 is known as a 
key amino acid in NLS2 [165]. To find out if these two mutations will affect the 
distribution of NS1, we firstly analyzed the intracellular location of NS1 using 
eGFP-NS1 fusion protein, which consisted of full-length NS1 gene. To avoid the 
interference of NS2, two additional stop codons were introduced after the original 
stop codon of NS1 (eGFP-QA23 NS1 and eGFP-WT702 NS1) to abolish the NS2 
expression. The results demonstrated that QA23 NS1 predominantly distributed in 
the cytoplasm, while WT702 NS1 predominantly accumulated in the nucleus in 
293T cells (Figure 6.1A, E, G, H and I), as well as MDCK (Figure 6.1B), A549 
(Figure 6.1C) and DF1 cells (Figure 6.1D). The distributions of NS1 in the 
nucleus, cytoplasm or both in those cells were analyzed by counting more than 
100 single cells in at least 5 different eyesights. The results of NS1 distribution 
pattern were consistent with the results of eGFP-NS1 localization study (Figure 
6.1F). We further introduced three single mutations into pEGFP-C1 vector 
(eGFP-WT702 NS1-M106T, eGFP-WT702 NS1-K217E and eGFP-WT702 NS1-
K219E), and the localization study displayed that 219K is the critical amino acid 
responsible for NS1 localization change from nucleus to cytoplasm (Figure 6.1E 
and I).  
We alternatively confirmed the enhanced accumulation of QA23 NS1 in 
the cytoplasm using immunostaining analysis with directly infected cells. We 
generated the viruses QA23 NS:7WT702 and WT702 using reverse genetics, and 
infected DF1 and MDCK cells with the virus at MOI=1 for 9h.  The 




nucleus (WT702) to cytoplasm (QA23:7WT702) (Figure 6.1J and K), which is 
consistent with the result of eGFP-NS1 fusion protein localization study (Figure 
6.1B and D). 
To directly analyze the accumulation of QA23 NS1 in the cytoplasm, we 
separated the nuclear and cytoplasmic fractions of the infected MDCK cells and 
detected the distribution of the NS1 in both fractions. MDCK cells were infected 
with virus QA23NS:7WT702 or WT702, and harvested at 8 and 24 h.p.i. Then the 
amount of NS1 in nuclear and cytoplasmic fractions was directly compared using 
Western blot. The result was confirmed the QA23 NS1 accumulated in the 
cytoplasm of the MDCK cells, while WT702 NS1 predominately distributed in 
the nucleus (Figure 6.1L and M).  
NLS2 is the major functional signal for the nuclear 
accumulation of NS1 in WT702 strain 
Amino acid residue 219 is located on the theoretical NLS 2, which is 
responsible for importing WT702 NS1 into the nucleus. There is another typical 
NLS 1 locates on 35 to 41, and conserved in all subtype of influenza viruses. 
Based on our observation, the single mutation of K219E in NS1 gene of WT702 
can change the NS1 accumulation pattern from nuclear to cytoplasmic (Figure 
6.1I). To find out whether the theoretical NLS1 plays the role for nuclear 
transportation of NS1, we substituted two critical amino acids of NLS1, Argnine-
38 and Lysine-41, into alanine. pEGFP-WT702 NS1-R38A and /or K41A, and 
pEGFP-QA23 NS1-R38A and/or K41A were transfected into 293T cells, and the 




NS1 distribution pattern of either QA23 or WT702 (Figure 6.2). Take together, 
the results indicated NLS2, but not NLS1 is the major functional signal for the 
accumulation of WT702 NS1 in the nucleus.  
QA23 NS1 leads to up-regulated viral protein synthesis in 
DF1 cells 
To investigate if the mutations of QA23 NS1 will affect the viral protein 
synthesis in the avian cells, we performed the minigenome assay with different 
NS1. WT702 PB1, PB2, PA and NP genes, the reporter (luciferase) and internal 
control (SEAP) genes were co-transfected into DF1 cells, as well as WT702 or 
QA23 NS1 gene. The results showed that at 24 and 48 h post transfection, QA23 
NS1 largely increase the viral protein synthesis compared with WT702 NS1 
(Figure 6.3A and B), which may related to the enhanced cytoplasmic 
accumulation of NS1. However, when infected DF1 cells with WT702 and QA23 
NS1: WT702 viruses at MOI=0.1, both viruses yield very low viral titer (HA titer 
of WT702 infected cells was 2, and HA titer of QA23 NS1: WT702 infected cells 
was 8 at 72 h.p.i.).  
This experiment has been performed two times. The statistics analysis was 
performed using ANOVA with Bonferroni's posttest, and t-test at 24, 48 and 72 h 
post-transfection was performed to compare the relative activity of QA23 NS1 




The predominant cytoplasmic distribution of NS1 does not 
affect its inhibition of host IFN-!  
NS1 may inhibit the production of interferon beta (IFN -!) induction by 
both pre-transcription (nucleus) and post-transcription (cytoplasm). The 
distribution pattern change of QA23 NS1 may affect the host immune response, 
and therefore, we detected the IFN-! expression level of mammalian and avian 
cells after infect with WT702 and different mutants. MDCK and DF1 cells were 
infected with virus QA23 NS: 7WT702, WT702, single mutants 217E or 219E at 
MOI=1.0. The IFN -! activities were detected at 12, 24 and 48 h.p.i. using ELISA 
kits. The results showed all viruses strongly decrease the induction of IFN-! in 
both MDCK cells (Figure 6.4A) and DF1 cells (Figure 6.4B), but there was no 
significant difference in IFN-! level amongst the different viruses (Figure 6.4A 
and B). Take together, the enhanced cytoplasmic and decrease nuclear distribution 
of NS1 did not affect the inhibition the induction of host IFN-!. However, both of 
the experiments have been performed only once. 
The predominant cytoplasmic distribution of NS1 
enhanced the anti-apoptotic activity level 
During the course of experiment we observed that A549 cells infected 
with WT702 rounded up and detached much earlier than the cells infected with 
virus QA23 NS:7WT702. To investigate the role of QA23 NS1 on regulating the 
apoptotic activity of the infected cell, a TUNEL assay was carried out in A549 




end labeling is an approach for detecting DNA fragmentation by labeling the 
terminal end of nucleic acids. During the infection of influenza viruses, 
endogenous endonuclease activities cleave the DNA of apoptotic cells into a 
population of 180- to 200-bp fragments, resulting in the morphological changes of 
the host cells; TUNEL could label those degraded DNA fragments in situ. Here 
we applied a DeadEnd colorimetric TUNEL kit to display the apoptotic level of 
infected A549 (Figure 6.5A) and HeLa cells (Figure 6.5B). The apoptotic DNA 
fragments were stained into dark brown. Compared with the cells infected with 
the virus carrying QA23 NS1, the cells infected with the virus carrying WT702 
NS1 showed much higher apoptotic level (more dark brown dots) at 16 h.p.i. in 
both A549 and HeLa cells (Figure 6.5A and B). In contrast, the uninfected 
(Mock) cells were negative for TUNEL staining, and the cells treated with the 
apoptosis-inducing agent staurosporine showed severe apoptotic changes (Figure 
6.5A and B). The results indicated that the cytoplasmic accumulation of QA23 
NS1 may enhance the anti-apoptosis function of the NS1 protein and lead to a 
reduced apoptotic activity of the host cells.  
The analysis of the apoptotic activity levels in DF1 and MDCK cells 
during infection is more relevant to this study. However, no dark brown dots were 
observed using the TUNEL staining after I infected DF1 and MDCK cells for 16 
h. The optimization of the infection condition is required to obtain the better 
images from these two cell lines.  
PI3K/Akt signaling pathway plays important role in host anti-apoptosis. 




downstream effector of PI3K [185]. To analysis the anti-apoptosis function of 
QA23 NS1 during infection, I performed the preliminary experiments on 
detecting phosphorylated Akt (Pho-Akt) level in infected HeLa and A549 cells. 
However, no Akt and Pho-Akt signal has been detected from infected A549 cell. 
Whereas, infected HeLa cells showed strong signals for both molecules in the 
western blot. The results showed Pho-Akt level up-regulated in QA23 
NS:7WT702 infected HeLa cells at 12 and 24 h.p.i compared with WT702 
infected cells (Figures 6.6 A and B). However, compared with QA23 NS1, the 
signal of WT702 NS1 during infection was very low, which indicated the Pho-
Akt level difference might be caused by the different expression levels between 
QA23 and WT702 NS1. The kinetics study showed virus QA23 NS:7WT702 
replicated more efficiently in Hela cells than WT702 (Figure 6.6C). In contrast, 
no significant difference on viral replication has been observed in A549 cell 
(Figure 6.6D).  
QA23 NS1 has no significant effect on the viral replication 
and transmission in Japanese quail 
Because the three amino acid substitutions M106T, K217E and K219E 
were generated through the wildtype duck H9N2 (WT702) virus serially 
prorogated 23 times in lung of quail, and obtained the capability to effectively 
infect and transmit in quail and chicken, we wanted to determine whether these 
three mutations also contribute to the replication and transmission of the adapted 
virus (QA23) in quail. Twelve 4-week-old Japanese quail were inoculated with 




same isolators to directly contact with the inoculated quail. The results showed 
the all quail inoculated WT702 or mutants and all direct contact quail were 
positive at 1 and 3 d.p.i and 3 d.p.i. , respectively (showed in Table 6.1.). The 
viral shedding was detected mainly from the upper respiratory tract (trachea), 
while only trace amount of virus (below the limit of detection in MDCK cells) 
was isolated from cloaca of some birds (showed in Table 6.1.). However, no 
significant difference of viral shedding had been detected from the inoculated 
birds (Figures 6.7A), or from the direct contact birds (Figures 6.7B), which 
suggested that QA23 NS1 has no significant effect on viral replication and 
transmission in quail compared with WT702 NS1. 
Discussion 
To better understand the molecular mechanism of the adaptation and 
interspecis transmission of influenza virus from wild aquaic birds to land-based 
poultry in nature, our lab established a model for virus adaptation by serially 
passing a wildtype duck H9N2, A/duck/Hong Kong/702/79 (WT702) virus, in the 
lung of Japanese quail for 23 times followed by 10 more passages in the lung of 
chicken, and generated adapted virus QA23 and QA23CkA10, respectively [98]. 
Quail carries both !-2,3 SA (avian-like) and !-2,6SA (human-like) receptors in 
the respiratory tract and thought to be the potential mix vessel to generate reassort 
influenza virus and an ideal environment for the adaptation of influenza virus 
from wild birds to land-based poultry and mammals [362,363,364]. Both QA23 
and QA23CkA10 gained the new phenotype of replicating and transmitting 




QA23Ck10, unlike WT702, were able to infect mice without any further 
adaptation, and showed faster growth kinetics in MDCK and CEK cells [98]. 
Amongst all of the amino acid substitutions on virus QA23, we particularly 
noticed three amino acid substitutions M106T, K217E and K219E on NS1 gene, 
which generated after the adaptation in quail.  
Firstly, we constructed eGFP-QA23 NS and eGFP-WT702 NS and 
analysis the distribution of NS1 in 4 mammalian or avian cell lines (293T, MDCK 
A549, and DF1). The result of localization study on Confocal displayed that, in all 
cell lines, WT702 NS1 predominantly distributed in the nucleus, while QA23 
NS1 mainly accumulated in the cytoplasm (Figure 6.1A-M). Three single 
mutations were introduced into GFP vector, and the result demonstrated 219K is 
the critical amino acid responsible for NS1 distribution pattern change of QA23 
from nucleus to cytoplasm (Figure 6.1E and I). We also infected DF1 and MDCK 
cells with viruses QA23 NS:7WT702 and WT702, respectively; and confirmed 
the enhanced cytoplasmic accumulation of NS1 by performed immunostaining 
assay (Figure 6.1J and K) and dissociation of nuclear and cytoplasmic fractions 
(Figure 6.1L and M). WT702 NS1 contains both theoretical NLS1 and NLS2. 
NLS1, containing 3 critical residues: Arg-35, Arg-38 and Lys-41, is highly 
conserved in most of the influenza strains; while NLS2 is deficient from a large 
number of the virus strains. However, based on our observation, seems NLS2 
plays the important role on nuclear importing of NS1 in this H9N2 strain, because 
a single mutation K219E could dramatically reduce the accumulation of NS1 in 




function of NLS 1 by substituting residue 38R and/ or 41K into alanine did not 
affect the predominantly distribution of WT702 NS1 in nucleus (Figure 6.2). The 
observation is similar to a recent NS1 localization study of a human H3N2 
influenza virus (A/Udorn/72), which showed, unlike H1N1 subtype, its C-
terminal NLS2/NoLS was the major signal for the transportation of the NS1 
protein into the nucleus [365]. Take together, the data indicated that the primary 
function of NLS1 and NLS2 could be strain-specific.  
NS1 can interact with a number of host proteins to overcome the innate 
protection of host and facilitates the viral replication during infection. The 
increased accumulation of NS1 in the cytoplasm may promote the interaction 
between NS1 and cytoplasmic factors. It’s reported that NS1 can suppress the 
host antiviral function by blocking 2’-5’-oligoadenylate synthetase (OAS) [192] 
and serine/threonine protein kinase R (PKR) [193]. More important, NS1 could 
inhibit RIG-I function on inducing of IFN-! by directly form the RIG-I-
NS1complex, and binding to TRIM25, which activates RIG-I by ubiquitinating 
RIG-I N-terminal CARD domain [172,173,174,175]. To determine if the 
enhanced cytopIasmic distribution affect NS1 function on antagonizing the host 
type I interferon, we infected MDCK and DF1 cells with WT702 and different 
mutants, and detected the IFN-! production in the supernatant. However, 
compared with virus WT702, those mutants did not show significant changes on 
the interferon expression level (Figure 6.4). 
To analyze the effect of cytoplasmic accumulation of NS1 on the viral 




NS:7WT702. However, both viruses replicated poorly in DF1 cells. We 
alternatively investigate the effect of NS1 on viral protein synthesis using 
minigenome assay. The results showed that QA23 NS1 up-regulated the viral 
protein synthesis at 24 and 48 h post transfection (Figure 6.3). In the cytoplasm, 
NS1 may enhance the viral protein synthesis by binding to Staufen [366] and 
binding eukaryotic translation initiation factor eIF4GI to viral mRNA 5’ 
untranslated region[191]; meanwhile, limits the expression of the host antiviral 
gene[137].  The cytoplasmic accumulation of NS1 may enhance the viral protein 
synthesis by increasing the interaction with those host factors located in the 
cytoplasm.  
NS1 may activate PI3K in the cytoplasm, and limit the programmed cells 
death. However, the role of NS1 in apoptosis is still unclear as both pro-apoptosis 
and anti-apoptosis were reported, and the function could be strain-specific or host-
specific [160,330,332,367]. In this study, we applied TUNEL assay to investigate 
whether QA23 NS1 enhance the function of pro-apoptosis or anti-apoptosis 
during infection. The results showed that, at 16 h.p.i., QA23 NS1 reduced the 
apoptotic activity level of A549 and HeLa cells (Figure 6.5), and suggested the 
cytoplasmic accumulation of NS1 may enhance the anti-apoptosis function of the 
protein during infection. DF1 and MDCK should be more relevant to this 
apoptosis assay in this study. However, TUNEL assay in these two cells resulted 
in poor staining. Optimization of the infection and TUNEL condition are needed 




PI3K/Akt is an important intracellular signaling pathway in apoptosis. 
During influenza infection, NS1 interacts with PI3K by direct binding to the 
subunit of p85!, and phosphorylate Akt consequently inhibits the apoptosis of the 
infected cells. However, when we detected the phosphorylated Akt (Pho-Akt) 
level in different cell-lines (including A549, MDCK, DF1 and HeLa cells) 
infected with WT702 or QA23 NS: 7WT702, the difference was only found in 
HeLa cells. It may be because the commercialized antibodies against Pho-Akt and 
Akt could only react with human, mouse, and rat; or because the Akt and Pho-Akt 
expression level are relative low in other cell-lines. More efforts need to be 
carried out on prove the role of QA23 NS1 on up-regulating the Pho-Akt in HeLa 
cells, as well as in DF1 and MDCK cells. 
To determine the contribution of QA23 NS1 gene to the adaptation of 
WT702 in chicken and quail, we performed the viral replication and transmission 
study in Japanese quail. The results showed: no significant difference in the viral 
shedding has been detected from the trachea (upper respiratory tract) or lung 
(lower respiratory tract) of the inoculated birds, or from the trachea of the direct 
contact birds (Figures 6.6A and B). The results suggested that the accumulation of 
NS1 in the cytoplasm does not affect the virus replication and transmission in 
quail.  
In this study, we demonstrated, for this H9N2 strain, the increased 
cytoplasmic accumulation of NS1 may enhance the viral replication and anti-
apoptosis activity level in the host cells. As the amino acid mutations on NS1 




cytoplasmic accumulation of NS1 may facilitate influenza virus to produce more 
mutants as the candidates for better fitness during this processing by utilize the 
host cell longer and more efficiently. This could be a strategy for the interspecies 
transmission of influenza virus. However, some of the experiments in this study 
were carried out only once, and more evidence needs to be provided before we 































Table 6.1. Replication and transmission of H9N2 viruses in Japanese quail. 
Virus/Group Days post-infection 
 1 3 5 7 9 11 
#  of positive 
HI/total # at 
14 dpi 
 T C T C T C T C T C T C  
WT702              
Infected 12/12 4/12 12/12 6/12 4/9 1/9 0/6 0/6 0/6 0/6 0/6 0/6 6/6 (26.7) 
Contacts NA NA 6/6 0/6 4/6 0/6 2/6 1/6 0/6 0/6 0/6 0/6 6/6 (18) 
QA23NS: 7WT702              
Infected 12/12 3/12 12/12 5/12 5/9 1/9 0/6 0/6 0/6 0/6 0/6 0/6 6/6 (41.3) 
Contacts NA NA 6/6 1/6 5/6 2/6 2/6 3/6 0/6 0/6 0/6 0/6 6/6 (4.3) 
WT702 NS1 217E              
Infected 12/12 4/12 12/12 5/12 5/9 1/9 0/6 0/6 0/6 0/6 0/6 0/6 6/6 (30.7) 
Contacts NA NA 6/6 0/6 5/6 1/6 2/6 2/6 1/6 0/6 0/6 0/6 6/6 (9.3) 
WT702 NS1 219E              
Infected 12/12 4/12 12/12 6/12 6/9 1/9 0/6 0/6 0/6 0/6 0/6 0/6 6/6 (44.0) 
Contacts NA NA 6/6 1/6 5/6 2/6 2/6 3/6 1/6 1/6 0/6 0/6 6/6 (4.7) 
WT702 NS1 106T              
Infected 12/12 3/12 12/12 5/12 4/9 0/9 0/6 0/6 0/6 0/6 0/6 0/6 6/6 (24.0) 










































Figure 6.1. Immunofluorescence of NS1 protein localization and cytoplasmic 
and nuclear and fractions of NS1. (A) 293T, (B) MDCK, (C) A549, and (D) 
DF1 cells were transfected with plasmids expressing the different GFP-NS1 
proteins and fixed at 24 h post-transfection for immunofluorescence analysis 
using a Zeiss Axiovert 200M (400x). (E) 293T were transfected with plasmids 
expressing the different GFP-NS1 proteins and fixed at 24 h post-transfection for 
immunofluorescence analysis using a Zeiss SM510 confocal microscope. (F) The 
distribution of NS1 in the cytoplasm, nucleus, and in both were analyzed in 293T, 
MDCK, A549 and DF1 cells by counting more than 100 single cells in at least 5 
different eyesights. 293T cells were transfected with plasmids expressing the 
different GFP-NS1 proteins and fixed at (G) 6 h, (H) 12h, and (I) 24 h post-
transfection for immunofluorescence analysis. (J) DF1 cells were infected with 
recombinant viruses QA23NS:7WT702 or WT702 cells at an MOI=1. At 9 h p.i., 
the cells were fixed for immunofluorescence analysis. GFP-NS1 fusion protein 
showed in green and DAPI (the nucleus) showed in blue. (K) MDCK cells were 
infected with recombinant viruses QA23NS:7WT702 or WT702 cells at an 
MOI=0.1. At 24 h.p.i., the cells were fixed for immunofluorescence analysis. 
MDCK cells were infected with the recombinant viruses QA23NS:7WT702 or 
WT702 at MOI=1.0. The cells were harvested (L) at 8 h.p.i. and (M) at 8 and 24 
h.p.i., and then fractionated for detection. Amounts of NS1 in cytoplasmic (C) and 
nuclear (N) fractions were analyzed by western blot analysis. GAPDH was used 










Figure 6.2. Immunofluorescence of NS1 mutants localization.  293T 
cells were transfected with QA23 and WT702 NS1 plasmids containing 41A and/or 
38A mutation(s) and fixed at 24 h post-transfection for immunofluorescence analysis. 









Figure 6.3. Minigenome assay.  DF1 cells were transfected with each of the 
influenza virus driven-luciferase reporter plasmids (GLuc) and PB2, PB1, PA, 
and NP plasmids, and (A). QA23 or WT702 NS and QA23 or WT702 NS1, and 
(B). QA23 or WT702 NS1, and pCMV/SEAP, which carries the secreted alkaline 
phosphatase gene was cotransfected into the cells to normalize transfection 













Figure 6.4. IFN-!  level induced by recombinant viruses.  (A) 
MDCK cells and (B) DF1 cells were infected with the recombinant viruses at 
MOI= 1. Supernatants were harvested at 12, 24, and 48 h p.i., and measurements 
were carried out using an IFN-! ELISA kits were performed. (These 2 
experiments were performed only once. The results showed significant difference 

















Figure 6.5. Apoptosis assay using TUNEL assay. (A) A549 and (B) HeLa cells were 
infected with the recombinant viruses QA23NS:5WT702:2PR8 H1N1 or 6WT702:2PR8 
H1N1, and fixed the cells at 16 h.p.i. The apoptotic activity level of the cells was detected 
using TUNEL assay kit. The apoptotic nucleus with the small DNA fragments was 










Figure 6.6. Influenza virus infection activates Akt 
phosphorylation. HeLa cells were infected by virus QA23NS:7WT702 or 
WT702. Cell lysates were collected at (A) 12, 24, and 48 h.p.i. ; or (B) 12, 24, and 
36 h.p.i. The amounts of phosphorylated Akt (pho-Akt) and total Akt evaluated 
by western blot using Akt and Pho-Akt antibodies. (C) HeLa and (D) A549 cells 
were infected with QA23 NS:7WT702 or WT702 at MOI=0.1. The supernatants 









Figure 6.7. Viral shedding from the trachea of quail.  The swabs 
from (A) infected and (B) contacted birds were collected at 1,3,5,7,9 and 11 dpi. 













Chapter 7: Perspective 
Influenza A viruses constantly circulate in a broad range of animal 
species, such as humans, birds, pigs, horses and dogs. In humans, the seasonal 
influenza virus infections cause epidemics every year, resulting in millions of 
cases with severe illness worldwide [368]; whereas the influenza pandemics occur 
sporadically, generally resulting in millions of death globally [18,19]. Meanwhile, 
the outbreaks of HPAI and LPAI cause the depopulation of flocks and major 
economic losses worldwide. Occasionally, the avian influenza viruses overcome 
the host barrier and directly cause the morbidity and mortality in humans, which 
highlight the threat of avian influenza viruses to public health. 
Vaccination is the main strategy to control and prevent influenza virus 
infections. Currently, inactivated vaccine, live attenuated vaccine and 
recombinant virus-like-particles (VLPs) vaccine are licensed in the US against 
human seasonal influenza epidemics [243,245]. In poultry manufactory, 
inactivated vaccine, recombinant fowlpox virus-vectored vaccine expressing the 
H5 HA gene, and recombinant Newcastle disease virus (NDV)-vector with the H5 
HA gene insert are approved to use for preventing avian influenza virus infection 
[255]. However, both licensed human seasonal influenza and avian influenza 
vaccines have some limitations, which stimulate the development of novel 
vaccines with other strategies. 
Our lab previously demonstrated the potential of an avian live attenuated 
master backbone WF10att for use in epidemic and pandemic influenza vaccines 




the HA gene combined with WF10att backbone could be used for in ovo 
vaccination against avian influenza in chickens. In “Chapter 4: Improved 
hatchability and efficient protection after in ovo vaccination with live-attenuated 
H7N2 and H9N2avian influenza viruses”, I investigated the strategy of replacing 
the HA cleavage site of H7 and H9 subtypes with that of H6’s to improve 
hatchability and protection efficiency. The results showed that the hatchabilities 
were greatly improved to more than 90% when in ovo vaccinated with those 
genetically modified live-attenuated viruses. More importantly, a single dose in 
ovo vaccination of 19-day-old egg embryos provided the high protectivity (>70%) 
against low pathogenic H7 and H9 challenge in the chickens at 2- or 6- week 
post-hatching. However, we conducted the in ovo vaccination manually in this 
study.  An automated egg vaccination machine system currently used in poultry 
industry would deliver the vaccines in a more efficient, accurate and uniform way 
compared to manual approach. Therefore, further investigation is needed to 
determine if the automated system would provide a higher protection efficiency 
for in ovo vaccination with our live-attenuated vaccines in a large number of the 
chicken egg embryos.  
Different methods were applied to generate the vaccine candidates in the 
emergence of the 2009 swine-origin pandemic H1N1 virus [262]. And more 
efforts were carried out to improve the functional HA yield of those vaccine 
strains in embryonated chicken eggs [262,347,353]. The amino acid substitutions 
generally present on the surface HA and NA proteins during egg adapation of 




residue 59 in PA, from glutamic acid to valine (PA E59V) is responsible for the 
enhanced HA and viral titers in egg embryos and MDCK cells on the live-
attenuated vaccine WF10att backbone (Chapter 5: Glutamic acid to valine 
substitution at position 59 in PA enhances growth of live-attenuated influenza 
vaccines in eggs and mammalian cells). The substitution PA E59V confers this 
backbone higher capability to replicate better in eggs with HA and NA derived 
from human-like influenza virus under the temperature sensitive phonotype; and 
PA 59V is not likely to be the critical amino acid responsible for the RNA-
dependent RNA polymerase activity of live-attenuated influenza virus. PA 59V 
may contribute to a regulation mechanism which confers the attenuated backbone 
enhanced HA yield under the temperature sensitive phenotype. However, the 
mechanism of PA E59V on enhancing the HA titer and viral replication of 
WF10att backbone in egg embryos needs to be further elucidated. Future study 
can be carried out to investigate whether the function of PA E59V is related to the 
amino acid mutations on PB1 and PB2, or HA tag on the c-terminus of PB1 on 
WF10att backbone. Meanwhile, the endonuclease assay with full-length PA or 
PA Nter (N-terminal 210 amino acid residues) may help us to further figure out 
the function of PA 59V on viral polymerase activity. 
NS1 of Influenza A virus has been identified as a multifunctional protein, 
which is responsible for the increased pathogenicity and virulence of the viruses. 
NS1 generally possesses two nuclear localization sequences (NLS1 and NLS2) 
and one nuclear export sequence (NES), which are responsible for the shuttling of 




Antagonizing the host innate immune response is one of the major functions of 
NS1: NS1 blocks the cellular mRNA maturation by binding to CPSF30 and 
PABII [170,171], and inhibits the activation of transcription factors in the IFN-! 
signaling pathway by binding to dsRNA [169,282]. NS1 could also directly bind 
to the cytosolic sensor RIG-I, form a complex, resulting in the inhibition of the 
IFN-! induction [172,173,174]. Meanwhile, NS1 has other important functions 
during infection, such as regulating PI3K/Akt pathway, which is involved in the 
host apoptotic activity [180,181,182,183].  
In “Chapter 6: Cytoplasmic accumulation of NS1 enhances the viral 
replication and anti-apoptosis of an avian influenza virus (H9N2)”, I had a 
particular interest in the NS1 from a quail-adapted H9N2 virus QA23.  Compared 
with the wild-type virus WT702, the NS1 accumulation pattern of the quail-
adapted virus QA23 (containing three identified mutations: M106T, K217E and 
K219E in the NS1 gene) changed from nucleus to cytoplasm in the infected cells. 
The theoretical nuclear localization sequence 2 (NLS2) and 219K in NS1 are 
critical to the accumulation of the protein in the nucleus. 
Both QA23 and WT702 NS1 have the effect on reducing the IFN-! 
induction level in DF1 cell and MDCK cells. However, no significant difference 
in the IFN-! expression level between QA23 and WT702 NS1 has been found. 
The results indicated that the cytoplasmic accumulation of NS1 does not affect 
NS1 function on blocking the induction of host IFN-!.  We also observed that 
different cell-lines, such as A549 and MDCK cells, infected with recombinant 




than the cells infected with recombinant QA23 NS: 7WT702. The results 
indicated that cytoplasmic accumulation of QA23 NS1 might relate to the reduced 
apoptotic activity of the host cells. PI3K/Akt is an important intracellular 
signaling pathway in apoptosis. During influenza infection, NS1 interacts with 
PI3K by direct binding to the subunit of p85!, and phosphorylate Akt 
consequently inhibits the apoptosis of the infected cells. However, when we 
detected the phosphorylated Akt (Pho-Akt) level in different cell-lines (including 
A549, MDCK, DF1 and HeLa cells) infected with WT702 or QA23 NS: 
7WT702, the difference was only found in HeLa cells. It may be because the 
commercialized antibodies against Pho-Akt and Akt could only react with human, 
mouse, and rat; or because the Akt and Pho-Akt expression level are relative low 
in other cell-lines. 
Investigating the role of QA23 NS1 on pro- or anti-apoptosis may help us 
to better understand how this protein contributes to the pathogenesis by 
modulating the host-cell signalings during infection. We may also alternatively 
detect expression level of other important host factors, which involve in either 
pro-apoptotic or anti-apoptotic function in the life cycle of the cells. For example, 
p53 and cytochrome c play the pro-apoptotic role, while Bcl-2, Bcl-XL, Bcl-W 














The primers used for sequencing and reverse genetics 
 
Primer name Primer sequence Function 
Ba-PB2 1F TATTGGTCTCAGGGAGCGAAAGCAGGTC Universal primer 
Ba-PB2 2341R ATATGGTCTCGTATTAGTAGAAACAAGGTCGTTT Universal primer 
Bm-PB1 1F TATTCGTCTCAGGGAGCGAAAGCAGGCA Universal primer 
Bm-PB1 2341R ATATCGTCTCGTATTAGTAGAAACAAGGCATTT Universal primer 
BmPA-1F TATTCGTCTCAGGGAGCGAAAGCAGGTAC Universal primer 
BmPA-2233R ATATCGTCTCGTATTAGTAGAAACAAGGTACTT Universal primer 
Bm-NP-1F TATTCGTCTCAGGGAGCAAAAGCAGGGTA Universal primer 
BmNP-1565R ATATCGTCTCGTATTAGTAGAAACAAGGGTATTTTT Universal primer 
Bm-NS-1F TATTCGTCTCAGGGAGCAAAAGCAGGGTG Universal primer 
Bm-NS-890R ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT Universal primer 
Bm-M-1F TATTCGTCTCAGGGAGCAAAAGCAGGTAG Universal primer 
Bm-M-1027R ATATCGTCTCGTATTAGTAGAAACAAGGTAGTTTTT Universal primer 
PB2  412R CCATGTTTCAACCTTTCAACC Internal primers 
PB2 1774R CAAACTCCATCTTATTGTA Internal primers 
WFPB2-1454BseR GCTAACTCTCACTCCTCTTAGTGAC Internal primers 
WF10 PB2 1381F GAACCCATCGACAATGTCATG Internal primers 
Ba-PB2-1768F TATTGGTCTCAGGGACAATCCTTGGTACCTA Internal primers 
WF10PB1-1195WTF CGAGAAAGAAAATTGAGAAAATAAGACCTC Internal primers 
WF10PB1-1766WTR CTTTGAGCGGGTCTGCTCCCACAGCTTCTTCAA Internal primers 
PB1 419R GTCCAATCATAAGTCTGGC Internal primers 
Bm-PB1-1473F TATTCGTCTCAGGGACATAAATAGGACAGG Internal primers 
BmPB1-620F TATTCGTCTCTGGTCACACAAAGAACAATAG Internal primers 
PA735F AACCGAACGGCTGCATTGAGGGC Internal primers 
PA1769R ATCATGCTCTCAATCTGTTG Internal primers 
PA336R CTTGGGCTTCTCAACCCCCG Internal primers 
PA-1807F AGCATGATTGAGGCCGAGTC Internal primers 
PA-930-953F CCACTATACGATGCAATCAAATGC Internal primers 
Sw HA 752F TAGAGCCGGGAGACAAAATAACAT Internal primers 
Sw HA 1213F ACACAGTTCACAGCAGTAGGTAAA Internal primers 
Sw HA 931R TCTGAAATGGGAGGCTGGTGTT Internal primers 
Sw HA 521R GGATTTGCTGAGCTTTGGGTATG Internal primers 
NP-700F GCACAAAGAGCAATGATGGA Internal primers 
NP-446R GTGAGACCAGCAGTTGCGTCTTCTCCATTGTTCGC Internal primers 
NP529F AGAATGTGCTCTCTGATGCAAGG Internal primers 
NP669R CTCCAGAAGTTCCGGTCATT Internal primers 
Sw NA 949F ATATGCAGTGGGATTTTCGGAGAC Internal primers 
Sw NA 1022R ACCCTTTTACTCCATTTGCTCCAT Internal primers 
Sw NA 451R GGGTTCGATATGGGCTCCTGTC Internal primers 
M-772F GCGATTCAAGTGATCCTCTCGTTA Internal primers 
M-915R CTCCTTCCGTAGAAGGCCCTC  Internal primers 
NS1_294-313F GTCAAGGGATTGGTTAATGC Internal primers 
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